Primate model of cardiac arrhythmia reveals SLC41a2 and a magnesium clock in pacemaker regulation

Lemurs and genetically modified non-human primates with SLC41A2 mutations serve as effective models for cardiac arrhythmia research, overcoming the limitations of mouse models and non-human primates, facilitating therapeutic screening for arrhythmias and sinus node dysfunction.

WO2026236202A1PCT designated stage Publication Date: 2026-11-12THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/US2026/026675
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-06
Filing Date
2026-05-05
Publication Date
2026-11-12

AI Technical Summary

Technical Problem

Current mouse models have limitations in accurately representing human cardiac arrhythmias due to anatomical, physiological, and genetic differences, making them inadequate for systematic genetic studies and preclinical testing of therapeutics, while non-human primates are costly and ethically challenging, necessitating a more suitable model for cardiac arrhythmia research.

Method used

Utilizing lemurs as animal models with naturally occurring arrhythmias resembling human ECG pathologies and genetically modifying non-human primates with a loss-of-function mutation in the SLC41A2 gene to create a primate model for cardiac arrhythmia research, along with induced pluripotent stem cell-derived sinoatrial nodal pacemaker cells to screen therapeutics.

Benefits of technology

Provides a tractable and valuable genetic model for cardiac arrhythmias, enabling effective screening of candidate agents for treating arrhythmias and sinus node dysfunction, addressing the limitations of existing models.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure US2026026675_12112026_PF_FP_ABST
    Figure US2026026675_12112026_PF_FP_ABST
Patent Text Reader

Abstract

Primate animal models of cardiac arrhythmias and methods of using such primate animal models for research and development and screening of therapeutics for treating cardiac arrhythmias are provided. In particular, lemurs were identified for use as animal models having different naturally occurring arrhythmias resembling human electrocardiographic (ECG) pathologies. In addition, genetically modified non-human primates and induced pluripotent stem cell-derived sinoatrial nodal pacemaker cells (iSANCs) comprising a loss-of-function mutation in an SLC41A2 gene linked to atrial arrhythmia and sinus node dysfunction and their use in screening therapeutics for treating atrial arrhythmia and sinus node dysfunction are also provided.
Need to check novelty before this filing date? Find Prior Art

Description

Atty. Dckt.: STAN-2271 WO Client Ref.: S25-149PRIMATE MODEL OF CARDIAC ARRHYTHMIA REVEALS SLC41 A2 AND A MAGNESIUM CLOCK IN PACEMAKER REGULATIONCROSS REFERENCE TO RELATED APPLICATIONS

[0001] This application claims benefit of U.S. Provisional Patent Application No. 63 / 800,671 , filed May 6, 2025, which application is incorporated herein by reference in its entirety.STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT

[0002] This invention was made with Government support under contracts HL130020 and HL145676 awarded by the National Institutes of Health. The Government has certain rights in the invention.INCORPORATION BY REFERENCE OF A SEQUENCE LISTING

[0003] A Sequence Listing is provided herewith as a Sequence Listing XML file, “STAN- 2271 WO”, created on April 20, 2026, and having a size of 85,440 bytes. The contents of the Sequence Listing XML file are incorporated by reference herein in their entirety.BACKGROUND OF THE INVENTION

[0004] Systematic genetic studies of a small number of phylogenetically diverse organisms have transformed our understanding of biology and medicine. Over the past several decades, mouse has emerged as the biomedical supermodel because of its short generation time for a mammal, ease in lab husbandry, and the ability to create gene knock-out, knock-in and transgenic mice that model human disease mutations (Milan, D. J. & MacRae, C. A. Animal models for arrhythmias. Cardiovasc. Res. 67, 426-437 (2005); Kapourchali, F. R. et al. Animal models of atherosclerosis. World J Clin Cases 2, 126-132 (2014); Getz, G. S. & Reardon, C. A. Animal models of atherosclerosis. Arterioscler. Thromb. Vase. Biol. 32, 1104-1115 (2012); Emini Veseli, B. et al. Animal models of atherosclerosis. Eur. J. Pharmacol. 816, 3-13 (2017); Duncker, D. J. et al. Animal and in silico models for the study of sarcomeric cardiomyopathies. Cardiovasc. Res.105, 439-448 (2015); Camacho, P., Fan, H., Liu, Z. & He, J.-Q. Small mammalian animal models of heart disease. Am. J. Cardiovasc. Dis. 6, 70-80 (2016)). However, with the expanding use of mouse models has come a greater appreciation and concern that the differences in anatomy, physiology, genetics, and biochemistry between mice and humans limit their utility for the study of many human genes and diseases, and for preclinical testing of therapeutics (Milan et aL, supra;Atty. Dckt.: STAN-2271 WO Client Ref.: S25-149Nerbonne, J. M. Mouse models of arrhythmogenic cardiovascular disease: challenges and opportunities. Curr. Opin. Pharmacol. 15, 107-114 (2014); Kaese, S. & Verheule, S. Cardiac electrophysiology in mice: a matter of size. Front. Physiol. 3, 345 (2012); Kapourchali et al., supra Getz et al., supra; Breckenridge, R. Heart failure and mouse models. Dis. Model. Meeh. 3, 138- 143 (2010)). Because of their greater similarity to humans, non-human primates are used in many areas of medical research and preclinical testing. However, ethical and practical considerations such as their large size, great cost, and long maturation and generation times limit their use and have precluded systematic genetic and mapping studies (Camacho, P., Fan, H., Liu, Z. & He, J.- Q. Large Mammalian Animal Models of Heart Disease. J Cardiovasc Dev Dis 3, (2016); Cox, L. A. et al. Baboons as a model to study genetics and epigenetics of human disease. ILAR J. 54, 106-121 (2013); Cox, L. A. et al. Nonhuman Primates and Translational Research-Cardiovascular Disease. ILAR J. 58, 235-250 (2017); Carvalho, C., Gaspar, A., Knight, A. & Vicente, L. Ethical and scientific pitfalls concerning laboratory research with non-human primates, and possible solutions. Animals (Basel) 9, 12 (2018); Huber, H. F., Nathanielsz, P. W. & Clarke, G. D. Summary and assessment of studies on cardiac aging in nonhuman primates. Comp. Med. 71 , 460-465 (2021)). Here we describe a systematic cardiac screen of mouse lemurs, among the smallest, fastest reproducing, and most abundant non-human primates, and show they are a tractable and valuable genetic model organism for cardiac arrhythmias.

[0005] Cardiac arrhythmias, irregularities of the heartbeat, afflict millions of people worldwide and cause one-fifth of all deaths, many from sudden cardiac death (Srinivasan, N. T. & Schilling, R. J. Sudden Cardiac Death and Arrhythmias. Arrhythm Electrophysiol Rev 7, 111-117 (2018)). Arrhythmias result from alterations or disruption of the cardiac conduction system, which controls the regular and rhythmic contraction of the atrial and ventricular heart chambers that pump blood to the lungs and then on to the rest of the body to circulate oxygen, nutrients, and other small molecules and blood cells. As in other areas of medical research, mouse models have risen to prominence in arrhythmia research, especially since the mapping of human familial arrhythmia genes and identification of many as cardiac ion channels and transporters ("channelopathies") whose mouse homologs were then similarly altered by gene targeting (Herrmann, S., Fabritz, L., Layh, B., Kirchhof, P. & Ludwig, A. Insights into sick sinus syndrome from an inducible mouse model. Cardiovasc. Res. 90, 38-48 (2011); Fenske, S. et al. Sick sinus syndrome in HCN1- deficient mice. Circulation 128, 2585-2594 (2013); Benson, D. W. et al. Congenital sick sinus syndrome caused by recessive mutations in the cardiac sodium channel gene (SCN5A). J. Clin. Invest. 112, 1019-1028 (2003); Abe, K. et al. Sodium channelopathy underlying familial sick sinusAtty. Dckt.: STAN-2271 WO Client Ref.: S25-149syndrome with early onset and predominantly male characteristics. Circ. Arrhythm. Electrophysiol.7, 511-517 (2014); Tanaka, T. et al. Four novel KVLQT1 and four novel HERG mutations in familial long-QT syndrome. Circulation 95, 565-567 (1997)). But the substantial differences between mice and humans in conduction system struct re, heart rate, action potential waveforms, and channel genes (Milan et al., supra; Nerbonne et al., supra; Kaese et aL, supra; Doevendans, P. A., Daemen, M. J., de Muinck, E. D. & Smits, J. F. Cardiovascular phenotyping in mice. Cardiovasc. Res. 39, 34-49 (1998)), and the lack of naturally-occurring arrhythmias in mice and failure of some targeted mutations to mimic the human arrhythmia, have spurred the search for better and complementary models (Nerbonne et aL, supra; Kaese et aL, supra; Clauss, S. et aL Animal models of arrhythmia: classic electrophysiology to genetically modified large animals. Nat. Rev. Cardiol. 16, 457-475 (2019)). There is a pressing need for such models because despite the progress in elucidating conduction system genes, mechanisms and therapeutics, the pathophysiology of arrhythmias is typically complex and remains poorly understood and often difficult to treat. Most available therapies are symptomatic so do not address the underlying defect, and unfortunately are ineffective in many patients. Although the rapidly improving ability to create, genetically modify, and interrogate human conduction system cell types in vitro holds great promise for the field (see below), it is not currently possible to recapitulate all the relevant cardiac cell types and other interacting cells that contribute to conduction system function and pathology in vivo.SUMMARY OF THE INVENTION

[0006] Primate animal models of cardiac arrhythmias and methods of using such primate animal models for research and development and screening of therapeutics for treating cardiac arrhythmias are provided. In particular, lemurs were identified for use as animal models having different naturally occurring arrhythmias resembling human electrocardiographic (ECG) pathologies, including sick sinus syndrome (SSS), premature atrial contractions (PACs), atrial fibrillation (Afib), premature ventricular contractions (PVCs), non-sustained ventricular tachycardia (NSVT), ST-segment depression (STD), inverted T-waves (iTWs), and ST-segment elevation (STE). In addition, genetically modified non-human primates and induced pluripotent stem cell-derived sinoatrial nodal pacemaker cells (iSANCs) comprising a loss-of-function mutation in an SLC41A2 gene linked to atrial arrhythmia and sinus node dysfunction and their use in screening therapeutics for treating atrial arrhythmia and sinus node dysfunction are also provided.Atty. Dckt.: STAN-2271 WO Client Ref.: S25-149

[0007] In one aspect, a method of screening a candidate agent for treating an arrhythmia is provided, the method comprising: administering the candidate agent to a lemur having the arrhythmia; and monitoring heart rhythm and heart rate of the lemur before and after administering the candidate agent, wherein detecting a normal heart rhythm or a closer to normal heart rhythm after administering the candidate agent compared to before administering the candidate agent indicates that the candidate agent is a potential therapeutic for treating the arrhythmia.

[0008] In certain embodiments, the lemur is Microcebus murinus, Microcebus rufus, or Microcebu s nova.

[0009] In certain embodiments, the arrhythmia is an atrial arrhythmia or a ventricular arrhythmia.In some embodiments, the arrhythmia is sinus bradycardia, sinus tachycardia, ventricular tachycardia, non-sustained ventricular tachycardia, supraventricular tachycardia, tachycardiabradycardia syndrome, atrial fibrillation, premature atrial contractions, premature ventricular contractions, sick sinus syndrome, or wandering atrial pacemaker. In some embodiments, the lemur has ST-segment depression, inverted T-waves, ST-segment elevation, ST-segment depression, small R-waves, tall R-waves, large S-waves and small R-waves, peaked T-waves, a right bundle branch block, a prolonged QRS-complex, or any combination thereof.

[0010] In certain embodiments, monitoring the heart rhythm and heart rate comprises performing single-lead, 3-lead, or 6-lead electrocardiography.

[0011] In certain embodiments, the method further comprises measuring rhythmic calcium transients and / or magnesium transients associated with pacemaker activity before and after administering the candidate agent, wherein detecting normal or a closer to normal rhythmic calcium transients and / or magnesium transients after administering the candidate agent compared to before administering the candidate agent indicates that the candidate agent is a potential therapeutic for treating sinus node dysfunction. In some embodiments, measuring calcium transients associated with pacemaker activity comprises performing functional calcium imaging. In some embodiments, the measuring magnesium transients associated with pacemaker activity comprises performing functional magnesium imaging.

[0012] In certain embodiments, the candidate agent is a small molecule, a peptide, a protein, a peptoid, an aptamer, an antibody, an antibody mimetic, an inhibitory nucleic acid, or a Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) system.

[0013] In certain embodiments, the candidate agent improves pacemaker function of a magnesium transporter. In some embodiments, the magnesium transporter is the SLC41A2 magnesium transporter.Atty. Dckt.: STAN-2271 WO Client Ref.: S25-149

[0014] In another aspect, a genetically modified non-human primate comprising a loss-of-function mutation in an SLC41 A2 gene is provided, wherein the non-human primate has atrial arrhythmia.

[0015] In certain embodiments, the atrial arrhythmia comprises intermittent bradycardia resembling human sick sinus syndrome (SSS).

[0016] In certain embodiments, the loss-of-function mutation results in slowed cardiac pacemaker firing compared to cardiac pacemaker firing in a non-genetically modified non-human primate having a wild-type SLC41 A2 gene.

[0017] In certain embodiments, the non-human primate is a lemur. In some embodiments, the lemur is Microcebus murinus, Microcebus rufus, or Microcebus nova.

[0018] In certain embodiments, both alleles of the SLC41 A2 gene comprise the loss-of-function mutation.

[0019] In certain embodiments, the loss-of-function mutation is an exon deletion, a frameshift mutation, a missense mutation, or a nonsense mutation. In some embodiments, the loss-of- function mutation comprises a deletion of all or a portion of exon 2 or exon 4 of the SLC41A2 gene. In some embodiments, the loss-of-function mutation comprises a deletion of all or a portion of exon 2 of the SLC41 A2 gene, a coding sequence deletion in codon 4 of the SLC41 A2 gene, a frameshift mutation in codon 4 of the SLC41 A2 gene, or any combination thereof.

[0020] In certain embodiments, the genetically modified non-human primate is a transgenic non- human primate.

[0021] In another aspect, a method of screening a candidate agent for treating atrial arrhythmia is provided, the method comprising: administering the candidate agent to a genetically modified non-human primate comprising a loss-of-function mutation in an SLC41A2 gene, as described herein; and monitoring heart rhythm and heart rate of the genetically modified non-human primate before and after administering the candidate agent, wherein detecting a normal heart rhythm or a closer to normal heart rhythm after administering the candidate agent compared to before administering the candidate agent indicates that the candidate agent is a potential therapeutic for treating the atrial arrhythmia. In certain embodiments, monitoring heart rhythm comprises performing single-lead, 3-lead, or 6-lead electrocardiography. In certain embodiments, the method further comprises measuring rhythmic calcium transients and / or magnesium transients associated with pacemaker activity before and after administering the candidate agent, wherein detecting normal or a closer to normal rhythmic calcium transients and / or magnesium transients after administering the candidate agent compared to before administering the candidate agent indicates that the candidate agent is a potential therapeutic for treating sinus node dysfunction.Atty. Dckt.: STAN-2271 WO Client Ref.: S25-149In some embodiments, measuring calcium transients associated with pacemaker activity comprises performing functional calcium imaging. In some embodiments, measuring magnesium transients associated with pacemaker activity comprises performing functional magnesium imaging. In certain embodiments, the candidate agent is a small molecule, a peptide, a protein, a peptoid, an aptamer, an antibody, an antibody mimetic, an inhibitory nucleic acid, or a Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) system. In certain embodiments, the candidate agent improves pacemaker function of a magnesium transporter. In certain embodiments, the magnesium transporter is the SLC41 A2 magnesium transporter.

[0022] In another aspect, an isolated cardiac sinoatrial nodal pacemaker cell from the genetically modified non-human primate comprising a loss-of-function mutation in an SLC41A2 gene, as described herein, is provided.

[0023] In another aspect, an induced pluripotent stem cell-derived sinoatrial nodal pacemaker cell (iSANC) comprising a loss-of-function mutation in an SLC41 A2 gene is provided.

[0024] In certain embodiments, the iSANC has slowed rhythmic calcium transients and magnesium transients compared to an iSANC having a wild-type SLC41 A2 gene.

[0025] In certain embodiments, the iSANC is a mammalian iSANC. In some embodiments, the mammalian iSANC is a human iSANC.

[0026] In certain embodiments, both alleles of the SLC41 A2 gene comprise the loss-of-function mutation.

[0027] In certain embodiments, the loss-of-function mutation in the iSANC is an exon deletion, a frameshift mutation, a missense mutation, or a nonsense mutation. In some embodiments, the loss-of-function mutation comprises a deletion of all or a portion of exon 2 or exon 4 of the SLC41A2 gene. In some embodiments, the loss-of-function mutation in the iSANC comprises a deletion of all or a portion of exon 2 of the SLC41 A2 gene, a coding sequence deletion in codon 4 of the SLC41A2 gene, a frameshift mutation in codon 4 of the SLC41A2 gene, or any combination thereof.

[0028] In certain embodiments, the iSANC is produced from an iPSC generated from a somatic cell obtained from a patient with sick sinus syndrome who has the loss-of-function mutation in at least one allele of the SLC41 A2 gene.

[0029] In certain embodiments, the iSANC is genetically modified to introduce the loss-of-function mutation into at least one allele of the SLC41 A2 gene.

[0030] In another aspect, a method of screening a candidate agent for treating sinus node dysfunction is provided, the method comprising: contacting an iSANC, described herein, with theAtty. Dckt.: STAN-2271 WO Client Ref.: S25-149candidate agent; and measuring calcium transients, magnesium transients, or both calcium transients and magnesium transients in the iSANC before and after contacting the iSANC with the candidate agent, wherein detecting increased calcium transients, increased magnesium transients, or increased calcium transients and increased magnesium transients after administering the candidate agent compared to before administering the candidate agent indicates that the candidate agent is a potential therapeutic for treating the sinus node dysfunction.

[0031] In certain embodiments, measuring calcium transients comprises performing functional calcium imaging of the iSANC.

[0032] In certain embodiments, measuring magnesium transients comprises performing functional magnesium imaging of the iSANC.

[0033] In certain embodiments, the candidate agent is a small molecule, a peptide, a protein, a peptoid, an aptamer, an antibody, an antibody mimetic, an inhibitory nucleic acid, or a Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) system.

[0034] In certain embodiments, the candidate agent improves pacemaker function of a magnesium transporter. In some embodiments, the magnesium transporter is the SLC41A2 magnesium transporter.

[0035] In another aspect, a method of producing a genetically modified non-human primate comprising a loss-of-function mutation in an SLC41A2 gene is provided, the method comprising genetically modifying a host non-human primate to introduce a loss-of-function mutation into the SLC41 A2 gene, wherein the genetically modified non-human primate has atrial arrhythmia.

[0036] In certain embodiments, genetically modifying the host non-human primate comprises using a clustered regularly interspaced short palindromic repeats (CRISPR) system, a transcription activator-like effector nuclease (TALEN), or a zinc-finger nuclease to introduce the loss-of-function mutation into the SLC41A2 gene. In some embodiments, the CRISPR system, TALEN, or zinc-finger nuclease is used to introduce the loss-of-function mutation into one allele of the SLC41A2 gene. In some embodiments, the CRISPR system, TALEN, or zinc-finger nuclease is used to introduce the loss-of-function mutation into both alleles of the SLC41 A2 gene. In certain embodiments, the loss-of-function mutation is an exon deletion, a frameshift mutation, a missense mutation, or a nonsense mutation. In some embodiments, the loss-of-function mutation comprises a deletion of all or a portion of exon 2 or exon 4 of the SLC41A2 gene. In some embodiments, the loss-of-function mutation comprises a deletion of all or a portion of exon 2 of the SLC41 A2 gene, a coding sequence deletion in codon 4 of the SLC41 A2 gene, a frameshiftAtty. Dckt.: STAN-2271 WO Client Ref.: S25-149mutation in codon 4 of the SLC41A2 gene, or any combination thereof. In some embodiments, the CRISPR system comprises Cas9 or Cas12a. In some embodiments, the CRISPR system comprises a single guide RNA (sgRNA) targeting a Cas nuclease to the SLC41 A2 gene. In some embodiments, the sgRNA specifically binds to a target sequence in a target region of exon 2 of the SLC41 A2 gene. In some embodiments, the target region comprises the sequence of SEQ ID NO:8. In some embodiments, the sgRNA comprises a sequence selected from the group consisting of SEQ ID NOS:1 -3 or a sequence displaying at least about 80-100% sequence identity thereto, including any percent identity within this range, such as 81 , 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99% sequence identity thereto, wherein the sgRNA is capable of targeting a Cas nuclease to a target site in exon 2 of the SLC41 A2 gene.

[0037] In another aspect, a method of producing an iSANC is provided, the method comprising genetically modifying a host iSANC or an induced pluripotent stem cell from which the host iSANC is produced to introduce a loss-of-function mutation into the SLC41A2 gene, wherein the genetically modified iSANC comprising the loss-of-function mutation in the SLC41A2 gene has slowed rhythmic calcium transients and magnesium transients compared to an iSANC having a wild-type SLC41 A2 gene.

[0038] In certain embodiments, genetically modifying the host iSANC or the iPSC from which the host iSANC is produced comprises using a clustered regularly interspaced short palindromic repeats (CRISPR) system, a transcription activator- 1 ike effector nuclease (TALEN), or a zinc- finger nuclease to introduce the loss-of-function mutation into the SLC41A2 gene. In some embodiments, the CRISPR system, TALEN, or zinc-finger nuclease is used to introduce the loss- of-function mutation into one allele of the SLC41A2 gene. In some embodiments, the CRISPR system, TALEN, or zinc-finger nuclease is used to introduce the loss-of-function mutation into both alleles of the SLC41A2 gene. In certain embodiments, the loss-of-function mutation is an exon deletion, a frameshift mutation, a missense mutation, or a nonsense mutation. In some embodiments, the loss-of-function mutation comprises a deletion of all or a portion of exon 2 or exon 4 of the SLC41A2 gene. In some embodiments, the loss-of-function mutation comprises a deletion of all or a portion of exon 2 of the SLC41 A2 gene, a coding sequence deletion in codon 4 of the SLC41A2 gene, a frameshift mutation in codon 4 of the SLC41A2 gene, or any combination thereof. In some embodiments, the CRISPR system comprises Cas9 or Cas12a. In some embodiments, the CRISPR system comprises a single guide RNA (sgRNA) targeting a Cas nuclease to the SLC41 A2 gene. In some embodiments, the sgRNA specifically binds to a target sequence in a target region of exon 2 of the SLC41A2 gene. In some embodiments, the targetAtty. Dckt.: STAN-2271 WO Client Ref.: S25-149region comprises the sequence of SEQ ID NO:8. In some embodiments, the sgRNA comprises a sequence selected from the group consisting of SEQ ID NOS:1-3 or a sequence displaying at least about 80-100% sequence identity thereto, including any percent identity within this range, such as 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99% sequence identity thereto, wherein the sgRNA is capable of targeting a Cas nuclease to a target site in exon 2 of the SLC41 A2 gene.BRIEF DESCRIPTION OF THE DRAWINGS

[0039] FIGS. 1A-1I. Systematic cardiovascular screening of mouse lemurs by point-of-care electrocardiography (ECG). (FIG. 1A) Portable human ECG monitor (KardiaMobile®, AliveCor) coupled to a smartphone app designed for ECG recording in real time at home. Device measures electric field differences between fingers placed on each conductive electrode pad that result from myocardial cell depolarization and repolarization spreading across the heart during each cardiac cycle (heartbeat). (FIG. 1B) Real time ECG recording of a resting (unanesthetized) mouse lemur as in FIG. 1 A except the lemur’s hands contact the electrode pads. Image is a single frame taken from a live video recording. (FIG. 1C) Custom modified KardiaMobile 6L® ECG monitor with a third electrode pad (brown) on its surface. This enables 6-lead mouse lemur ECG detection (as shown in panel e) when the lemur’s foot contacts the third pad while its hands contact the other two pads as above. (FIG. 1D) (Top) Human cardiac conduction system (black). The sinoatrial node (SAN) pacemaker in the right atrium (RA) fires rhythmically to initiate each cardiac cycle, and this contraction signal spreads to the atrioventricular node (AVN) and through the His- Purkinje system (right and left bundle branches (RBB and LBB) and Purkinje fibers) to initiate contraction of the right and left ventricles (RV, LV). (Bottom) The six classical ECG limb leads. Electric field changes caused by the spreading wave of myocardial depolarization and repolarization during the cardiac cycle are captured by the three electrode pads and integrated to derive the six electrical vectors shown: limb leads I, II, III, aVR, aVL, and aVF. (FIG. 1E) A 6-lead lemur ECG trace (2 seconds) captured by the customized device in FIG. 1C. Scale bar for ECG trace, 0.2 seconds, 0.5 millivolts. (FIG. 1F) Single cardiac ECG waveforms of human, lemur, and mouse captured with the six lead device. The three waves correspond to atrial depolarization (P), ventricular depolarization (QRS), and ventricular repolarization (T). Note the mouse lemur waveform resembles the human waveform, but in mouse there is no discrete T wave (fused with QRS). Scale bars for ECG traces, 50 milliseconds, 0.2 millivolts. (FIG. 1G) Scheme of the lemur ECG screen and overview of results. (FIG. 1H) ECG tracing (2 seconds) of lemur normal sinusAtty. Dckt.: STAN-2271 WO Client Ref.: S25-149rhythm. (FIG. 11) ECG tracings of the four physiological variations detected: three heart rate variations (sinus tachycardia, sinus bradycardia, sinus arrhythmia) and J-point elevation, a typically benign waveform variant indicating early repolarization in younger individuals. Dots (sinus arrhythmia), R-waves of each heartbeat to highlight the beat-to-beat variability from rapid changes in vagal tone during inspiration and expiration. Dots (J-point elevation), elevated takeoff of each ST- segment (see inset).

[0040] FIGS. 2A-2B. Eight cardiac arrhythmias and other pathologies identified in lemur ECG screen. ECG traces (2 seconds) and waveform pathologies (insets at right) of ECG variants detected in the screen that resemble ECG abnormalities of human arrhythmias and pathologies, the basis for the assigned names of the lemur ECG variants. FIG. 2A. Three pathologies that arise in the atria. FIG. 2B. Five ventricular pathologies. Lemur ID, age (if known) when ECG was taken, and heart rate (HR, in beats per minute, bpm, if integral to the arrhythmia diagnosis) are indicated above each trace. Dots, pathological beats. Gray shading, pathological beats magnified at right to highlight abnormality. Atrial fibrillation (Afib): Dots mark the R-wave of abnormal beats. Note the variable intervals between R-waves (e.g., dashed lines), illustrating the classic irregularly irregular rhythm of atrial fibrillation. Inset, most pronounced irregularity. Note lack of sinus P- waves, another hallmark of Afib. Premature atrial contraction (PAC): early beats (dots) that arise from an ectopic atrial focus and commonly result in a compensatory pause (dashed extension from dot) before the next normal beat (+) resumes. Inset, normal sinus beat followed by a PAC. Note absence of the ectopic P-wave of the latter, which is fused with the T-wave of the former. Sick sinus syndrome (SSS): an episodic, substantially reduced heart rate (bradycardia) that does not meet physiological need (see FIG. 4). Premature ventricular contraction (PVC): each PVC (dot) arises from an ectopic ventricular focus. Inset, classic wide and unusual shape of the QRS- complex, which is followed by a normal sinus beat. Non-sustained ventricular tachycardia (NSVT): the three consecutive PVCs (dots) represent an episode of NSVT. ST depression (STD): each beat shows ST-segment depression (dots), in which the initiation of the ST-segment is below the isoelectric point (dashed line in inset). Inverted T-wave (iTW): each beat shows an iTW (dots), in which T-wave orientation is flipped 180 degrees from normal (inset). ST elevation (STE): each beat shows ST-segment elevation (dots above trace), in which initiation of the ST- segment is above the isoelectric point (dashed line, inset). When STE is accompanied by a small R-wave (+ below trace), this can represent an evolving myocardial infarction (in humans). Scale bar for ECG traces, 0.1 seconds, 0.2 millivolts.Atty. Dckt.: STAN-2271 WO Client Ref.: S25-149

[0041] FIG. 3. Seven potentially pathologic cardiac variants identified in the lemur ECG screen.ECG traces (2 secs) of lemur cardiac variants identified in the ECG screen as in FIG. 2 but resembling human variants that can be pathological but require additional clinical testing for diagnosis. Supraventricular tachycardia (SVT): a substantially increased heart rate with no P- waves detected (dots mark R-wave of abnormal beats). Wandering atrial pacemaker (WAP): an irregularly irregular rhythm (dots) in which different (“wandering”) ectopic atrial foci initiate beats. Note the variable R-R intervals (dashed lines show the longest intervals) and three distinct P- wave morphologies (numbered 1 - 3) resulting from the wandering foci. Right bundle branch block (RBBB): prolonged QRS-complex (dots) from delayed depolarization through the right bundle branch. Inset, single cardiac beat showing an abnormal R-S-R’ of a prolonged QRS complex (bracket). Large S and small R-waves (S>R): amplitude of S-wave (dots) is greater than that of R-wave. Isolated small R-waves (Small R): small R-wave amplitude (dots) relative to the T-wave. Tall R-waves (Tall R): tall R-wave (dots) relative to the P- and T-waves. peaked T- waves (pTWs): T-wave amplitude (dots) approaches that of the R-wave. Scale bar for ECG traces, 0.1 seconds, 0.2 mV.

[0042] FIGS. 4A-4B. Lemur sick sinus syndrome pedigree. FIG. 4A. Longitudinal ECG studies (2 sec tracings) of three lemurs (name / ID number at left) with symptomatic sinus bradycardia (SB). Above each trace is the age when the ECG was taken, diagnosed ECG abnormalities and associated pathologies (SB, sinus bradycardia; ST, sinus tachycardia; STD, ST-segment depression; iTW, inverted T-wave), heart rate (HR, in bpm), and abnormal signs on physical exam. All three lemurs have tachy-brady syndrome (TBS), in which all ECGs showed either SB or ST (and none showed normal sinus rhythm). Dots, individual heartbeats during SB or ST.300AB and 300AC manifest intermittently with a pathological ECG triad of SB (dots), STD (tick, not indicated for 300AC), and iTW (+). Scale bar, 0.1 seconds, 0.2 mV. FIG. 4B. Six generation pedigree of a lemur family that includes five individuals (the above three plus 261 BBA and 241 EA) with symptomatic SB and the associated pathologies or symptoms indicated by black fill of the individual’s symbol (see legend). Presumed carriers (inferred from the pedigree based on autosomal recessive inheritance and supported by genotyping in FIG. 5) are indicated by a central dot in the symbol. ?0, ?1 , ?2, identity of father not yet resolved. Four lemurs were found dead in their cages at a young age: 261 BA (3.6 yrs), 385A (2.9 yrs), 314C (2.2 yrs), 262DC (2.3 yrs). X1 , X2, X3, X4, lemurs that died several days after birth (before naming). *, 381 C diagnosed with iTW (age 1.6), persistent tachycardia, weakness / lethargy. **, 262DBA diagnosed with PACs and low activity (age 3.5).Atty. Dckt.: STAN-2271 WO Client Ref.: S25-149

[0043] FIGS. 5A-5D. Genetic mapping of lemur sick sinus syndrome and the candidate genes in the mapped interval. (FIG. 5A) Genetic mapping scheme. Whole genome sequencing was done on: 6 of the 7 SSS lemurs identified in the screen, 5 presumed carriers and unaffected family members, and 24 unaffected (outside immediate family) controls in the lab colony (Table 4). Single nucleotide sequence polymorphisms (SNP) and insertion / deletion (indel) polymorphisms (variants) were identified across the genome (~45M total), and those that co-segregated with the SSS trait based on autosomal recessive inheritance were identified (365 variants). The positions of 354 linked variants are shown on the mouse lemur diploid genome (32 autosomes, 1 pair of sex chromosomes, and a haploid mitochondrial genome); the remaining 11 variants mapped to two unplaced scaffolds (not shown, see Table S3). The total number of variants identified on each chromosome (in millions, M), regardless of SSS linkage, is shown below each chromosome. The map locations of the lemur orthologues of the two genes (SCN5A, HCN4) known to cause human SSS are indicated. (FIG. 5B) Expanded view and graphic (Integrative Genomics Viewer) showing the variant genotypes of the 35 sequenced lemurs (rows) in the 1.4 Mb genomic interval on chromosome 7 containing the 352 variants linked to SSS (shaded columns). (Many variants are tightly clustered along the chromosome so at this resolution appear as a shaded block rather than a shaded thin line.) Each row in the plot shows the genotype (homozygous wild-type reference, light gray shading; heterozygous wild-type / variant, dark gray; homozygous variant, black) of one of the 35 sequenced lemurs whose SSS phenotype / carrier status is indicated at left. Note that all the SSS lemurs are homozygous variant (black fill) in this interval and all the carriers are heterozygous, whereas the unaffected controls are either homozygous wild-type reference or heterozygous, as expected for an autosomal recessive trait. The locations of the 21 genes (horizontal black bars) in the interval are shown below the graphic; thicker portions of the bars indicate exons, and arrowheads below bar show direction of transcription. The 9 candidate genes associated with or neighboring 1 or more of the 352 SSS-linked variants are named and described in the table below along with the number of associated variants (shown in parentheses at top of the table along with the number of intergenic variants). The other 12 genes (P1 to P12) with no associated or neighboring intergenic variants are similarly detailed in Table 5. The gene descriptions in the table include (top to bottom): gene product function (Gene product), lemur heart cell types in which the gene is highly and differentially expressed (Lemur heart expression) from the lemur transcriptomic atlas42 (“-” indicates gene is not detected or differentially expressed), and mouse knockout phenotypes of the orthologous gene in published literature (Mouse KO) or determined by the International Mouse Phenotyping Consortium (Mouse IMPC).Atty. Dckt.: STAN-2271 WO Client Ref.: S25-149(FIG. 5C) Structures of lemur SLC41A2 gene (top) and spliced mRNA (bottom). Numbers, exons 1-11. White / no shading, protein coding sequence in mRNA; gray shading, non-coding sequences (5’- untranslated region, 5’UTR; 3’ untranslated region, 3’UTR). (FIG. 5D) Map of the 33,108 bp intergenic region between 3’ end of SLC41A2 and 3’ end of CHST11 showing positions of the 20 SSS-linked variants in this region. Numbers (in parentheses) indicate the number of linked variants clustered at that position; the 2 variants downstream and associated with SLC41A2 (as assigned by SnpEff) are indicated by an asterisk; the other 18 are assigned as intergenic variants. Of these 20 variants, 10 are conserved between lemur and human including one of the SLC41A2- associated variants (FIG. 10).

[0044] FIGS. 6A-6G. Expression and knockout of SLC41A2 in human sinoatrial node cells. (FIG.6A) Structures of human SLC41A2 gene (top) and spliced mRNA (bottom) and the site of the introduced SLC41A2 gene knockout (KO) in human sinoatrial node cells (iSANCs). The SLC41A2 KO (SLC41A2- / -) is an 118 bp deletion in exon 2, causing an early truncation and frameshift of the coding sequence (FIG. 12B), which was created in human induced pluripotent stem cells (iPSCs) by CRISPR-Cas9-mediated gene targeting prior to their differentiation into iSANCs, as described in panel c and FIGS. 12A, 12B. Numbers, exons 1-10. Dark blue shading, protein coding sequence in mRNA; light blue shading, non-coding sequences (5’-untranslated region, 5’UTR; 3’ untranslated region, 3’UTR). (FIG. 6B) Model of the membrane topology of human SLC41 A2 with 11 transmembrane (TM) domains, modified from Sahni et al.44,47 based on flow cytometry of epitope tagged SLC41A2 heterologously expressed in DT40 chicken cells. Sequence comparisons of lemur, human, and mouse SLC41 A2 are shown in FIG. 11. (FIG. 6C) Experimental scheme and timeline for constructing human SLC41A2-I- iSANCs and analyzing the effects of the gene knockout (see Methods for details). (FIG. 6D) Immunofluorescence photomicrographs of wild-type iSANCs co-stained for SLC41A2 (green) and phospholamban (PLN, red), a sarcoplasmic reticulum (SR) transmembrane protein, with DAPI counterstain (blue, nuclei). Insets, close up of boxed region showing a single iSANC. Note colocalization of SLC41 A2 with SR-marker PLN. No SLC41A2 staining was detected in SLC41A2- / - iSANCs (FIG. 12c), as expected for the early truncation and frameshift deletion. Scale bar, 10 pm. n=3 technical replicates. (FIG. 6E) Functional calcium imaging with Fluo-4 AM of cultured wild-type control and SLC41A2- / - SANCs. Representative traces (left, amplitude normalized to Fpeak / FO) showing the rhythmic calcium transients (spikes) of wild-type SANCs and the slower firing rate of SLC41A2- / - SANCs. Violin plots quantify the effects of SLC41A2- / - knockout on calcium transient firing rate, amplitude, time to peak, tau decay time, and duration at 50%. Dark dotted line, median; lightAtty. Dckt.: STAN-2271 WO Client Ref.: S25-149dotted lines, quartiles. n= number of cells analyzed (28 WT, 37 SLC41A2- / - SANCs); p-values (two-tailed with Mann-Whitney test): *, <0.05; **, <0.005; ***, <0.0005; <0.00005; ns, not significant. Scale bar for tracings, 1 second, 1 normalized units. (FIG. 6F) Functional magnesium imaging with Mag-Fluo-4 AM of cultured wild-type control and SLC41A2- / - SANCs. Representative traces (top, amplitude normalized to Fpeak / FO) showing rhythmic magnesium transients of wild-type SANCs (top left), and three examples of altered waveforms of SLC41A2- / -SANCs (bottom left, ectopic, stunted, and irregular mini-transients; top right, ectopic, stunted transients appearing to fuse with normal transients to produce an irregular rhythm; bottom right, transients with delayed time to peak, tau decay time, and duration at 50%). Irregular rhythm plot quantifies % of SANCs that manifest mini-transients. Violin plots as above quantify the effects of SLC41A2- / - knockout on magnesium transient firing rate, amplitude, time to peak, tau decay time, and duration at 50%. n=number of SANCs analyzed (27 WT, 30 SLC41A2- / - iSANCs) (statistics and significance as above, except p-value for irregular rhythm plot determined by two-tailed Fisher’s exact test). Scale bar for tracings, 1 second, 0.2 normalized units. (FIG. 6G) Model of SLC41A2 and magnesium dynamics in human SANCs, the cardiac pacemaker cells (modified from Weisbrod D et al.50). Current models for cyclical firing of SANCs (“automaticity”) invokes two cyclically-active and coupled cellular “clocks”: a voltage membrane clock and an intracellular, sarcoplasmic reticulum-based calcium clock49-51. The cardiac cycle begins by hyperpolarization activation of plasma membrane channel HCN4 that initiates the membrane clock (which generates the If funny current and causes Na+ influx, alone or in combination with other Na+ influx channels including NACLN, TRPM7, TRPM4, and T- type calcium channels (CaT: CACNA1G and CACNA1H that result in Ca2+influx) and calcium clock (the SR-transmembrane ryanodine receptor, RYR1, which pumps Ca2+from the SR into the cytoplasm and activates the plasma membrane Na+-Ca2+exchanger (NCX, encoded by SLC8) that in turn exchanges the cytoplasmic Ca2+for Na+into the cell). The resulting increase in membrane potential produced by the coupled clocks activates plasma membrane L-type calcium channels (LTGC), causing a rapid but transient Ca2+influx (calcium transient, gold sunburst) and the upstroke of the action potential (phase 0 depolarization), triggering each cycle of cardiac contraction. Much like the dynamic regulation of calcium, we observed cyclical magnesium transients (blue sunburst) in wild-type SANCs and slower and broader calcium transients and altered magnesium transient dynamics and waveforms in SLC41A2- / - SANCs. We hypothesize a third clock, the “magnesium clock”, which interacts with and influences the membrane and calcium clocks, and involves the SLC41 A2 magnesium transporter and dynamic regulation of the intracellular distribution of Mg2+betweenAtty. Dckt.: STAN-2271 WO Client Ref.: S25-149the sarcoplasmic reticulum and cytosol. Transient high levels of cytosolic Mg2+counteract the Ca2+and thereby slow the pacemaker firing rate, perhaps through the known ability of Mg2+to directly compete with Ca2+for binding to the key L-type calcium channel (LTCQ72-75.

[0045] FIG. 7. Extended lemur sick sinus syndrome pedigree. Extension of the lemur sick sinus syndrome (SSS) pedigree (FIG. 4) showing the relationship to the seventh affected mouse lemur (397C, diagnosed at 1.5 yrs). Note the relationship between 397C and 300A, her great great aunt and an SSS-carrier in the main SSS pedigree (FIG. 4). Further pedigree construction and genome sequencing are required to resolve the relationship between the primary SSS pedigree and 3970 in this extended pedigree. ?3, ?4, ?5, paternities not yet resolved (see Methods). His sister (397B), was notably found to have decreased grip strength (**, 397B, at 1.5 yrs).

[0046] FIG. 8. Lemur family with premature atrial contractions and atrial fibrillation. Two of the lemurs diagnosed with premature atrial contractions (PACs) are brothers: 169AFA was diagnosed at age 2.6 yrs, and 169AFB at 3.1 yrs. 169AFB was subsequently diagnosed with paroxysmal atrial fibrillation (Afib, 4.6 yrs). In humans, PAOs are a known precursor to Afib.

[0047] FIGS. 9A-9B. Mouse SLC41A2 knockout deep phenotyping by KOMP2. FIG. 9A. Results of deep organ-wide phenotyping of SLC41A2- / - mice (C57BL / 6NJ- Slc41a2em1 (IMPC)J / Mm ax) generated and analyzed by the Knockout Mouse Phenotyping Program (KOMP2) at The Jackson Laboratory43,76 and reproduced here. The SLC41A2- / - knockout is a CRISPR / Cas9-generated 467 bp deletion encompassing SLC41A2 exon 5 and a flanking 322 bp intronic region that includes the splice donor and acceptor. Deep phenotyping of 348 SLC41A2- / - mice by the assays indicated surveying >50 traits revealed a single abnormality: an adult cardiovascular conduction system defect manifesting as a widened QRS complex on ECG (lone black diamond on right). Subsequent phenotyping has also detected isolated skin and vocalization abnormalities43. Note that no other ECG abnormalities (black diamonds: heart rate, HR; RR interval, RR; PR interval, PR; ST segment, ST; abnormal rhythms, Abnormal ECG detected) were detected; the absence of HR and RR interval abnormalities are notable here because they indicate normal SA node pacemaker function in the SLC41A2 knockout. FIG. 9B. Quantification of the QRS interval in ECGs of adult SLC41A2 wild-type (WT) and homozygous SLC41A2- / - knockout (HOM) female and male mice. n=164 female WT, 169 male WT, 10 female HOM, 5 male HOM; p-values (two- tailed Fisher’s exact test), ms, milliseconds.

[0048] FIGS. 10A-10B. DNA sequence conservation between lemur, human, and mouse in the SLC41 A2-CHST1 intergenic region. FIG. 10A. Cross-species DNA sequence comparison using NCBI nucleotide discontiguous Mega BLAST+ (v. 2.16.0) of the lemur SLC41A2-CHST11Atty. Dckt.: STAN-2271 WO Client Ref.: S25-149intergenic region (33,108 bp query, top, see FIG. 5D) with the corresponding intergenic region of human (39,785 bp) and mouse (34,972 bp). The positions of the 20 lemur SSS-linked variants are indicated in parentheses above the line representing the lemur intergenic region, and the 10 that are conserved in humans are similarly indicated below the bar representing the human intergenic region. The mouse intergenic region is divergent from the primates, and none of the 20 SSS-linked variants are conserved. Query Cover, proportion of the lemur intergenic sequence that aligned to the human or mouse intergenic sequence. % Identity, percentage of base pairs that are identical within the aligned regions. Colors of the bars, discontiguous Mega BLAST alignment scores for the corresponding regions (higher scores represent better alignment). FIG.10B. Lemur (SEQ ID NO:10) versus human (SEQ ID NO:11) nucleotide sequences and conservation (vertical lines) surrounding each of the 10 conserved SSS-linked variants (boxed). Numbers (at left), positions of the sequence shown in the respective intergenic region.

[0049] FIGS. 11A-11C. Pairwise cross-species alignments (NCBI protein blastp, BLAST+ v.2.16.0+) of SLC41A2 protein sequences of lemur (SEQ ID NO:5), human (SEQ ID NO:6), and mouse (SEQ ID NO:7). Values above each alignment show percent amino acid identity.

[0050] FIGS. 12A-12C. Structure and confirmation of CRISPR / Cas9 knockout of human SLC41A2. FIG. 12A. Nucleotide sequences of the sgRNAs (“multi-guide”, SEQ ID NOS:1-3) designed and used to target human SLC41A2 for gene knockout in iPSCs (FIGS. 6A, 6C), and the Sanger sequencing primer (SP, SEQ ID NO:4) used to verify the deletion. FIG. 12B. Map of the first coding exon (exon 2) of human SLC41A2 (exon 2 sequence (SEQ ID NO:8) with translation (SEQ ID NO:9) showing the hybridization positions of each sgRNA (G1, 2, 3) and the sequencing primer (SP). Light gray, portion of the 5’-untranslated region (5’UTR) in exon 2. Dark gray, coding sequence. Enlarged region below shows Benchling alignment (Multiple Alignment using Fast Fourier Transform, MAFFT v. 7.505) of amplicons generated by Sanger sequencing of genomic DNA harvested from control WT iSANCs (similarly derived from parental wild-type iPSC) and the SLC41A2- / - iSANC knockout clone created and used in this study. Note CRISPR / Gas9 targeting resulted in a 118 bp deletion in exon 2 of SLC41A2- / - iSANCs, producing a coding sequence deletion and frameshift at codon 4 resulting in a translation termination codon (STOP) five codons later (residue 9). FIG. 12C. Fluorescence micrographs of control wild-type (top) and SLC41A2- / - knockout (bottom) iSANCs co-stained for SLC41A2 and sarcoplasmic reticulum marker PLN, with DAPI counterstain (nuclei, blue). SLC41A2 staining is absent in knockout mutant cells. Scale bar, 10 pm. n=3 technical replicates.Atty. Dckt.: STAN-2271 WO Client Ref.: S25-149DETAILED DESCRIPTION

[0051] Primate animal models of cardiac arrhythmias and methods of using such primate animal models for research and development and screening of therapeutics for treating cardiac arrhythmias are provided. In particular, lemurs were identified for use as animal models having different naturally occurring arrhythmias resembling human electrocardiographic (ECG) pathologies. In addition, genetically modified non-human primates and induced pluripotent stem cell-derived sinoatrial nodal pacemaker cells (iSANCs) comprising a loss-of-function mutation in an SLC41A2 gene linked to atrial arrhythmia and sinus node dysfunction and their use in screening therapeutics for treating atrial arrhythmia and sinus node dysfunction are also provided.

[0052] Before the methods and animal models and cellular models are further described, it is to be understood that this invention is not limited to a particular method or animal model described, as such may, of course, vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting, since the scope of the present invention will be limited only by the appended claims.

[0053] Where a range of values is provided, it is understood that each intervening value, to the tenth of the unit of the lower limit unless the context clearly dictates otherwise, between the upper and lower limits of that range is also specifically disclosed. Each smaller range between any stated value or intervening value in a stated range and any other stated or intervening value in that stated range is encompassed within the invention. The upper and lower limits of these smaller ranges may independently be included or excluded in the range, and each range where either, neither or both limits are included in the smaller ranges is also encompassed within the invention, subject to any specifically excluded limit in the stated range. Where the stated range includes one or both of the limits, ranges excluding either or both of those included limits are also included in the invention.

[0054] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, some potential and preferred methods and materials are now described. All publications mentioned herein are incorporated herein by reference to disclose and describe the methods and / or materials in connection with which the publications are cited.

[0055] It is understood that the present disclosure supersedes any disclosure of an incorporated publication to the extent there is a contradiction.Atty. Dckt.: STAN-2271 WO Client Ref.: S25-149

[0056] As will be apparent to those of skill in the art upon reading this disclosure, each of the individual embodiments described and illustrated herein has discrete components and features which may be readily separated from or combined with the features of any of the other several embodiments without departing from the scope or spirit of the present invention. Any recited method can be carried out in the order of events recited or in any other order which is logically possible.

[0057] As used herein the singular forms "a", "an", and "the" include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to "an agent" includes a plurality of such agents and reference to "the inhibitor" includes reference to one or more inhibitors and equivalents thereof, e.g., antagonists, known to those skilled in the art, and so forth.

[0058] The publications discussed herein are provided solely for their disclosure prior to the filing date of the present application. Nothing herein is to be construed as an admission that the present invention is not entitled to antedate such publication by virtue of prior invention. Further, the dates of publication provided may be different from the actual publication dates which may need to be independently confirmed.

[0059] The term "about," particularly in reference to a given quantity, is meant to encompass deviations of plus or minus five percent.

[0060] The terms “arrhythmia”, “cardiac arrhythmia”, and “heart arrhythmia” are used interchangeably to refer to an abnormal or irregular heartbeat. A cardiac arrhythmia may include an abnormal heartbeat rate such as an abnormally fast heartbeat (tachycardia, e.g., greater than 100 beats per minute (bpm) for a human, greater than 553 bpm for M. murinus, greater than 458 bpm for M. rufus, greater than 421 bpm for M. nova) or an abnormally slow heartbeat (bradycardia, e.g., less than 60 bpm for a human, less than 309 bpm for M. murinus, less than 260 bpm for M. rufus, less than 237 bpm for M. nova), or an irregular or erratic heartbeat rhythm (e.g., pauses, premature or late heartbeats, or extra beats). An irregular or erratic heartbeat rhythm may be caused, for example, by premature atrial contractions, premature ventricular contractions, and / or premature junctional contractions. The term cardiac arrhythmia encompasses atrial arrhythmias and ventricular arrhythmias such as, but not limited to, sinus bradycardia, sinus tachycardia, ventricular tachycardia, non-sustained ventricular tachycardia, supraventricular tachycardia, tachycardia-bradycardia syndrome, atrial fibrillation, premature atrial contractions, premature ventricular contractions, sinus node dysfunction (e.g., sick sinus syndrome), or wandering atrial pacemaker. The arrhythmia may be associated with ST-segment depression, inverted T-waves, ST-segment elevation, ST-segment depression, small R-waves, tall R-waves, large S-waves andAtty. Dckt.: STAN-2271 WO Client Ref.: S25-149small R-waves, peaked T-waves, a right bundle branch block, a prolonged QRS-complex, or any combination thereof.

[0061] As used herein, the term “determining” refers to both quantitative and qualitative determinations and as such, the term “determining” is used interchangeably herein with “assaying,” “measuring,” and the like.

[0062] "Substantially" or "essentially" means nearly totally or completely, for instance, 95% or greater of some given quantity.

[0063] “Isolated” refers to an entity of interest that is in an environment different from that in which it may naturally occur. “Isolated” is meant to include entities that are within samples that are substantially enriched for the entity of interest and / or in which the entity of interest is partially or substantially purified.

[0064] "Substantially purified" generally refers to isolation of a substance (e.g., compound, small molecule, drug, polynucleotide, protein, polypeptide, antibody, aptamer, inhibitor, antagonist, agonist) such that the substance comprises the majority percent of the sample in which it resides. Typically in a sample, a substantially purified component comprises 50%, preferably 80%-85%, more preferably 90-95% of the sample. Techniques for purifying polynucleotides and polypeptides of interest are well-known in the art and include, for example, ion-exchange chromatography, affinity chromatography and sedimentation according to density.

[0065] As used herein, "reference sequence" is a defined sequence used as a basis for sequence comparison. A reference sequence may be a subset or the entirety of a specified sequence; for example, as a segment of a full-length gene, exon, or intron, or a full-length protein or protein fragment. A reference sequence can comprise, for example, a sequence identifiable in a database such as GenBank and UniProt and others identifiable to those skilled in the art.

[0066] Algorithms and programs for comparing primary biological sequence information between any two sequences are identifiable by a skilled person. Non-limiting examples of such mathematical algorithms are the algorithm of Myers and Miller (Myers and Miller 1988), the local homology algorithm of Smith et al. (Smith and Waterman 1981); the homology alignment algorithm of Needleman and Wunsch (Needleman and Wunsch 1970)); the search-for-similarity- method of Pearson and Lipman (Pearson and Lipman 1988).); the algorithm of Karlin and Altschul (Karlin and Altschul 1990)., modified as in Karlin and Altschul (Karlin and Altschul 1993)). Computer implementations of these mathematical algorithms can be utilized for comparison of sequences to determine sequence identity. Such implementations include, but are not limited to: CLUSTAL in the PC / Gene program (available from Intelligenetics, Mountain View, Calif.); theAtty. Dckt.: STAN-2271 WO Client Ref.: S25-149ALIGN program (Version 2.0) and GAP, BESTFIT, BLAST, FASTA (Pearson and Lipman 1988).);, and TFASTA in the Wisconsin Genetics Software Package, Version 8 (available from Genetics Computer Group (GCG), 575 Science Drive, Madison, Wis., USA). Alignments using these programs can be performed using the default parameters and allowing a user to identify database sequences that resemble the reference sequence (query sequence) above a certain threshold of confidence.

[0067] Algorithms and programs for comparing primary biological sequence information between any two sequences typically provide an output comprising percent identity between the sequence retrieved and the reference sequence.

[0068] A person skilled in the art would understand that identity between sequences is typically measured by a process that comprises the steps of aligning the two polypeptide or polynucleotide sequences to form aligned sequences, then detecting the number of matched characters, i.e. characters similar or identical between the two aligned sequences, and calculating the total number of matched characters divided by the total number of aligned characters in each polypeptide or polynucleotide sequence, including gaps. The similarity result is expressed as a percentage of identity.

[0069] As used herein, "percentage of sequence identity" means the value determined by comparing two optimally aligned sequences over a comparison window, wherein the portion of the polynucleotide sequence in the comparison window may comprise additions or deletions (gaps) as compared to the reference sequence (which does not comprise additions or deletions) for optimal alignment of the two sequences. The percentage is calculated by determining the number of positions at which the identical nucleic acid base or amino acid residue occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the window of comparison, and multiplying the result by 100 to yield the percentage of sequence identity.

[0070] The term "genetic modification" means any process that adds, deletes, alters, or disrupts an endogenous nucleotide sequence and includes, but is not limited to viral mediated gene transfer, liposome mediated transfer, transformation, transfection and transduction, e.g., viral mediated gene transfer such as the use of vectors based on DNA viruses such as lentivirus, adenovirus, retroviruses, adeno-associated virus and herpes virus. Also included are methods of genome engineering using, for example CRISPR / CAS9 systems for modification.

[0071] "Variant" refers to polypeptides having amino acid sequences that differ to some extent from a native sequence polypeptide. Ordinarily, amino acid sequence variants will possess atAtty. Dckt.: STAN-2271 WO Client Ref.: S25-149least about 80% sequence identity, more preferably, at least about 90% homologous by sequence. The amino acid sequence variants may possess substitutions, deletions, and / or insertions at certain positions within the reference amino acid sequence.

[0072] “Introducing,” “introduce,” “introduced” (and grammatical variations thereof) in the context of a polynucleotide and / or polypeptide of interest means presenting a nucleotide sequence of interest (e.g., polynucleotide, a nucleic acid construct, and / or a guide nucleic acid) and / or polypeptide of interest to a host organism or cell of said organism (e.g., a mammalian cell) in such a manner that the nucleotide sequence and / or polypeptide gains access to the interior of a cell.

[0073] A “heterologous” or a “recombinant” nucleotide sequence is a nucleotide sequence not naturally associated with a host cell into which it is introduced, including non-naturally occurring multiple copies of a naturally occurring nucleotide sequence. For example, a heterologous polynucleotide encoding a SLC41A2 protein or portion thereof can be a nucleic acid sequence that is not naturally present in a cell in which it is present and / or can be an additional nucleic acid sequence compared to the presence of a naturally occurring nucleotide sequence in a cell in which it is present.

[0074] The terms “specific binding,” “specifically binds,” “selectively binds,” and the like, refer to non-covalent or covalent preferential binding to a molecule relative to other molecules or moieties in a solution or reaction. In some embodiments, the affinity of one molecule for another molecule to which it specifically binds is characterized by a KD (dissociation constant) of 10-5M or less (e.g., 106M or less, 107M or less, 108M or less, 109M or less, 1010M or less, 1011M or less, 1012M or less). "Affinity" refers to the strength of binding, increased binding affinity being correlated with a lower KD. In an embodiment, affinity is determined by surface plasmon resonance (SPR), e.g., as used by Biacore systems. The affinity of one molecule for another molecule is determined by measuring the binding kinetics of the interaction, e.g., at 25°C.

[0075] By “test agent,” “candidate agent,” and grammatical equivalents herein, which terms are used interchangeably herein, is meant any molecule including macromolecules (e.g., proteins, antibodies, polynucleotides), small molecules (e.g., 5-1000 Da, 100-750 Da, 200-500 Da, or less than 500 Da in size), organic or inorganic molecules, drugs, etc. that are to be tested for activity (e.g., specifically binding to and altering activity of the SLC41A2 magnesium transporter or another magnesium transporter; restoring normal heartbeat rate or rhythm, or restoring normal calcium or magnesium flux) in a subject assay.Atty. Dckt.: STAN-2271 WO Client Ref.: S25-149

[0076] "Pharmaceutically acceptable excipient or carrier" refers to an excipient that may optionally be included in the compositions of the invention and that causes no significant adverse toxicological effects to the patient.

[0077] "Pharmaceutically acceptable salt" includes, but is not limited to, amino acid salts, salts prepared with inorganic acids, such as chloride, sulfate, phosphate, diphosphate, bromide, and nitrate salts, or salts prepared from the corresponding inorganic acid form of any of the preceding, e.g., hydrochloride, etc., or salts prepared with an organic acid, such as malate, maleate, fumarate, tartrate, succinate, ethylsuccinate, citrate, acetate, lactate, methanesulfonate, benzoate, ascorbate, para-toluenesulfonate, palmoate, salicylate and stearate, as well as estolate, gluceptate and lactobionate salts. Similarly, salts containing pharmaceutically acceptable cations include, but are not limited to, sodium, potassium, calcium, aluminum, lithium, and ammonium (including substituted ammonium).

[0078] By "subject" is meant any member of the subphylum Chordata, including, without limitation, humans and other primates, including non-human primates such as lemurs, chimpanzees and other apes, and monkey species; farm animals such as cattle, sheep, pigs, goats and horses; domestic mammals such as dogs and cats; laboratory animals including rodents such as mice, rats and guinea pigs; birds, including domestic, wild and game birds such as chickens, turkeys and other gallinaceous birds, ducks, geese, and the like.

[0079] The term "animal" is used herein to include all vertebrate animals, except humans. The term also includes animals at all stages of development, including embryonic, fetal, neonate, and adult stages. Animals may include any member of the subphylum Chordata, including, without limitation, non-human primates such as lemurs, chimpanzees and other apes, and monkey species; farm animals such as cattle, sheep, pigs, goats and horses; domestic mammals such as dogs and cats; laboratory animals including rodents such as mice, rats and guinea pigs; birds, including domestic, wild and game birds such as chickens, turkeys and other gallinaceous birds, ducks, geese, and the like.

[0080] By "transgenic animal" is meant a non-human animal, usually a mammal (e.g., primate), having a genetically modified sequence (e.g., a loss-of-function mutation in one or both alleles of an SLC41A2 gene) or a non-endogenous (i.e., heterologous or foreign) nucleic acid sequence present as an extrachromosomal element in a portion of its cells or stably integrated into its germ line DNA (i.e., in the genomic sequence of most or all of its cells). A loss-of-function mutation is introduced into the germ line of such transgenic animals by genetic manipulation of, for example, embryos or embryonic stem cells of the host animal according to methods well known in the art.Atty. Dckt.: STAN-2271 WO Client Ref.: S25-149By genetically modifying a fertilized oocyte or cells from an early embryo, the resulting transgenic animal may be able to transmit the genetic modification in its germline.

[0081] The term "stem cell" refers to a cell that retains the ability to renew itself through mitotic cell division and that can differentiate into a diverse range of specialized cell types. Mammalian stem cells can be divided into three broad categories: embryonic stem cells, which are derived from blastocysts, adult stem cells, which are found in adult tissues, and cord blood stem cells, which are found in the umbilical cord. In a developing embryo, stem cells can differentiate into all of the specialized embryonic tissues. In adult organisms, stem cells and progenitor cells act as a repair system for the body by replenishing specialized cells. Totipotent stem cells are produced from the fusion of an egg and sperm cell. Cells produced by the first few divisions of the fertilized egg are also totipotent. These cells can differentiate into embryonic and extraembryo nic cell types. Pluripotent stem cells are the descendants of totipotent cells and can differentiate into cells derived from any of the three germ layers. Multipotent stem cells can produce only cells of a closely related family of cells (e.g., hematopoietic stem cells differentiate into red blood cells, white blood cells, platelets, etc.). Unipotent cells can produce only one cell type, but have the property of self-renewal, which distinguishes them from non-stem cells. Induced pluripotent stem cells are a type of pluripotent stem cell derived from adult cells that have been reprogrammed into an embryonic-like pluripotent state. Induced pluripotent stem cells can be derived, for example, from adult somatic cells such as peripheral blood mononuclear cells, fibroblasts, keratinocytes, epithelial cells, endothelial progenitor cells, mesenchymal stem cells, adipose derived stem cells, leukocytes, hematopoietic stem cells, bone marrow cells, or hepatocytes.

[0082] As used herein, “reprogramming factors” refers to one or more, i.e., a cocktail, of biologically active factors that act on a cell to alter transcription, thereby reprogramming a cell to multipotency or to pluripotency. Reprogramming factors may be provided individually or as a single composition, that is, as a premixed composition, of reprogramming factors to the cells, e.g., somatic cells from an individual with a family history or genetic make-up of interest, such as a patient who has a neurological disorder or a neurodegenerative disease. The factors may be provided at the same molar ratio or at different molar ratios. The factors may be provided once or multiple times in the course of culturing the cells of the subject invention. In some embodiments the reprogramming factor is a transcription factor, including without limitation, Oct3 / 4; Sox2; Klf4; c-Myc; Nanog; and Lin-28.

[0083] The somatic cells may include, without limitation, peripheral blood mononuclear cells, fibroblasts, keratinocytes, epithelial cells, endothelial progenitor cells, mesenchymal stem cells,Atty. Dckt.: STAN-2271 WO Client Ref.: S25-149adipose derived stem cells, leukocytes, hematopoietic stem cells, bone marrow cells, or hepatocytes, etc., which are contacted with reprogramming factors, as defined above, in a combination and quantity sufficient to reprogram the cell to pluripotency. Reprogramming factors may be provided to the somatic cells individually or as a single composition, that is, as a premixed composition, of reprogramming factors. In some embodiments the reprogramming factors are provided as a plurality of coding sequences on a vector.

[0084] Induced pluripotent stem cell-derived cardiac sinoatrial nodal pacemaker cells (iSANCs) (iSANCs) can be generated from iPSCs by a multistep differentiation protocol, including differentiation of the iPSCs into cardiomyocyte-like cells followed by differentiation of the cardiomyocyte-like cells into iSANCs. In an exemplary protocol, iPSCs are first differentiated in a medium containing a glycogen synthase kinase-3 inhibitor / WNT activator (e.g., CHIR99021), bone morphogenetic protein 4 (BMP4), activin A, and insulin. To induce cardiomyocyte differentiation, the cells are cultured in a medium comprising with a WNT inhibitor (e.g., XAV939) followed by differentiation in a medium comprising RPMI media supplemented with B27TMsupplement, GlutaMAX™ L-alanyl-L-glutamine dipeptide supplement, and non-essential amino acids (NEAA). For differentiation into iSANCs, the cells are cultured in a medium containing cucurbitacin, retinoic acid, a MEK / ERK pathway inhibitor (e.g., SU5402) and B27 supplement minus insulin (RB27-INS), followed by addition of an inhibitor of tankyrase 1 and tankyrase 2 (e.g., XAV939) to the medium, culturing in a medium containing a JAK2 / EGFR inhibitor (e.g., tyrphostin AG 490) in B27 supplement plus insulin (RB27+INS), adding chidamide to the medium, and culturing in a RPMI medium supplemented with GlutaMAX, NEAA, and RB27+INS. Starvation of cells is carried out through iSANC differentiation and purification to enrich for nodal cells (fattyacid metabolism) over iPSCs (anaerobic metabolism); hence, glucose and insulin are not added to the base culture medium until about day 51 at the beginning of “SANC maturation” (see, e.g., Example 1 and Ghazizadeh et al. (2022) iScience 25, 104153; herein incorporated by reference in its entirety). However, any suitable method of inducing differentiation of iPSCs into iSANCs may be used.

[0085] Mature iSANCs can be identified by their morphology (small, spindle-like cells forming clusters for functional synchronization) and beating rate (e.g., about 100 beats per minute) using light microscopy. Cultures may also be empirically tested by staining for the presence of markers of interest. The cells are optionally enriched by performing a positive or negative selection step, panning, density gradient centrifugation, efc. Positive and / or negative selection may be performed, wherein the selection is based on expression of one or more of the markers found onAtty. Dckt.: STAN-2271 WO Client Ref.: S25-149cardiac sinoatrial nodal pacemaker cells, such as hyperpolarization-activated cyclic nucleotide- gated channel 4 (HCN4), hyperpolarization activated cyclic nucleotide gated potassium channel 1 (HCN1), hyperpolarization activated cyclic nucleotide gated potassium channel 2 (HCN2), calcium voltage-gated channel subunit alphal G (CACNA1G), CD34, T-box transcription factor 3 (TBX3), SHOX homeobox 2 (SHOX2), ISL LIM homeobox 1 (ISL1 ), signal regulatory protein alpha (SIRPA), and the like. Selection may utilize panning methods, magnetic particle selection, particle sorter selection, and the like.

[0086] The terms "polynucleotide," "oligonucleotide," "nucleic acid" and "nucleic acid molecule" are used herein to include a polymeric form of nucleotides of any length, either ribonucleotides or deoxyribonucleotides. This term refers only to the primary structure of the molecule. Thus, the term includes triple-, double- and single-stranded DNA, as well as triple-, double- and singlestranded RNA. It also includes modifications, such as by methylation and / or by capping, and unmodified forms of the polynucleotide. More particularly, the terms "polynucleotide," "oligonucleotide," "nucleic acid" and "nucleic acid molecule" include polydeoxyribonucleotides (containing 2-deoxy-D-ribose), polyribonucleotides (containing D-ribose), any other type of polynucleotide which is an N- or C-glycoside of a purine or pyrimidine base, and other polymers containing nonnucleotidic backbones, for example, polyamide (e.g., peptide nucleic acids (PNAs)) and polymorpholino (commercially available from the Anti-Virals, Inc., Corvallis, Oreg., as Neugene) polymers, and other synthetic sequence-specific nucleic acid polymers providing that the polymers contain nucleobases in a configuration which allows for base pairing and base stacking, such as is found in DNA and RNA. There is no intended distinction in length between the terms "polynucleotide," "oligonucleotide," "nucleic acid" and "nucleic acid molecule," and these terms will be used interchangeably. Thus, these terms include, for example, 3'-deoxy-2',5'- DNA, oligodeoxyribonucleotide N3' P5' phosphoramidates, 2'-O-alkyl-substituted RNA, double- and single-stranded DNA, as well as double- and single-stranded RNA, microRNA, DNA:RNA hybrids, and hybrids between PNAs and DNA or RNA, and also include known types of modifications, for example, labels which are known in the art, methylation, "caps," substitution of one or more of the naturally occurring nucleotides with an analog (e.g., 2-aminoadenosine, 2- thiothymidine, inosine, pyrrolo-pyrimidine, 3-methyl adenosine, C5-propynylcytidine, C5- propynyluridine, C5-bromouridine, C5-fluorouridine, C5-iodouridine, C5-methylcytidine, 7- deazaadenosine, 7-deazaguanosine, 8-oxoadenosine, 8-oxoguanosine, O(6)-methylguanine, and 2-thiocytidine), internucleotide modifications such as, for example, those with uncharged linkages (e.g., methyl phosphonates, phosphotriesters, phosphoramidates,Atty. Dckt.: STAN-2271 WO Client Ref.: S25-149carbamates, etc.), with negatively charged linkages (e.g., phosphorothioates, phosphorodithioates, etc.), and with positively charged linkages (e.g., aminoalklyphosphoramidates, aminoalkylphosphotriesters), those containing pendant moieties, such as, for example, proteins (including nucleases, toxins, antibodies, signal peptides, poly-L- lysine, etc.), those with intercalators (e.g., acridine, psoralen, etc.), those containing chelators (e.g., metals, radioactive metals, boron, oxidative metals, etc.), those containing alkylators, those with modified linkages (e.g., alpha anomeric nucleic acids, etc.), as well as unmodified forms of the polynucleotide or oligonucleotide. The term also includes locked nucleic acids (e.g., comprising a ribonucleotide that has a methylene bridge between the 2'-oxygen atom and the 4'- carbon atom). See, for example, Kurrecket al. (2002) Nucleic Acids Res. 30: 1911-1918; Elayadi et al. (2001) Curr. Opinion Invest. Drugs 2: 558-561 ; Orum et al. (2001) Curr. Opinion Mol. Ther.3: 239-243; Koshkin et al. (1998) Tetrahedron 54: 3607-3630; Obika et al. (1998) Tetrahedron Lett. 39: 5401-5404.

[0087] A solute carrier family 41 member 2 (SLC41A2) polynucleotide, nucleic acid, oligonucleotide, protein, polypeptide, or peptide refers to a molecule derived from any source. The molecule need not be physically derived from an organism, but may be synthetically or recombinantly produced. A number of SLC41A2 nucleic acid and protein sequences are known. Representative lemur and human SLC41A2 genomic nucleic acid sequences are presented in SEQ ID NO:10 and 11, respectively, and representative lemur, human, and mouse SLC41A2 protein sequences are presented in SEQ ID NO:5, SEQ ID NO:6, and SEQ ID NO:7, respectively. Additional representative sequences are listed in the National Center for Biotechnology Information (NCBI) database, including sequences of isoforms of SLC41A2 from different species. See, for example, NCBI entries: Accession Nos. XM 012772738, XM_012772737, XM_012772736, NM 001031483, NM_001387127, NM 001352169, NM 001387128, NM 001352172, NM 001387126, XM 038680106, XM 038680105, XM 081595672, NM_177388, NM_001401081, XM 082634448, XM 082816448, XM 024991808, XM 059886475, XM_060413157, XM 060413155, XM 072844278, XM 072844277, XM 045553064, XM 045553063, XM 045553062, XM 045553061 , XP_012628196, XP_012628195, XP_012628193, XP 01262819, XP 054229405, XP 054229404, XP 054229403, XP 054229402, XP 054229401 , XP 054229400, XP 054229399, XP 054229398, XP 054229397, XP_016875502, XP_011537113, XP 005269236, XP 038536034, XP 038536033, XP 059742458, XP 059742457, XP 059742456, XP 060269140, XP 060269139, XP 060269136, XP 060269135, NP 001388010,Atty. Dckt.: STAN-2271 WO Client Ref.: S25-149NP 001102212, and NP 001388011 ; all of which sequences (as entered by the date of filing of this application) are herein incorporated by reference. Additional, examples of SLC41A2 genes and protein sequences can be found in public gene databases such as NCBI, Uniprot, Ensembl, and other public genomic and protein sequence databases identifiable to a person skilled in the art.

[0088] The term "homologous region" refers to a region of a nucleic acid with homology to another nucleic acid region. Thus, whether a "homologous region" is present in a nucleic acid molecule is determined with reference to another nucleic acid region in the same or a different molecule. Further, since a nucleic acid is often double-stranded, the term "homologous, region," as used herein, refers to the ability of nucleic acid molecules to hybridize to each other. For example, a single-stranded nucleic acid molecule can have two homologous regions which are capable of hybridizing to each other. Thus, the term "homologous region" includes nucleic acid segments with complementary sequence. Homologous regions may vary in length, but will typically be between 4 and 40 nucleotides (e.g., from about 4 to about 40, from about 5 to about 40, from about 5 to about 35, from about 5 to about 30, from about 5 to about 20, from about 6 to about 30, from about 6 to about 25, from about 6 to about 15, from about 7 to about 18, from about 8 to about 20, from about 8 to about 15, etc.).

[0089] The term "complementary" and "complementarity" are interchangeable and refer to the ability of polynucleotides to form base pairs with one another. Base pairs are typically formed by hydrogen bonds between nucleotide units in antiparallel polynucleotide strands or regions. Complementary polynucleotide strands or regions can base pair in the Watson-Crick manner (e.g., A to T, A to U, C to G). 100% complementary refers to the situation in which each nucleotide unit of one polynucleotide strand or region can hydrogen bond with each nucleotide unit of a second polynucleotide strand or region. Less than perfect complementarity refers to the situation in which some, but not all, nucleotide units of two strands or two regions can hydrogen bond with each other and can be expressed as a percentage.

[0090] A "target site" or "target sequence" for an inhibitory nucleic acid is the nucleic acid sequence recognized (i.e., sufficiently complementary for hybridization) by an antisense oligonucleotide or inhibitory RNA molecule.

[0091] The term "transfection" is used to refer to the uptake of foreign DNA or RNA by a cell. A cell has been "transfected" when exogenous DNA or RNA has been introduced inside the cell membrane. A number of transfection techniques are generally known in the art. See, e.g., Graham et al. (1973) Virology, 52:456, Sambrook et al. (2001) Molecular Cloning, a laboratory manual,Atty. Dckt.: STAN-2271 WO Client Ref.: S25-1493rd edition, Cold Spring Harbor Laboratories, New York, Davis et al. (1995) Basic Methods in Molecular Biology, 2nd edition, McGraw-Hill, and Chu et al. (1981) Gene 13:197. Such techniques can be used to introduce one or more exogenous DNA or RNA moieties into suitable host cells. The term refers to both stable and transient uptake of the genetic material, and includes uptake, for example, of microRNA, siRNA, piRNA, IncRNA, or antisense nucleic acids.

[0092] A “CRISPR system" refers collectively to transcripts and other elements involved in the expression of or directing the activity of CRISPR-associated ("Cas") genes. In some embodiments, one or more elements of a CRISPR system is derived from a type I, type II, or type III CRISPR system. In some embodiments, one or more elements of a CRISPR system is derived from a particular organism comprising an endogenous CRISPR system, such as Streptococcus pyogenes. In general, a CRISPR system is characterized by elements that promote the formation of a CRISPR complex at the site of a target sequence.

[0093] The term "Cas9" as used herein encompasses type II clustered regularly interspaced short palindromic repeats (CRISPR) system Cas9 endonucleases from any species, and also includes biologically active fragments, variants, analogs, and derivatives thereof that retain Cas9 endonuclease activity (i.e., catalyze site-directed cleavage of DNA to generate double-strand breaks).

[0094] A Cas9 endonuclease binds to and cleaves DNA at a site comprising a sequence complementary to its bound guide RNA (gRNA). For purposes of Cas9 targeting, a gRNA may comprise a sequence "complementary" to a target sequence (e.g., major or minor allele), capable of sufficient base-pairing to form a duplex (i.e., the gRNA hybridizes with the target sequence). Additionally, the gRNA may comprise a sequence complementary to a PAM sequence, wherein the gRNA also hybridizes with the PAM sequence in a target DNA.

[0095] By "selectively binds" with reference to a guide RNA is meant that the guide RNA binds preferentially to a target sequence of interest or binds with greater affinity to the target sequence than to other genomic sequences. For example, a gRNA will bind to a substantially complementary sequence and not to unrelated sequences. A gRNA that "selectively binds" to a particular allele, such as a particular mutant allele (e.g., allele comprising a substitution, insertion, or deletion), denotes a gRNA that binds preferentially to the particular target allele, but to a lesser extent to a wild-type allele or other sequences. A gRNA that selectively binds to a particular target DNA sequence will selectively direct binding of Gas9 to a substantially complementary sequence at the target site and not to unrelated sequences.Atty. Dckt.: STAN-2271 WO Client Ref.: S25-149

[0096] The term "donor polynucleotide" refers to a polynucleotide that provides a sequence of an intended edit to be integrated into the genome at a target locus by homology directed repair (HDR).

[0097] A "target site" or "target sequence" is the nucleic acid sequence recognized (i.e., sufficiently complementary for hybridization) by a guide RNA (gRNA) or a homology arm of a donor polynucleotide. The target site may be allele-specific (e.g., a major or minor allele).

[0098] By "homology arm" is meant a portion of a donor polynucleotide that is responsible for targeting the donor polynucleotide to the genomic sequence to be edited in a cell. The donor polynucleotide typically comprises a 5' homology arm that hybridizes to a 5' genomic target sequence and a 3' homology arm that hybridizes to a 3' genomic target sequence flanking a nucleotide sequence comprising the intended edit to the genomic DNA. The homology arms are referred to herein as 5' and 3' (i.e., upstream and downstream) homology arms, which relates to the relative position of the homology arms to the nucleotide sequence comprising the intended edit within the donor polynucleotide. The 5' and 3' homology arms hybridize to regions within the target locus in the genomic DNA to be modified, which are referred to herein as the ”5' target sequence" and ”3' target sequence," respectively. The nucleotide sequence comprising the intended edit is integrated into the genomic DNA by HDR or recombineering at the genomic target locus recognized (i.e., sufficiently complementary for hybridization) by the 5' and 3' homology arms.

[0099] "Administering" a nucleic acid, such as an inhibitory or regulatory nucleic acid (e.g., microRNA, siRNA, piRNA, snRNA, antisense nucleic acid, or IncRNA), or a CRISPR system (expressing, e.g., a donor polynucleotide, guide RNA, Cas protein (e.g., Cas9, Cas12a, Cas12d, Cas13, or dCas9)) to a cell comprises transducing, transfecting, electroporating, translocating, fusing, phagocytosing, shooting or ballistic methods, etc., i.e., any means by which a nucleic acid can be transported across a cell membrane.Primate Model for Cardiac Arrhythmias

[0100] Non-human primate animal models of cardiac arrhythmias are provided, which can be used for identifying novel candidate genes and therapeutic targets for developing drugs for treating human arrhythmias and for screening therapeutics. To establish a primate genetic model organism for arrhythmias, electrocardiographic (ECG) screening was performed on laboratory and wild mouse lemurs (Microcebus spp.) to identify lemurs having arrhythmias resembling human ECG pathologies.Atty. Dckt.: STAN-2271 WO Client Ref.: S25-149

[0101] By “arrhythmia” is meant an abnormal or irregular heartbeat. A cardiac arrhythmia may include an abnormal heartbeat rate such as an abnormally fast heartbeat (tachycardia, e.g., greater than 100 beats per minute (bpm) for a human, greater than 553 bpm for M. murinus, greater than 458 bpm for M. rufus, greater than 421 bpm for M. nova) or an abnormally slow heartbeat (bradycardia, e.g., less than 60 bpm for a human, less than 309 bpm for M. murinus, less than 260 bpm for M. rufus, less than 237 bpm for M. nova), or an irregular or erratic heartbeat rhythm (e.g., pauses, premature or late heartbeats, or extra beats). An irregular or erratic heartbeat rhythm may be caused, for example, by premature atrial contractions, premature ventricular contractions, and / or premature junctional contractions. The term cardiac arrhythmia encompasses atrial arrhythmias and ventricular arrhythmias such as, but not limited to, sinus bradycardia, sinus tachycardia, ventricular tachycardia, non-sustained ventricular tachycardia, supraventricular tachycardia, tachycardia-bradycardia syndrome, atrial fibrillation, premature atrial contractions, premature ventricular contractions, sinus node dysfunction (e.g., sick sinus syndrome), or wandering atrial pacemaker. The arrhythmia may be associated with ST-segment depression, inverted T-waves, ST-segment elevation, ST-segment depression, small R-waves, tall R-waves, large S-waves and small R-waves, peaked T-waves, a right bundle branch block, a prolonged QRS-complex, or any combination thereof.

[0102] Lemurs, including, but not limited to, those of the species Microcebus murinus, Microcebus rufus, and Microcebus nova having cardiac arrhythmias can be used as models of cardiac arrhythmias for research and development. The heart rate and heart rhythm of a lemur can be monitored, for example, by single-lead or multi-lead electrocardiography with each lead contacting a hand or leg or the chest. In certain embodiments, monitoring the heart rhythm and heart rate comprises performing single-lead, 3-lead, or 6-lead electrocardiography.

[0103] In some embodiments, a naturally-occurring non-human primate (e.g., a lemur) having an arrhythmia is used as an animal model of arrhythmia. In other embodiments, a non-human primate is genetically modified to introduce a mutation linked to the development of an arrhythmia, as further described below.Genetically Modifying a Non-Human Primate to Introduce Mutation Associated with Arrhythmia

[0104] In some embodiments, the genome of a non-human primate is genetically modified to introduce a loss-of-function mutation in an SLC41 A2 gene (e.g., gene knockout or knockdown to reduce or eliminate activity of the SLC41 A2 magnesium transporter) using standard methods in the art. In certain embodiments, the loss-of-function mutation is an exon deletion, a frameshiftAtty. Dckt.: STAN-2271 WO Client Ref.: S25-149mutation, a missense mutation, or a nonsense mutation. In some embodiments, the loss-of- function mutation comprises a deletion of all or a portion of exon 2 of the SLC41 A2 gene, a coding sequence deletion in codon 4 of the SLC41A2 gene, a frameshift mutation in codon 4 of the SLC41 A2 gene, or any combination thereof.

[0105] Various gene editing approaches can be used for this purpose, including, without limitation, the use of genome editing systems comprising clustered regularly interspaced short palindromic repeats (CRISPR) / CRISPR-associated (Cas) nucleases, meganucleases, zinc-finger nucleases (ZFNs), and transcription activator-like effector nucleases (TALENs). See, e.g., CRISPR Gene Editing: Methods and Protocols (edited by Luo, Humana, 2019), Genome Editing and Engineering: From TALENs, ZFNs and CRISPRs to Molecular Surgery (edited by Appasani and Church, Cambridge University Press, 2018); herein incorporated by reference in their entireties. These gene editing techniques involve creating a double-strand break (DSB) in the DNA at a target site of the intended gene edit. SLC41 A2 gene knockout may be achieved through either the non-homologous end joining (NHEJ) or the microhomology-mediated end-joining (MMEJ) DNA repair pathways, which generate small nucleotide insertions or deletions (indels) at the site of the DSB. Gene knockout results if an indel shifts the reading frame or introduces a premature stop codon in an SLC41A2 coding sequence. In some embodiments, a CRISPR system is used with a guide RNA (gRNA) to direct a Cas9 RNA-guided nuclease to create a DSB at a target site in an exon of the SLC41 A2 gene. For example, the SLC41A2 can be inactivated by using a CRISPR system with a gRNA designed to guide a Cas9 nuclease to a target site to create a site-specific DNA break in an exon of the SLC41A2 gene, wherein introduction of an indel in the exon results in production of a truncated non-functional protein. Alternatively, CRISPR can be performed with a donor DNA template using homologous recombination (HR) to replace a portion of the genomic sequence with a modified sequence comprising a loss-of-function mutation.

[0106] In some embodiments, a site-specific nuclease is used to create a DNA break that can be repaired by homology directed repair (HDR) or non-homologous end joining (NHEJ) to produce a knockout of the SLC41 A2 gene. In HDR, a donor polynucleotide is used comprising an intended edit sequence to be integrated into the genomic target locus. The donor polynucleotide can be used, for example, to delete all or a portion of the SLC41A2 gene or introduce a frameshift, missense, or nonsense mutation. In NHEJ, the two DNA ends at the DNA break, produced by a site-specific nuclease, are ligated together imperfectly, resulting in incorporation of insertions or deletions of base pairs to create a frameshift mutation into the SLC41 A2 gene.Atty. Dckt.: STAN-2271 WO Client Ref.: S25-149

[0107] A DNA break may be created by a site-specific nuclease, such as, but not limited to, a Cas nuclease (e.g., Cas9, Cpf1, or C2c1), an engineered RNA-guided Fokl nuclease, a zinc finger nuclease (ZFN), a transcription activator-like effector-based nuclease (TALEN), a restriction endonuclease, a meganuclease, a homing endonuclease, and the like. Any site-specific nuclease that selectively cleaves a sequence at a target site for knockout of a SLC41 A2 gene may be used. For a description of genome editing using site-specific nucleases, see, e.g., Targeted Genome Editing Using Site-Specific Nucleases: ZFNs, TALENs, and the CRISPR / Cas9 System (T. Yamamoto ed., Springer, 2015); Genome Editing: The Next Step in Gene Therapy (Advances in Experimental Medicine and Biology, T. Cathomen, M. Hirsch, and M. Porteus eds., Springer, 2016); Aachen Press Genome Editing (CreateSpace Independent Publishing Platform, 2015); herein incorporated by reference.

[0108] In some embodiments, genome modification is performed using HDR with a donor polynucleotide comprising a sequence comprising an intended genome edit flanked by a pair of homology arms responsible for targeting the donor polynucleotide to the target locus to be edited in a cell. The donor polynucleotide typically comprises a 5' homology arm that hybridizes to a 5' genomic target sequence and a 3' homology arm that hybridizes to a 3' genomic target sequence. The homology arms are referred to herein as 5' and 3' (i.e. , upstream and downstream) homology arms, which relates to the relative position of the homology arms to the nucleotide sequence comprising the intended edit within the donor polynucleotide. The 5' and 3' homology arms hybridize to regions within the target locus in the genomic DNA to be modified, which are referred to herein as the "5' target sequence" and "3' target sequence," respectively.

[0109] The homology arm must be sufficiently complementary for hybridization to the target sequence to mediate homologous recombination between the donor polynucleotide and genomic DNA at the target locus. For example, a homology arm may comprise a nucleotide sequence having at least about 80-100% sequence identity to the corresponding genomic target sequence, including any percent identity within this range, such as at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity thereto, wherein the nucleotide sequence comprising the intended edit is integrated into the genomic DNA by HDR at the genomic target locus recognized (i.e., sufficiently complementary for hybridization) by the 5' and 3' homology arms.

[0110] In certain embodiments, the corresponding homologous nucleotide sequences in the genomic target sequence (i.e., the "5' target sequence" and "3' target sequence") flank a specific site for cleavage and / or a specific site for introducing the intended edit. The distance between theAtty. Dckt.: STAN-2271 WO Client Ref.: S25-149specific cleavage site and the homologous nucleotide sequences (e.g., each homology arm) can be several hundred nucleotides. In some embodiments, the distance between a homology arm and the cleavage site is 200 nucleotides or less (e.g., 0, 10, 20, 30, 50, 75, 100, 125, 150, 175, and 200 nucleotides). In most cases, a smaller distance may give rise to a higher gene targeting rate. In a preferred embodiment, the donor polynucleotide is substantially identical to the target genomic sequence, across its entire length except for the sequence changes to be introduced to a portion of the genome that encompasses both the specific cleavage site and the portions of the genomic target sequence to be altered.

[0111] A homology arm can be of any length, e.g., 10 nucleotides or more, 50 nucleotides or more, 100 nucleotides or more, 250 nucleotides or more, 300 nucleotides or more, 350 nucleotides or more, 400 nucleotides or more, 450 nucleotides or more, 500 nucleotides or more, 1000 nucleotides (1 kb) or more, 5000 nucleotides (5 kb) or more, 10000 nucleotides (10 kb) or more, etc. In some instances, the 5' and 3' homology arms are substantially equal in length to one another, e.g., one may be 30% shorter or less than the other homology arm, 20% shorter or less than the other homology arm, 10% shorter or less than the other homology arm, 5% shorter or less than the other homology arm, 2% shorter or less than the other homology arm, or only a few nucleotides less than the other homology arm. In other instances, the 5' and 3' homology arms are substantially different in length from one another, e.g., one may be 40% shorter or more, 50% shorter or more, sometimes 60% shorter or more, 70% shorter or more, 80% shorter or more, 90% shorter or more, or 95% shorter or more than the other homology arm.

[0112] The donor polynucleotide is used in combination with a site-specific nuclease. In some embodiments, the site-specific nuclease is an RNA-guided nuclease, which is targeted to a particular genomic sequence (i.e., genomic target sequence to be modified) by a guide RNA (gRNA). A target-specific guide RNA comprises a nucleotide sequence that is complementary to a genomic target sequence, and thereby mediates binding of the nuclease-gRNA complex by hybridization at the target site. For example, the gRNA can be designed with a sequence complementary to a target sequence in the SLC41 A2 gene, such as a target sequence in an exon or intron, wherein homologous recombination with the donor polynucleotide results in deletion of a coding sequence or introduction of a frameshift, missense, or nonsense mutation in the SLC41 A2 gene.

[0113] In certain embodiments, a CRISPR system is used to knockdown or knockout a SLC41 A2 gene in the non-human primate. In such embodiments, the RNA-guided nuclease used for genome modification is a CRISPR system Cas nuclease. Any RNA-guided Cas nuclease capableAtty. Dckt.: STAN-2271 WO Client Ref.: S25-149of catalyzing site-directed cleavage of DNA to allow integration of donor polynucleotides by the HDR mechanism can be used in genome editing, including CRISPR system type I, type II, or type III Cas nucleases. Examples of Gas proteins include Cas1, Cas1B, Cas2, Cas3, Cas4, Cas5, Cas5e (CasD), Cas6, Cas6e, Cas6f, Cas7, Cas8a1 , Cas8a2, Cas8b, Cas8c, Cas9 (Csn1 or Csx12), Cas10, CaslOd, Cas12a (Cpf1), Cas12b (C2c1), Cas12c (C2c3), Cas12d (CasY), Cas12e (CasX), CasF, CasG, CasH, Csy1, Csy2, Csy3, Cse1 (CasA), Cse2 (CasB), Cse3 (CasE), Cse4 (CasC), Csc1 , Csc2, Csa5, Csn2, Csm2, Csm3, Csm4, Csm5, Csm6, Cmr1 , Cmr3, Cmr4, Cmr5, Cmr6, Csb1, Csb2, Csb3, Csx17, Csx14, Csx10, Csx16, CsaX, Csx3, Csx1 , Csx15, Csf1 , Csf2, Csf3, Csf4, and Cu1966, and homologs or modified versions thereof.

[0114] In certain embodiments, a type II CRISPR system Cas9 endonuclease is used. Cas9 nucleases from any species, or biologically active fragments, variants, analogs, or derivatives thereof that retain Cas9 endonuclease activity (i.e., catalyze site-directed cleavage of DNA to generate double-strand breaks) may be used to perform genome modification as described herein. The Cas9 need not be physically derived from an organism, but may be synthetically or recombinantly produced. Cas9 sequences from a number of bacterial species are well known in the art and listed in the National Center for Biotechnology Information (NCBI) database. See, for example, NCBI entries for Cas9 from: Streptococcus pyogenes (WP 002989955, WP 038434062, WP_011528583); Campylobacter jejuni (WP_022552435, YP_002344900), Campylobacter coli (WP_060786116); Campylobacter fetus (WP 059434633); Corynebacterium ulcerans (NC_015683, NC_017317); Corynebacterium diphtheria (NC_016782, NC_016786); Enterococcus faecalis (WP_033919308); Spiroplasma syrphidicola (NC_021284); Prevotella intermedia (NC_017861); Spiroplasma taiwanense (NC_021846); Streptococcus iniae (NC_021314); Belliella ba / t / ca(NC_018010); Psychroflexus torquisl (NC_018721); Streptococcus thermophilus (YP_820832), Streptococcus mutans (WP_061046374, WP_024786433); Listeria innocua (NP_472073); Listeria monocytogenes (WP_061665472); Legionella pneumophila (WP 062726656); Staphylococcus aureus (WP_001573634); Francisella tularensis (WP 032729892, WP_014548420), Enterococcus faecalis (WP_033919308); Lactobacillus rhamnosus (WP_048482595, WP_032965177); and Neisseria meningitidis (WP_061704949, YP 002342100); all of which sequences (as entered by the date of filing of this application) are herein incorporated by reference. Any of these sequences or a variant thereof comprising a sequence having at least about 70-100% sequence identity thereto, including any percent identity within this range, such as 70, 71 , 72, 73, 74, 75, 76, 77, 78, 79, 80, 81 , 82, 83, 84, 85, 86, 87, 88, 89, 90, 91 , 92, 93, 94, 95, 96, 97, 98, or 99% sequence identity thereto, can be used for genomeAtty. Dckt.: STAN-2271 WO Client Ref.: S25-149editing, as described herein. See also Fonfara et al. (2014) Nucleic Acids Res. 42(4):2577-90; Kapitonov et al. (2015) J. Bacteriol. 198(5):797-807, Shmakov et al. (2015) Mol. Cell. 60(3):385- 397, and Chylinski et al. (2014) Nucleic Acids Res. 42(10):6091-6105); for sequence comparisons and a discussion of genetic diversity and phylogenetic analysis of Cas9.

[0115] The CRISPR-Cas system naturally occurs in bacteria and archaea where it plays a role in RNA-mediated adaptive immunity against foreign DNA. The bacterial type II CRISPR system uses the endonuclease, Cas9, which forms a complex with a guide RNA (gRNA) that specifically hybridizes to a complementary genomic target sequence, where the Cas9 endonuclease catalyzes cleavage to produce a double-stranded break. Targeting of Cas9 typically further relies on the presence of a 5' protospacer-adjacent motif (PAM) in the DNA at or near the gRNA-binding site.

[0116] The genomic target site will typically comprise a nucleotide sequence that is complementary to the gRNA, and may further comprise a protospacer adjacent motif (PAM). In certain embodiments, the target site comprises 20-30 base pairs in addition to a 3 base pair PAM. Typically, the first nucleotide of a PAM can be any nucleotide, while the two other nucleotides will depend on the specific Cas9 protein that is chosen. Exemplary PAM sequences are known to those of skill in the art and include, without limitation, NNG, NGN, NAG, and NGG, wherein N represents any nucleotide. In certain embodiments, the allele targeted by a gRNA comprises a mutation that creates a PAM within the allele, wherein the PAM promotes binding of the Cas9- gRNA complex to the allele.

[0117] In certain embodiments, the gRNA is 5-50 nucleotides, 10-30 nucleotides, 15-25 nucleotides, 18-22 nucleotides, or 19-21 nucleotides in length, or any length between the stated ranges, including, for example, 10, 11 , 12, 13, 14, 15, 16, 17, 18, 19, 20, 21 , 22, 23, 24, 25, 26, 27, 28, 29, 30, 31 , 32, 33, 34, or 35 nucleotides in length. The guide RNA may be a single guide RNA (sgRNA) comprising crRNA and tracrRNA sequences in a single RNA molecule, or the guide RNA may comprise two RNA molecules with crRNA and tracrRNA sequences residing in separate RNA molecules.

[0118] In some embodiments, the sgRNA specifically binds to a target sequence in a target region of exon 2 of the SLC41 A2 gene. In some embodiments, the target region comprises the sequence of SEQ ID NO:8. In some embodiments, the sgRNA comprises a sequence selected from the group consisting of SEQ ID NOS:1 -3 or a sequence displaying at least about 80-100% sequence identity thereto, including any percent identity within this range, such as 81, 82, 83, 84, 85, 86,Atty. Dckt.: STAN-2271 WO Client Ref.: S25-14987, 88, 89, 90, 91 , 92, 93, 94, 95, 96, 97, 98, 99% sequence identity thereto, wherein the sgRNA is capable of targeting a Gas nuclease to a target site in exon 2 of the SLC41 A2 gene.

[0119] In another embodiment, the CRISPR nuclease from Prevotella and Francisella 1 (Cpf1, also known as Gas12a) is used. Cpf1 is another class II CRISPR / Cas system RNA-guided nuclease with similarities to Cas9 and may be used analogously. Unlike Cas9, Cpf 1 does not require a tracrRNA and only depends on a crRNA in its guide RNA, which provides the advantage that shorter guide RNAs can be used with Cpf1 for targeting than Cas9. Cpf 1 is capable of cleaving either DNA or RNA. The PAM sites recognized by Cpf 1 have the sequences 5'-YTN-3' (where "Y" is a pyrimidine and "N" is any nucleobase) or 5'-TTN-3', in contrast to the G-rich PAM site recognized by Cas9. Cpf 1 cleavage of DNA produces double-stranded breaks with a sticky- ends having a 4 or 5 nucleotide overhang. For a discussion of Cpf 1 , see, e.g., Ledford et al. (2015) Nature. 526 (7571 ) :17-17, Zetsche et al. (2015) Cell. 163 (3):759-771 , Murovec et al. (2017) Plant Biotechnol. J. 15(8):917-926, Zhang et al. (2017) Front. Plant Sci. 8:177, Fernandes et al. (2016) Postepy Biochem. 62(3):315-326; herein incorporated by reference.

[0120] Cas12b (C2c1) is another class II CRISPR / Cas system RNA-guided nuclease that may be used. C2c1 , similarly to Cas9, depends on both a crRNA and tracrRNA for guidance to target sites. For a description of Cas12b, see, e.g., Shmakov et al. (2015) Mol Cell. 60(3):385-397, Zhang et al. (2017) Front Plant Sci. 8:177; herein incorporated by reference.

[0121] In yet another embodiment, an engineered RNA-guided Fokl nuclease may be used. RNA-guided Fokl nucleases comprise fusions of inactive Cas9 (dCas9) and the Fokl endonuclease (Fokl-dCas9), wherein the dCas9 portion confers guide RNA-dependent targeting on Fokl. For a description of engineered RNA-guided Fokl nucleases, see, e.g., Havlicek et al. (2017) Mol. Then 25(2):342-355, Pan et al. (2016) Sci Rep. 6:35794, Tsai et al. (2014) Nat Biotechnol. 32(6):569-576; herein incorporated by reference.

[0122] An RNA-guided nuclease can be provided in the form of a protein, such as the nuclease complexed with a gRNA, or provided by a nucleic acid encoding the RNA-guided nuclease, such as an RNA (e.g., messenger RNA) or DNA (expression vector). In some embodiments, the RNA- guided nuclease and the gRNA are both provided by vectors. Both can be expressed by a single vector or separately on different vectors. The vector(s) encoding the RNA-guided nuclease an gRNA may be included in a CRISPR expression system to target a SLC41A2 gene in the nonhuman animal.

[0123] Codon usage may be optimized to improve production of an RNA-guided nuclease in a particular cell or organism. For example, a nucleic acid encoding an RNA-guided nuclease orAtty. Dckt.: STAN-2271 WO Client Ref.: S25-149reverse transcriptase can be modified to substitute codons having a higher frequency of usage in a human cell, a non-human cell, a mammalian cell, a rodent cell, a mouse cell, a rat cell, or any other host cell of interest, as compared to the naturally occurring polynucleotide sequence. When a nucleic acid encoding the RNA-guided nuclease is introduced into cells (e.g., neurons or glia), the protein can be transiently, conditionally, or constitutively expressed in the cell.

[0124] In another embodiment, CRISPR interference (CRISPRi) is used to repress gene expression of a SLC41 A2 gene in the non-human animal. CRISPRi is performed with a complex of a catalytically inactive Cas9 (dCas9) with a guide RNA that targets the gene of interest. An engineered nuclease-deactivated Cas9 (dCas9) is used to allow sequence-specific targeting without cleavage. Nuclease-deactivated forms of Cas9 may be engineered by mutating catalytic residues at the active site of Cas9 to destroy nuclease activity. Any such nuclease deficient Cas9 protein from any species may be used as long as the engineered dCas9 retains gRNA-mediated sequence-specific targeting. In particular, the nuclease activity of Cas9 from Streptococcus pyogenes can be deactivated by introducing two mutations (D10A and H841 A) in the RuvC1 and HNH nuclease domains. Other engineered dCas9 proteins may be produced by similarly mutating the corresponding residues in other bacterial Cas9 isoforms. For a description of engineered nuclease-deactivated forms of Cas9, see, e.g., Qi et al. (2013) Cell 152:1173-1183, Dominguez et al. (2016) Nat. Rev. Mol. Cell. Biol. 17(1):5-15; herein incorporated by reference in their entireties.

[0125] The dCas9 protein can be designed to target the SLC41 A2 gene by altering its guide RNA sequence. A target-specific single guide RNA (sgRNA) comprises a nucleotide sequence that is complementary to a target site, and thereby mediates binding of the dCas9-sgRNA complex by hybridization at the target site. CRISPRi can be used to sterically repress transcription by blocking either transcriptional initiation or elongation by designing a sgRNA with a sequence complementary to a promoter or exonic sequence. The sgRNA may be complementary to the non-template strand or the template strand, but preferably is complementary to the non-template strand to more strongly repress transcription.

[0126] The target site will typically comprise a nucleotide sequence that is complementary to the sgRNA, and may further comprise a protospacer adjacent motif (PAM). In certain embodiments, the target site comprises 20-30 base pairs in addition to a 3 base pair PAM. Typically, the first nucleotide of a PAM can be any nucleotide, while the two other nucleotides will depend on the specific Cas9 protein that is chosen. Exemplary PAM sequences are known to those of skill in theAtty. Dckt.: STAN-2271 WO Client Ref.: S25-149art and include, without limitation, NNG, NGN, NAG, and NGG, wherein N represents any nucleotide.

[0127] In certain embodiments, the sgRNA comprises 5-50 nucleotides, 10-30 nucleotides, 15- 25 nucleotides, 18-22 nucleotides, 19-21 nucleotides, and any length between the stated ranges, including, for example, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 nucleotides.

[0128] The sgRNAs are readily synthesized by standard techniques, e.g., solid phase synthesis via phosphoramidite chemistry, as disclosed in U.S. Patent Nos. 4,458,066 and 4,415,732, incorporated herein by reference; Beaucage et aL, Tetrahedron (1992) 48:2223-2311; and Applied Biosystems User Bulletin No. 13 (1 April 1987). Other chemical synthesis methods include, for example, the phosphotriester method described by Narang et al., Meth. Enzymol. (1979) 68:90 and the phosphodiester method disclosed by Brown et aL, Meth. Enzymol. (1979) 68:109.

[0129] In some embodiments, the dCas9 is fused to a transcriptional repressor domain capable of further repressing transcription of the gene of interest, e.g., by inducing heterochromatinization. For example, a Kruppel associated box (KRAB) can be fused to dCas9 to repress transcription of a target gene in human cells (see, e.g., Gilbert et al. (2013) Cell. 154 (2): 442-45, O'Geen et al. (2017) Nucleic Acids Res. 45(17):9901 -9916; herein incorporated by reference).

[0130] Alternatively, dCas9 can be used to introduce epigenetic changes that reduce expression of a SLC41 A2 gene by fusion of dCas9 to an epigenetic modifier such as a chromatin-modifying epigenetic enzyme. The promoter for the gene of interest can be silenced, for example, by methylation or acetylation (e.g., histone H3 lysine 9 [H3K9] methylation, histone H3 lysine 27 [H3K27] methylation, and / or DNA methylation). For example, fusion of dCas9 to a DNA methyltransferase such as DNA methyltransferase 3 alpha (DNMT3A) or a chimeric Dnmt3a / Dnmt3L methyltransferase (DNMT3A3L) allows targeted DNA methylation. Fusion of dCas9 to histone demethylase LSD1 allows targeted histone demethylation (see, e.g., Liu et al. (2016) Cell 167(1):233-247, Lo et al. (2017) FWOORes. 6. pii: F1000 Faculty Rev-747, and Stepper et al. (2017) Nucleic Acids Res. 45(4):1703-1713; herein incorporated by reference).

[0131] In yet other embodiments, an RNA-targeting CRISPR-Cas13 system is used to perform RNA interference to reduce expression of a SLC41A2 gene. Members of the Cas13 family are RNA-guided RNases containing two HEPN domains having RNase activity. In particular, Cas13a (C2c2), Cas13b (C2c6), and Cas13d can be used for RNA knockdown. Cas13 proteins can be made to target and cleave transcribed RNA using a gRNA with complementarity to the targetAtty. Dckt.: STAN-2271 WO Client Ref.: S25-149transcript sequence. The gRNA is typically about 64 nucleotides in length with a short hairpin crRNA and a 28-30 nucleotide spacer that is complementary to the target site on the RNA transcript. Cas13 recognition and cleavage of a target transcript results in degradation of the transcript as well as nonspecific degradation of any nearby transcripts. See, e.g., Abudayyeh et al. (2017) Nature 550:280-284, Hameed et al. (2019) Microb. Pathog. 133:103551, Wang et al. (2019) Biotechnol Adv. 37(5):708-729, Aman et al. (2018) Viruses 10(12). pii: E732, and Zhang et al. (2018) Cell 175(1 ):212-223; herein incorporated by reference.

[0132] In some embodiments, the genetically modified non-human primate is transgenic.Transgenic animals can be generated with a loss-of-function mutation in one or both alleles of the SLC41 A2 gene such that the loss of function mutation is stably integrated into its germ line DNA (i.e., in the genomic sequence of most or all of its cells). A loss-of-function mutation is introduced into the germ line of such transgenic animals by genetic manipulation of, for example, a fertilized ovum, embryo, or embryonic stem cells of the host animal according to methods well known in the art. By genetically modifying a fertilized oocyte or cells from an early embryo, the resulting transgenic animal may be able to transmit the SLC41A2 gene loss-of-function mutation in its germline, wherein progeny of the genetically modified animal also have this genetic modification.Isolated Cardiac Sinoatrial Nodal Pacemaker Cells with a Loss-Of-Function Mutation in SLC41 A2

[0133] Cardiac sinoatrial nodal pacemaker cells may be isolated from a genetically modified non- human primate, particularly cells with a loss-of-function mutation in one or both alleles of the SLC41 A2 gene. Cardiac sinoatrial nodal pacemaker cells are isolated using standard procedures. Cardiac sinoatrial nodal pacemaker cell lines may be derived from such isolated cells, and immortalized using standard techniques, e.g., through use of viruses. The isolated cardiac sinoatrial nodal pacemaker cells and cell lines derived therefrom are useful for testing candidate agents for their ability to increase calcium transients and magnesium transients and restore sinus node function.Induced Pluripotent Stem Cell-Derived Sinoatrial Nodal Pacemaker Cells as Cellular Model of Sinus Node Dysfunction

[0134] Induced pluripotent stem cell-derived sinoatrial nodal pacemaker cells (iSANCs) comprising a mutation associated with an arrhythmia are provided, which can be used as cellular models of sinus node dysfunction for research and development and screening of therapeutic agents for treating sinus node dysfunction. In some embodiments, the iSANCs have one or moreAtty. Dckt.: STAN-2271 WO Client Ref.: S25-149characteristics of sinus node dysfunction such as slowed rhythmic calcium transients and magnesium transients compared to normal iSANCs not having the mutation associated with the arrhythmia (i.e. , wild-type).

[0135] In some embodiments, the genome of an iSANC or the iPSC or somatic cell, from which the iSANC is derived, is genetically modified to introduce a loss-of-function mutation in one or both alleles of the SLC41A2 gene (e.g., gene knockout or knockdown to reduce or eliminate activity of the SLC41A2 magnesium transporter) using standard methods in the art. In certain embodiments, the loss-of-function mutation in the iSANC is an exon deletion, a frameshift mutation, a missense mutation, or a nonsense mutation in the SLG41A2 gene. In some embodiments, the loss-of-function mutation comprises a deletion of all or a portion of one or more exons of the SLC41A2 gene. In some embodiments, the loss-of-function mutation comprises a deletion of all or a portion of exon 2 or exon 4 of the SLC41 A2 gene. In some embodiments, the loss-of-function mutation comprises a deletion of all or a portion of exon 2 of the SLC41 A2 gene, a coding sequence deletion in codon 4 of the SLC41 A2 gene, a frameshift mutation in codon 4 of the SLC41 A2 gene, or any combination thereof. The various gene editing approaches described above for genome editing of an animal, including the use of genome editing systems comprising CRISPR-associated (Cas) nucleases, meganucleases, zinc-finger nucleases (ZFNs), or transcription activator-like effector nucleases (TALENs) can also be applied to genome editing of cells.

[0136] In certain embodiments, iSANCs are produced from iPSCs generated from somatic cells obtained from a patient who has an arrhythmia. IPSCs may be generated from somatic cells including, without limitation, fibroblasts (e.g., dermal fibroblasts), peripheral blood mononuclear cells (PBMCs), keratinocytes, epithelial cells (e.g., urinary epithelial cells), endothelial progenitor cells, adipose-derived stem cells, cardiac-derived progenitor cells, and other cell types capable of differentiating into iSANCs. The biological sample comprising somatic cells is typically whole blood, buffy coat, PBMCS, skin, fat, or a biopsy, but can be any sample from bodily fluids, tissue or cells that contain suitable somatic cells. A biological sample can be obtained from a subject by conventional techniques. For example, blood can be obtained by venipuncture, and solid tissue samples can be obtained by surgical techniques according to methods well known in the art.

[0137] The IPSCs can be generated by reprogramming the somatic cells obtained from the subject into pluripotent stem cells followed by redifferentiation into iSANCs. Somatic cells can be induced into forming pluripotent stem cells, for example, by treating them with reprograming factors such as Yamanaka factors, including but not limited to, OCT3, OCT4, SOX2, KLF4, c-Atty. Dckt.: STAN-2271 WO Client Ref.: S25-149MYC, NANOG, and LIN28 (see, e.g., Takahashi et al. (2007) Cell. 131 (5):861 -872; herein incorporated by reference in its entirety). Somatic cells are contacted with reprogramming factors in a combination and quantity sufficient to reprogram the cells to pluripotency. Reprogramming factors may be provided to the somatic cells individually or as a single composition, that is, as a premixed composition, of reprogramming factors. In some embodiments the reprogramming factors are provided as a plurality of coding sequences on a vector.

[0138] Methods for "introducing a cell reprogramming factor into somatic cells are not limited in particular, and known procedures can be selected and used as appropriate. For example, when a cell reprogramming factor as described above is introduced into somatic cells of the above- mentioned type in the form of proteins, such methods include ones using protein introducing reagents, fusion proteins with protein transfer domains (PTDs), electroporation, and microinjection. When a cell reprogramming factor as described above is introduced into somatic cells of the above-mentioned type in the form of nucleic acids encoding the cell reprogramming factor, a nucleic acid(s), such as cDNA(s), encoding the cell reprogramming factor can be inserted in an appropriate expression vector comprising a promoter that functions in somatic cells, which then can be introduced into somatic cells by procedures such as infection, lipofection, liposomes, electroporation, calcium phosphate coprecipitation, DEAE-dextran, microinjection, and electroporation. Examples of an "expression vector" include viral vectors, such as lentiviruses, retroviruses, adenoviruses, adeno-associated viruses, and herpes viruses; and expression plasmids for animal cells. For example, retroviral or Sendai virus (SeV) vectors are commonly used to introduce a nucleic acid(s) encoding a cell reprogramming factor as described above into somatic cells.

[0139] After in vitro expansion, the IPSCs derived from the somatic cells can be redifferentiated into iSANCs by a multistep differentiation protocol, including differentiation of the iPSCs into cardiomyocyte-like cells followed by differentiation of the cardiomyocyte-like cells into iSANCs. In an exemplary protocol, iPSCs are first differentiated in a medium containing a glycogen synthase kinase-3 inhibitor / WNT activator (e.g., CHIR99021), bone morphogenetic protein 4 (BMP4), activin A, and insulin. To induce cardiomyocyte differentiation, the cells are cultured in a medium comprising with a WNT inhibitor (e.g., XAV939) followed by differentiation in a medium comprising RPMI media supplemented with B27™ supplement, GlutaMAX™ L-alanyl-L-glutamine dipeptide supplement, and non-essential amino acids (NEAA). For differentiation into iSANCs, the cells are cultured in a medium containing cucurbitacin, retinoic acid, a MEK / ERK pathway inhibitor (e.g., SU5402) and B27 supplement minus insulin (RB27-INS), followed by addition of an inhibitor ofAtty. Dckt.: STAN-2271 WO Client Ref.: S25-149tankyrase 1 and tankyrase 2 (e.g., XAV939) to the medium, culturing in a medium containing a JAK2 / EGFR inhibitor (e.g., tyrphostin AG 490) in B27 supplement plus insulin (RB27+INS), adding chidamide to the medium, and culturing in a RPMI medium supplemented with GlutaMAX, NEAA, and RB27+INS. Starvation of cells is carried out through iSANC differentiation and purification to enrich for nodal cells (fatty-acid metabolism) over iPSCs (anaerobic metabolism); hence, glucose and insulin are not added to the base culture medium until about day 51 at the beginning of “SANG maturation” (see, e.g., Example 1 and Ghazizadeh et al. (2022) iScience 25, 104153; herein incorporated by reference in its entirety). However, any suitable method of inducing differentiation of iPSCs into iSANCs may be used.

[0140] The iSANCs are harvested at an appropriate stage of development, which may be determined based on the expression of markers and phenotypic characteristics of the desired cell type (e.g., after 7 to 8 weeks in culture). Mature iSANCs can be identified by their morphology (small, spindle-like cells forming clusters for functional synchronization) and beating rate (e.g., about 100 beats per minute for human iSANCs) using light microscopy. Cultures may also be empirically tested by staining for the presence of markers of interest. The cells are optionally enriched by performing a positive or negative selection step, panning, density gradient centrifugation, etc. Positive selection may be performed, wherein the selection is based on expression of one or more of the markers found on cardiac sinoatrial nodal pacemaker cells, such as hyperpolarization-activated cyclic nucleotide-gated channel 4 (HCN4), hyperpolarization activated cyclic nucleotide gated potassium channel 1 (HCN1), hyperpolarization activated cyclic nucleotide gated potassium channel 2 (HCN2), calcium voltage-gated channel subunit alphal G (CACNA1G), CD34, T-box transcription factor 3 (TBX3), SHOX homeobox 2 (SHOX2), ISL LIM homeobox 1 (ISL1), signal regulatory protein alpha (SIRPA), and the like. The cells are optionally enriched before or after a positive selection step by drug selection, panning, density gradient centrifugation, etc. In some embodiments, a negative selection is performed based on expression of one or more of the markers found on the somatic cells (e.g., dermal fibroblasts, PBMCs, keratin ocytes, epithelial cells, endothelial progenitor cells, adipose-derived stem cells, cardiac- derived progenitor cells, or other somatic cell types capable of differentiating into iSANCs) but not the iSANCs to separate the differentiated iSANCs from the somatic cells or partially differentiated cells. Positive or negative selection may utilize panning methods, magnetic particle selection, particle sorter selection, and the like.

[0141] The somatic cells, from which the IPSCs are derived, may be obtained from a patient having a genetic mutation associated with an arrhythmia such that the iSANCs also have theAtty. Dckt.: STAN-2271 WO Client Ref.: S25-149mutation. Alternatively, the iPSCs or iSANCs may be genetically modified to express a mutation associated with an arrhythmia using engineered nucleases such as, but not limited to, CRISPR / GAS9, meganucleases, zinc finger nucleases, or transcription activator-like effector nucleases (TALENs) for gene editing. See, e.g., CRISPR Gene Editing: Methods and Protocols (edited by Luo, Humana, 2019), Genome Editing and Engineering: From TALENs, ZFNs and CRISPRs to Molecular Surgery (edited by Appasani and Church, Cambridge University Press, 2018); herein incorporated by reference in their entireties.Screening for Agents for Treating Cardiac Arrhythmias

[0142] A variety of different test agents may be screened for their effects on cardiac arrhythmia and sinus node dysfunction using the non-human primate models (e.g., genetically modified or naturally occurring non-human primates having arrythmias) and / or cellular models (e.g., iSANCs or cardiac sinoatrial nodal pacemaker cells derived from a non-human primate having an arrythmia) described herein. In some embodiments, the non-human primate model or the cellular model, used in screening the test agents, has a loss-of-function mutation in one or both alleles of the SLC41A2 gene. In some embodiments, the non-human primate model is a genetically modified or naturally occurring lemur (e.g., Microcebus murinus, Microcebus rufus, or Microcebus nova) having an arrythmia. In some embodiments, the iSANCs are human iSANCs.

[0143] Candidate agents encompass numerous chemical classes, e.g., small organic compounds having a molecular weight of more than 50 daltons and less than about 10,000 daltons, less than about 5,000 daltons, or less than about 2,500 daltons. Test agents can comprise functional groups necessary for structural interaction with proteins, e.g., hydrogen bonding, and can include at least an amine, carbonyl, hydroxyl or carboxyl group, or at least two of the functional chemical groups. The test agents can comprise cyclical carbon or heterocyclic structures and / or aromatic or polyaromatic structures substituted with one or more of the above functional groups. Test agents are also found among biomolecules including peptides, peptide fragments, receptor fragments, co-receptor fragments, saccharides, fatty acids, steroids, purines, pyrimidines, derivatives, structural analogs or combinations thereof.

[0144] Test agents are obtained from a wide variety of sources including libraries of synthetic or natural compounds. For example, numerous means are available for random and directed synthesis of a wide variety of organic compounds and biomolecules, including expression of randomized oligonucleotides and oligopeptides. Alternatively, libraries of natural compounds in the form of bacterial, fungal, plant and animal extracts are available or readily produced.Atty. Dckt.: STAN-2271 WO Client Ref.: S25-149Additionally, natural or synthetically produced libraries and compounds are readily modified through conventional chemical, physical and biochemical means, and may be used to produce combinatorial libraries. Known pharmacological agents may be subjected to directed or random chemical modifications, such as acylation, alkylation, esterification, amidification, etc. to produce structural analogs. Moreover, screening may be directed to known pharmacologically active compounds and chemical analogs thereof, or to new agents with unknown properties such as those created through rational drug design.

[0145] In some embodiments, test agents are synthetic compounds. A number of techniques are available for the random and directed synthesis of a wide variety of organic compounds and biomolecules, including expression of randomized oligonucleotides. See for example WO 94 / 24314, hereby expressly incorporated by reference, which discusses methods for generating new compounds, including random chemistry methods as well as enzymatic methods.

[0146] In another embodiment, the test agents are provided as libraries of natural compounds in the form of bacterial, fungal, plant and animal extracts that are available or readily produced. Additionally, natural or synthetically produced libraries and compounds are readily modified through conventional chemical, physical and biochemical means. Known pharmacological agents may be subjected to directed or random chemical modifications, including enzymatic modifications, to produce structural analogs.

[0147] In some embodiments, the test agents are organic moieties. In this embodiment, test agents are synthesized from a series of substrates that can be chemically modified. “Chemically modified” herein includes traditional chemical reactions as well as enzymatic reactions. These substrates generally include, but are not limited to, alkyl groups (including alkanes, alkenes, alkynes and heteroalkyl), aryl groups (including arenes and heteroaryl), alcohols, ethers, amines, aldehydes, ketones, acids, esters, amides, cyclic compounds, heterocyclic compounds (including purines, pyrimidines, benzodiazepins, beta-lactams, tetracylines, cephalosporins, and carbohydrates), steroids (including estrogens, androgens, cortisone, ecodysone, etc.), alkaloids (including ergots, vinca, curare, pyrollizdine, and mitomycines), organometallic compounds, hetero-atom bearing compounds, amino acids, and nucleosides. Chemical (including enzymatic) reactions may be done on the moieties to form new substrates or candidate agents which can then be tested using the present invention.

[0148] In some embodiments test agents are assessed for any cytotoxic activity they may exhibit toward a living eukaryotic cell, using well-known assays, such as trypan blue dye exclusion, anAtty. Dckt.: STAN-2271 WO Client Ref.: S25-149MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2 H-tetrazolium bromide) assay, and the like. Agents that do not exhibit significant cytotoxic activity are considered candidate agents.

[0149] Candidate agents can be detectably labeled by well-known techniques. Detectable labels include, for example, radioactive isotopes, fluorescent labels, chemiluminescent labels, bioluminescent labels and enzyme labels. Such labeled agents can be used to determine cellular uptake efficiency, quantitate binding of candidate agents at target sites, or visualize localization of a candidate agent in an animal or cell.

[0150] Assays may further include suitable controls (e.g., untreated with candidate agent).Generally, a plurality of tests is run in parallel with different agent concentrations used on different test subjects or cells to obtain a differential response to the various concentrations. Typically, one of these concentrations serves as a negative control, i.e., at zero concentration or below the level of detection.

[0151] In certain embodiments, candidate agents are tested in a non-human primate to determine if an agent has antiarrhythmic activity (i.e., restores normal or closer to normal heart rate or rhythm). For example, a candidate agent can be administered to a non-human primate experiencing arrhythmias to determine if the candidate agent has antiarrhythmic activity. The heart rhythm and heart rate of the non-human primate are monitored before and after administering the candidate agent to the non-human primate to determine the effects of the candidate agent on the heart of the non-human primate, wherein a normal heart rate or rhythm or a closer to normal heart rate or rhythm after administering the candidate agent compared to before administering the candidate agent indicates that the candidate agent has antiarrhythmic activity and is a potential therapeutic for treating the arrhythmia.

[0152] Various methods are known in the art for measuring heart rate and heart rhythm to detect arrhythmias in a subject. For example, an electrocardiogram (ECG) can be used to measure electrical activity of the heart. ECGs may be obtained using a standard (non-portable) 12-lead ECG machine or a portable or handheld 3 lead, 6-lead, or 12-lead ECG device such as a Holter monitor, KardiaMobile 6L portable ECG monitor, EMAY portable ECG monitor, or QT Medical PCA 500 portable ECG monitor. In some embodiments, the heart rate and heart rhythm of a non- human primate are monitored by single-lead or multi-lead electrocardiography. Leads may contact the chest, a hand, or a leg of the non-human primate. In certain embodiments, monitoring the heart rhythm and heart rate comprises performing single-lead, 3-lead, 6-lead, or 12-lead electrocardiography on the non-human primate.Atty. Dckt.: STAN-2271 WO Client Ref.: S25-149

[0153] In particular, agents that affect the activity of the SLC41 A2 magnesium transporter or other magnesium transporters may be useful in treating arrhythmias and restoring sinus node function. Accordingly, candidate agents may be screened for their ability to restore normal rhythmic magnesium transients. In addition, sinus node dysfunction is often associated with slowed rhythmic calcium transients and rhythmic magnesium transients. Therefore, candidate agents may be screened for their ability to restore normal calcium and magnesium flux to treat sinus node dysfunction. Magnesium functional imaging and calcium functional imaging can be used to measure magnesium flux and calcium flux, respectively. In some embodiments, magnesium functional imaging and calcium functional imaging are performed on iSANCs comprising a loss- of-function mutation in an SLC41 A2 gene to determine the ability of a candidate agent to increase calcium flux and / or magnesium flux associated with cardiac pacemaker function.

[0154] Functional calcium imaging of iSANCs comprising a loss-of-function mutation in an SLC41A2 gene can be performed, for example, using microscopy with a calcium indicator such as a fluorescent dye that changes intensity upon binding to calcium (e.g., Fluo-4 or Fura-2) or a genetically encoded calcium indicator (e.g., GCaMP). Functional magnesium imaging of the iSANCs can be performed similarly using a magnesium indicator such as a fluorescent dye that changes intensity upon binding to magnesium (e.g., Mag-Fluo-4, Mag-Rhod-2, or Mag-520) or a genetically encoded magnesium indicator. For a further description of functional calcium and magnesium imaging, see also, e.g., Zhang et al. (2021 ) STAR Protoc. 2:100859, Liu et al. (2018) RSC Adv8(23):12573-12587, and Trapani et al. (2012) Methods Enzymol 505:421-44; herein incorporated by reference in their entireties. Candidate agents that increase calcium and / or magnesium flux in iSANCs may be further tested in a non-human primate having an arrhythmia to determine whether the candidate agent is also effective in restoring normal or closer to normal heart rate or rhythm.Kits

[0155] Also provided are kits comprising any of the non-human primate models of cardiac arrhythmia or the cellular models of sinus node dysfunction such as cardiac sinoatrial nodal pacemaker cells or iSANCs comprising a mutation associated with arrhythmia. In certain embodiments, the kit comprises a genetically modified non-human primate comprising a loss-of- function mutation in the SLC41 A2 gene, wherein the non-human primate has an atrial arrhythmia. In certain embodiments, the kit comprises an iSANC comprising a loss-of-function mutation in the SLC41 A2 gene.Atty. Dckt.: STAN-2271 WO Client Ref.: S25-149

[0156] In addition to the above components, the subject kits may further include (in certain embodiments) instructions for practicing the subject methods. These instructions may be present in the subject kits in a variety of forms, one or more of which may be present in the kit. One form in which these instructions may be present is as printed information on a suitable medium or substrate, e.g., a piece or pieces of paper on which the information is printed, in the packaging of the kit, in a package insert, and the like. Yet another form of these instructions is a computer readable medium, e.g., diskette, compact disk (CD), DVD, Blu-ray, flash drive, and the like, on which the information has been recorded. Yet another form of these instructions that may be present is a website address which may be used via the internet to access the information at a removed site.Examples of Non-Limiting Aspects of the Disclosure

[0157] Aspects, including embodiments, of the present subject matter described above may be beneficial alone or in combination, with one or more other aspects or embodiments. Without limiting the foregoing description, certain non-limiting aspects of the disclosure numbered 1-71 are provided below. As will be apparent to those of skill in the art upon reading this disclosure, each of the individually numbered aspects may be used or combined with any of the preceding or following individually numbered aspects. This is intended to provide support for all such combinations of aspects and is not limited to combinations of aspects explicitly provided below.1. A genetically modified non-human primate comprising a loss-of-function mutation in an SLC41 A2 gene, wherein the non-human primate has atrial arrhythmia.2. The genetically modified non-human primate of aspect 1, wherein the atrial arrhythmia comprises intermittent bradycardia resembling human sick sinus syndrome (SSS).3. The genetically modified non-human primate of aspect 1 or 2, wherein the loss-of- function mutation results in slowed cardiac pacemaker firing compared to cardiac pacemaker firing in a non-genetically modified non-human primate having a wild-type SLC41A2 gene.4. The genetically modified non-human primate of any one of aspects 1-3, wherein the non-human primate is a lemur.Atty. Dckt.: STAN-2271 WO Client Ref.: S25-1495. The genetically modified non-human primate of aspect 4, wherein the lemur is Microcebus murinus, Microcebus rufus, or Microcebus nova.6. The genetically modified non-human primate of any one of aspects 1-5, wherein both alleles of the SLC41 A2 gene comprise the loss-of-function mutation.7. The genetically modified non-human primate of aspect 6, wherein the loss-of-function mutation is an exon deletion, a frameshift mutation, a missense mutation, or a nonsense mutation.8. The genetically modified non-human primate of aspect 7, wherein the loss-of-function mutation comprises a deletion of all or a portion of exon 2 or exon 4 of the SLC41A2 gene.9. The genetically modified non-human primate of aspect 7 or 8, wherein the loss-of-function mutation comprises a deletion of all or a portion of exon 2 of the SLC41 A2 gene, a coding sequence deletion in codon 4 of the SLC41A2 gene, a frameshift mutation in codon 4 of the SLC41 A2 gene, or any combination thereof.10. The genetically modified non-human primate of any one of aspects 1-9, wherein the genetically modified non-human primate is a transgenic non-human primate.11. A method of screening a candidate agent for treating atrial arrhythmia, the method comprising:administering the candidate agent to the genetically modified non-human primate of any one of aspects 1-10; andmonitoring heart rhythm and heart rate of the genetically modified non-human primate before and after said administering the candidate agent, wherein detecting a normal heart rhythm or a closer to normal heart rhythm after said administering the candidate agent compared to before said administering the candidate agent indicates that the candidate agent is a potential therapeutic for treating the atrial arrhythmia.Atty. Dckt.: STAN-2271 WO Client Ref.: S25-14912. The method of aspect 11 , wherein said monitoring the heart rhythm and heart rate comprises performing single-lead, 3-lead, or 6-lead electrocardiography.13. The method of aspect 11 or 12, further comprising measuring rhythmic calcium transients and / or magnesium transients associated with pacemaker activity before and after said administering the candidate agent, wherein detecting normal or a closer to normal rhythmic calcium transients and / or magnesium transients after said administering the candidate agent compared to before said administering the candidate agent indicates that the candidate agent is a potential therapeutic for treating sinus node dysfunction.14. The method of aspect 13, wherein said measuring calcium transients associated with pacemaker activity comprises performing functional calcium imaging.15. The method of aspect 13 or 14, wherein said measuring magnesium transients associated with pacemaker activity comprises performing functional magnesium imaging.16. The method of any one of aspects 11-15, wherein the candidate agent is a small molecule, a peptide, a peptoid, a protein, an aptamer, an antibody, an antibody mimetic, an inhibitory nucleic acid, or a Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) system.17. The method of any one of aspects 11-16, wherein the candidate agent improves pacemaker function of a magnesium transporter.18. The method of aspect 17, wherein the magnesium transporter is the SLC41 A2 magnesium transporter.19. An isolated cardiac sinoatrial nodal pacemaker cell from the genetically modified non-human primate of any one of aspects 1-10.20. A method of producing the genetically modified non-human primate of any one of aspects 1-10, the method comprising genetically modifying a host non-human primate toAtty. Dckt.: STAN-2271 WO Client Ref.: S25-149introduce a loss-of-function mutation into the SLC41 A2 gene, wherein the genetically modified non-human primate has atrial arrhythmia.21. The method of aspect 20, wherein said genetically modifying the host non-human primate comprises using a clustered regularly interspaced short palindromic repeats (CRISPR) system, a transcription activator-like effector nuclease (TALEN), or a zinc-finger nuclease to introduce the loss-of-function mutation into the SLC41 A2 gene.22. The method of aspect 21 , wherein the CRISPR system, TALEN, or zinc-finger nuclease is used to introduce the loss-of-function mutation into one allele of the SLC41 A2 gene.23. The method of aspect 21 , wherein the CRISPR system, TALEN, or zinc-finger nuclease is used to introduce the loss-of-function mutation into both alleles of the SLC41 A2 gene.24. The method of any one of aspects 20-23, wherein the loss-of-function mutation is an exon deletion, a frameshift mutation, a missense mutation, or a nonsense mutation.25. The method of aspect 24, wherein the loss-of-function mutation comprises a deletion of all or a portion of exon 2 or exon 4 of the SLC41 A2 gene.26. The method of aspect 24 or 25, wherein the loss-of-function mutation comprises a deletion of all or a portion of exon 2 of the SLC41 A2 gene, a coding sequence deletion in codon 4 of the SLC41A2 gene, a frameshift mutation in codon 4 of the SLC41A2 gene, or any combination thereof.27. The method of any one of aspects 21 -26, wherein the CRISPR system comprises Cas9 or Cas12a.28. The method of any one of aspects 21 -27, wherein the CRISPR system comprises a single guide RNA (sgRNA) targeting a Cas nuclease to the SLC41 A2 gene.Atty. Dckt.: STAN-2271 WO Client Ref.: S25-14929. The method of aspect 28, wherein the sgRNA specifically binds to a target sequence in a target region of exon 2 of the SLC41 A2 gene.30. The method of aspect 29, wherein the target region comprises the sequence of SEQ ID NO:8.31. The method of aspect 29 or 30, wherein the sgRNA comprises a sequence selected from the group consisting of SEQ ID NOS:1-3 or a sequence having at least 90% identity to a sequence selected from the group consisting of SEQ ID NOS:1-3.32. An induced pluripotent stem cell-derived sinoatrial nodal pacemaker cell (iSANC) comprising a loss-of-function mutation in an SLC41 A2 gene.33. The iSANC of aspect 32, wherein the iSANC has slowed rhythmic calcium transients and magnesium transients compared to an iSANC having a wild-type SLC41 A2 gene.34. The iSANC of aspect 32 or 33, wherein the iSANC is a mammalian iSANC.35. The iSANC of aspect 34, wherein the mammalian iSANC is a human iSANC.36. The iSANC of any one of aspects 32-35, wherein both alleles of the SLC41 A2 gene comprise the loss-of-function mutation.37. The iSANC of any one of aspects 32-36, wherein the loss-of-function mutation is an exon deletion, a frameshift mutation, a missense mutation, or a nonsense mutation.38. The iSANC of aspect 37, wherein the loss-of-function mutation comprises a deletion of all or a portion of exon 2 or exon 4 of the SLC41 A2 gene.39. The iSANC of aspect 37 or 38, wherein the loss-of-function mutation comprises a deletion of all or a portion of exon 2 of the SLC41 A2 gene, a coding sequence deletion in codon 4 of the SLC41A2 gene, a frameshift mutation in codon 4 of the SLC41A2 gene, or any combination thereof.Atty. Dckt.: STAN-2271 WO Client Ref.: S25-14940. The iSANC of any one of aspects 32-39, wherein the iSANC is produced from an iPSC generated from a somatic cell obtained from a patient with sick sinus syndrome who has the loss-of-function mutation in at least one allele of the SLC41 A2 gene.41. The iSANC of any one of aspects 32-39, wherein the iSANC is genetically modified to introduce the loss-of-function mutation into at least one allele of the SLC41 A2 gene.42. A method of screening a candidate agent for treating sinus node dysfunction, the method comprising:contacting the iSANC of any one of aspects 32-41 with the candidate agent; and measuring calcium transients, magnesium transients, or both calcium transients and magnesium transients in the iSANC before and after said contacting the iSANC with the candidate agent, wherein detecting increased calcium transients, increased magnesium transients, or increased calcium transients and increased magnesium transients after said administering the candidate agent compared to before said administering the candidate agent indicates that the candidate agent is a potential therapeutic for treating the sinus node dysfunction.43. The method of aspect 42, wherein said measuring calcium transients comprises performing functional calcium imaging of the iSANC.44. The method of aspect 42 or 43, wherein said measuring magnesium transients comprises performing functional magnesium imaging of the iSANC.45. The method of any one of aspects 42-44, wherein the candidate agent is a small molecule, a peptide, a protein, a peptoid, an aptamer, an antibody, an antibody mimetic, an inhibitory nucleic acid, or a Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) system.46. The method of any one of aspects 42-45, wherein the candidate agent improves pacemaker function of a magnesium transporter.Atty. Dckt.: STAN-2271 WO Client Ref.: S25-14947. The method of aspect 46, wherein the magnesium transporter is the SLC41 A2 magnesium transporter.48. A method of producing the iSANC of any one of aspects 32-41 , the method comprising genetically modifying a host iSANC or an induced pluripotent stem cell from which the host iSANC is produced to introduce a loss-of-function mutation into the SLC41A2 gene, wherein the genetically modified iSANC comprising the loss-of-function mutation in the SLC41 A2 gene has slowed rhythmic calcium transients and magnesium transients compared to an iSANC having a wild-type SLC41 A2 gene.49. The method of aspect 48, wherein said genetically modifying comprises using a clustered regularly interspaced short palindromic repeats (CRISPR) system, a transcription activator-like effector nuclease (TALEN), or a zinc-finger nuclease to introduce the loss-of-function mutation into the SLC41 A2 gene.50. The method of aspect 49, wherein the CRISPR system, TALEN, or zinc-finger nuclease is used to introduce the loss-of-function mutation into one allele of the SLC41 A2 gene.51. The method of aspect 49, wherein the CRISPR system, TALEN, or zinc-finger nuclease is used to introduce the loss-of-function mutation into both alleles of the SLC41 A2 gene.52. The method of any one of aspects 48-51 , wherein the loss-of-function mutation is an exon deletion, a frameshift mutation, a missense mutation, or a nonsense mutation.53. The method of aspect 52, wherein the loss-of-function mutation comprises a deletion of all or a portion of exon 2 or exon 4 of the SLC41 A2 gene.54. The method of aspect 52 or 53, wherein the loss-of-function mutation comprises a deletion of all or a portion of exon 2 of the SLC41 A2 gene, a coding sequence deletion in codon 4 of the SLC41A2 gene, a frameshift mutation in codon 4 of the SLC41A2 gene, or any combination thereof.Atty. Dckt.: STAN-2271 WO Client Ref.: S25-14955. The method of any one of aspects 49-54, wherein the CRISPR system comprises Cas9 or Cas12a.56. The method of any one of aspects 49-55, wherein the CRISPR system comprises a single guide RNA (sgRNA) targeting a Cas nuclease to the SLC41 A2 gene.57. The method of aspect 56, wherein the sgRNA specifically binds to a target sequence in a target region of exon 2 of the SLC41 A2 gene.58. The method of aspect 57, wherein the target region comprises the sequence of SEQ ID NO:8.59. The method of aspect 57 or 58, wherein the sgRNA comprises a sequence selected from the group consisting of SEQ ID NOS:1-3 or a sequence having at least 90% identity to a sequence selected from the group consisting of SEQ ID NOS:1-3.60. A method of screening a candidate agent for treating an arrhythmia, the method comprising:administering the candidate agent to a lemur having the arrhythmia; andmonitoring heart rhythm and heart rate of the lemur before and after said administering the candidate agent, wherein detecting a normal heart rhythm or a closer to normal heart rhythm after said administering the candidate agent compared to before said administering the candidate agent indicates that the candidate agent is a potential therapeutic for treating the arrhythmia.61. The method of aspect 60, wherein the lemur is Microcebus murinus, Microcebus rufus, or Microcebus nova.62. The method of aspect 60 or 61 , wherein the arrhythmia is an atrial arrhythmia or a ventricular arrhythmia.63. The method of aspect 62, wherein the arrhythmia is sinus bradycardia, sinus tachycardia, ventricular tachycardia, non-sustained ventricular tachycardia, supraventricularAtty. Dckt.: STAN-2271 WO Client Ref.: S25-149tachycardia, tachycardia-bradycardia syndrome, atrial fibrillation, premature atrial contractions, premature ventricular contractions, sick sinus syndrome, or wandering atrial pacemaker.64. The method of any one of aspects 60-63, wherein the lemur has ST-segment depression, inverted T-waves, ST-segment elevation, ST-segment depression, small R-waves, tall R-waves, large S-waves and small R-waves, peaked T-waves, a right bundle branch block, a prolonged QRS-complex, or any combination thereof.65. The method of any one of aspects 60-64, wherein said monitoring the heart rhythm and heart rate comprises performing single-lead, 3-lead, or 6-lead electrocardiography.66. The method of any one of aspects 60-65, further comprising measuring rhythmic calcium transients and / or magnesium transients associated with pacemaker activity before and after said administering the candidate agent, wherein detecting normal or a closer to normal rhythmic calcium transients and / or magnesium transients after said administering the candidate agent compared to before said administering the candidate agent indicates that the candidate agent is a potential therapeutic for treating sinus node dysfunction.67. The method of aspect 66, wherein said measuring calcium transients associated with pacemaker activity comprises performing functional calcium imaging.68. The method of aspect 66 or 67, wherein said measuring magnesium transients associated with pacemaker activity comprises performing functional magnesium imaging.69. The method of any one of aspects 60-68, wherein the candidate agent is a small molecule, a peptide, a protein, an aptamer, an antibody, an antibody mimetic, an inhibitory nucleic acid, or a Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) system.70. The method of any one of aspects 60-69, wherein the candidate agent improves pacemaker function of a magnesium transporter.Atty. Dckt.: STAN-2271 WO Client Ref.: S25-14971. The method of aspect 70, wherein the magnesium transporter is the SLC41 A2 magnesium transporter.EXPERIMENTAL

[0158] The following examples are put forth so as to provide those of ordinary skill in the art with a complete disclosure and description of howto make and use the present invention, and are not intended to limit the scope of what the inventors regard as their invention nor are they intended to represent that the experiments below are all or the only experiments performed. Efforts have been made to ensure accuracy with respect to numbers used (e.g. amounts, temperature, etc.) but some experimental errors and deviations should be accounted for. Unless indicated otherwise, parts are parts by weight, molecular weight is weight average molecular weight, temperature is in degrees Centigrade, and pressure is at or near atmospheric.

[0159] All publications and patent applications cited in this specification are herein incorporated by reference as if each individual publication or patent application were specifically and individually indicated to be incorporated by reference.

[0160] The present invention has been described in terms of particular embodiments found or proposed by the present inventor to comprise preferred modes for the practice of the invention. It will be appreciated by those of skill in the art that, in light of the present disclosure, numerous modifications and changes can be made in the particular embodiments exemplified without departing from the intended scope of the invention. For example, due to codon redundancy, changes can be made in the underlying DNA sequence without affecting the protein sequence. Moreover, due to biological functional equivalency considerations, changes can be made in protein structure without affecting the biological action in kind or amount. All such modifications are intended to be included within the scope of the appended claims.Example 1A Primate Model Organism for Cardiac Arrhythmias Identifies a Magnesium Transporter in Pacemaker Function

[0161] Cardiac arrhythmias afflict tens of millions of people, causing one-fifth of all deathsl..Although mouse models have aided understanding of some pacemaker genes and arrhythmias, mice are not known to naturally acquire arrhythmias, and the substantial differences betweenAtty. Dckt.: STAN-2271 WO Client Ref.: S25-149mouse and human cardiac anatomy and physiology have limited their utility in preclinical studies and pharmacological testinq2-6.

[0162] Many aspects of mouse lemur physiology, behavior, ecology, and phylogeny have been elucidated over the past half century by studies in their native rainforests in Madagascar and in laboratory colonies in Europe and the United States?. To determine if mouse lemurs could be used for genetic interrogation of primate biology, behavior, and diseases, we and our collaborators systematically screened laboratory and wild mouse lemurs to find individual, heritable traits that could be genetically and molecularly mapped, the classical genetic approaches that have proven so powerful for the canonical genetic model organisms and for human diseases24,25. We phenotyped hundreds of individual lemurs using dozens of assays for diverse anatomical, clinical, and behavioral traits, like the phenotyping assays used to characterize targeted gene knockouts in mice (IMPC)26. Here we describe the results of an electrocardiograph (ECG) screen of lemurs to detect cardiac pathologies, and the subsequent pedigree analysis and genetic mapping of one of the eight identified familial, human-like arrhythmias. This uncovered a new gene, molecules, and mechanism of the primate cardiac pacemaker.RESULTSMouse lemur cardiovascular phenotyping by electrocardiography

[0163] The cardiac conduction system of mammals has three major components (FIG. 1D)27.One is the sinoatrial node (SAN), electrically specialized cardiomyocytes that autonomously and rhythmically generate the action potentials that initiate each cardiac cycle (heartbeat). SAN cells (SANCs) serve as the pacemaker that normally dictates heart rate, increasing or decreasing their firing rate to match physiological demand. These electrical signals spread through and contract atrial cardiomyocytes, reaching the atrioventricular node (AVN) and His-Purkinje system (left and right bundle branches, LBB and RBB, and Purkinje fibers), the other two components that rapidly spread the contraction signal to ventricular cardiomyocytes to complete the cardiac cycle. Genetic, physical, or chemical alteration, dysregulation, or destruction of any of these three components can cause arrhythmias, as can creation of ectopic sites of cardiac electrical activity or repolarization. The specific site and component affected, and how it is affected, determines the type and clinical significance of the arrhythmia, and its prognosis and therapies. Many arrhythmias and other cardiac pathologies can be detected by electrocardiography (ECG), which usesAtty. Dckt.: STAN-2271 WO Client Ref.: S25-149sensitive electrodes placed on the body surface to measure electrical changes in the heart, including depolarization and repolarization of the conduction cells and contracting cardiomyocytes as the pacemaker signal propagates through the heart during each beat.

[0164] For rapid, point-of-care mouse lemur cardiovascular phenotyping, we used a simple commercial human home ECG monitor in which a mouse lemur subject was placed on the device with each hand positioned on an electrode pad (FIG. 1 B), where fingers of a human subject are normally placed (FIG. 1 A). The animals are quite docile, even wild mouse lemurs (see below), most needing only gentle guidance for hand placement, which typically remained in place for the full recording period (10 to 30 secs). This allowed capture of mouse lemur electrocardiogram traces (FIG. 1 E) in the subject’s native state, without need for sedation or anesthesia, cardiorespiratory-depressing agents that are typically required for ECG assessment of mouse and other animals. We modified the standard commercial instrument by putting a third electrode pad near the others (FIG. 1 C), on which a foot of the lemur was positioned. This provides a 3- electrode ECG (two hands and a foot), from which a conventional 6-lead ECG can be derived (FIGA. 1D ,1 E).

[0165] A typical cardiac cycle from an ECG of a laboratory M. murinus lemur displays the classical features of a healthy cardiac waveform in humans (FIG. 1F). Each cycle comprises three sequential electrical waves: the P-wave (representing atrial depolarization), QRS-complex (ventricular depolarization), and T-wave (ventricular repolarization). The M. murinus waveform resembles that of human more closely than mouse does: its T-waves are, like human, more curved and rounded, and there is a discrete T-wave separated from the QRS-complex as for human, whereas there is no discrete T-wave in mouse because ventricular repolarization begins immediately after the R-wave so the T-wave is partially fused with the QRS-complex (FIG. 1 F). This suggests that chamber-specific ion channel expression and function may be better conserved between the two primates than between either primate and mouse. Other differences between mouse and human conduction systems are described in Table 3.

[0166] In the normal lemur heart at rest (normal sinus rhythm, NSR), each cardiac cycle was detected discretely from the preceding and successive beats. The heart rate (HR) for M. murinus was 431 ±61 beats per min (bpm, mean ±SD, n=334; range 309 - 553 (95% confidence interval), comparable to the value (427 ±43 bpm) for lab M. murinus obtained by continuous 1 -lead invasive cardiac telemetry28. We determined NSR as 309 - 389 bpm (see Methods), with values outside this range demarcating slower (sinus bradycardia, SB) or faster (sinus tachycardia, ST) heart rates. Using our portable ECG monitor in and around Ranomafana Rainforest in Madagascar, weAtty. Dckt.: STAN-2271 WO Client Ref.: S25-149obtained slightly slower NSR values for wild M. rufus (260 - 458 bpm, 95% Cl with mean 359 ±49, n=65) and a newly discovered but as yet unnamed species that we refer to here as M. species nova or M. nova for short (237 - 421 bpm, 95% Cl with mean 329 ±46, n=37). The normal mouse lemur heart rate is intermediate between that of humans (60 - 100 bpm)29-31 and mice (600 - 800 bpm)6. The slower heart rate of mouse lemurs than mouse is valuable experimentally because it is less prone to artifacts and easier to detect arrhythmias and other ECG variants, and it may predispose to naturally-occurring arrhythmias (see below) that so far remain elusive in mice.ECG screening identifies eight lemur cardiac arrhythmias and pathological variants

[0167] The point-of-care ECG monitor was used to evaluate cardiac function in 356 mouse lemurs. We performed a total of 702 ECGs: 565 on 255 M. murinus lemurs from MNHN laboratory colony, and 137 ECGs on 101 wild M. rufus and M. nova lemurs (FIG. 1G). ECGs were typically repeated for each animal on the same day and, when possible, on separate days for corroboration; serial recordings were generally consistent except for gradually slowing heart rates indicating acclimation of the subject to the ECG procedure. Some lemurs were followed longitudinally, including ones with detected ECG pathologies (see below). Automated human ECG readers did not reliably interpret mouse lemur ECGs, so each ECG was independently read and validated by two to three board-certified cardiologists. This identified 19 different naturally- occurring mouse lemur arrhythmias and ECG variants (FIG. 1G), each resembling a known human condition including eight human arrhythmias and pathological variants (FIG. 2), seven other ECG variants that can be pathological in humans but require further diagnostic tests (FIG.3), and four physiological or benign human variants (FIG. 11).

[0168] Among the 356 mouse lemurs screened, 22 (6.2%) had ECG abnormalities resembling pathological human arrhythmias or variants (Table 1). Five lemurs (1.4%) had more than one ECG-diagnosed pathology including three lemurs with three different pathologies, indicating serious underlying cardiovascular disease (see below). The identified cardiac pathologies included major arrhythmias arising from both the atrial and ventricular chambers. One detected atrial arrhythmia was atrial fibrillation (Afib), identified in a 4.6 year old male (169AFB) in the lab colony (FIG. 2; typical mouse lemur lifespan ~6 vears32). Afib is the most common human arrhvthmia27,33, marked by chaotic activation of multiple pathological atrial foci causing both atria to fibrillate and flow to stagnate, predisposing to blood clots and stroke. Hyperlipidemia- induced atherosclerosis, obesity, and premature atrial contractions (FACs), which arise in humans fromAtty. Dckt.: STAN-2271 WO Client Ref.: S25-149extranodal atrial tissue that fires before and suppresses sinoatrial node pacemaking, are all significant Afib risk factors in humans. The afflicted lemur (169AFB) showed several risk factors including PACs detected on ECG a year earlier (age 3.1 ). PACs were also found in two other lab lemurs and four wild lemurs (Table 1). A third atrial arrhythmia, resembling human sick sinus syndrome (SSS), was found in eight lemurs and is described in a separate section below.

[0169] The screen also identified five arrhythmias and ECG pathologies of ventricular origin (FIG.2, bottom). A 2.1 yr old lab lemur (351 BA) showed premature ventricular contractions (PVCs), extra beats that arise from extranodal ventricular tissue in humans and form broad and bizarre QRS complexes like those seen in this lemur (FIG. 2). Such complexes in humans typically indicate cardiac pathology, notably myocyte irritability from ischemia or from structural alterations caused by cardiomyopathies, myocarditis, or valvular heart disease27. A PVC burden (fraction of normal beats) of 5% or more in human patients is considered high and places them at risk for sustained ventricular tachycardia (VT) and arrhythmia-induced pathological ventricular remodeling and heart failure; the PVC burden of the afflicted lemur (351 BA) was 23%, over four times this human clinical threshold. A wild M. nova male (243) had non-sustained ventricular tachycardia (NSVT), three or more consecutive PVCs (FIG. 2). This pathology in humans most commonly results from coronary ischemia, and if sustained (VT), leads to decreased cardiac output, hypotension, and syncope; VT is the leading cause of sudden cardiac death in adults27,34.

[0170] ST-segment depression (STD) and inverted T-waves (iTW) are ventricular repolarization pathologies that in human patients commonly arise from myocardial ischemia from coronary artery disease. Four lab lemurs showed both of these ECG pathologies. Three of them were also afflicted with the episodic bradycardia of sick sinus syndrome (see below), whereas 308A was persistently tachycardic (Table 1). One lab lemur (283A, FIG. 2) and one wild lemur (308, Table 1) showed STD alone, and another lab lemur (381 C, FIG. 2) showed only iTW, detected when she was just 1.6 yrs old. 283A was persistently tachycardic on all other ECGs (3 on 3 different days, avg 463 bpm) and 381 C was tachycardic on all ECGs (4 on 4 different days, avg 458 bpm). One young lab lemur (300AEC) was tachycardic (500 bpm) with ST-segment elevation (STE) in conjunction with a small R-wave (FIG. 2; see below), which in humans diagnosed on 12-lead ECG is highly sensitive for acute myocardial infarction, a cardiac emergency known as ST- elevation myocardial infarction (STEMI) where the infarct spans the full thickness of the heart wall (transmural)27. STEMI manifests classically with elevation of the ST-segment in a convex mannerAtty. Dckt.: STAN-2271 WO Client Ref.: S25-149(resembling a tombstone), and a small R-wave due to loss of R-wave voltage as the myocardium becomes necrotic, both seen here in lemur 300AEC’s ECG.Identification of seven potentially pathological lemur ECG variants

[0171] In addition to the arrhythmias and pathological variants described above, we identified four physiological or benign variants in heart rate and waveform (FIG. 11) along with seven potentially pathological variants that can be pathological in humans but depend on other physical symptoms and signs for definitive diagnosis (FIG. 3).

[0172] Potentially pathological variants include supraventricular tachycardia (SVT), found in 14 lab lemurs. In humans, SVT can result either from high but benign activity of the sinoatrial node pacemaker that obscures the normal P-wave, or from the pathological activity of extranodal atrial tissue driving an atrial tachyarrhythmia such as atrial fibrillation. Another potentially pathological variant we uncovered was wandering atrial pacemaker (WAP). This is usually a benign condition in humans found incidentally in young, healthy athletic individuals caused by changes in vagal tone (e.g., from stress, diet, transient electrolyte disturbances) that stimulate ectopic foci and produce an irregularly irregular rhythm. However, it can also occur in the elderly caused by sinus node dysfunction or chronic lung conditions. Two wild lemurs were identified with WAP, and both also had intermittent peaked T-waves (see below), which too is often a normal variant in young patients or caused by electrolyte changes. One lab lemur (300AF, 1.6 yrs old) was found with right bundle branch block (RBBB), a widening of the QRS complex caused by delayed depolarization of the right bundle branch of the conduction system. Although RBBB in humans is typically beniqn35, it is a common presentation of several congenital heart diseases and can be a sequela of several primary cardiac and lung diseases. Large S and small R-waves (S>R) are associated with right deviation of the cardiac axis in humans from right heart strain, and was found in four lab lemurs. Small R-waves were found in 17 lab lemurs and one wild lemur. This is a common ECG finding in humans resulting from loss of cardiac tissue from myocardial infarction or cardiac fibrosis, or from normal variation in heart orientation27. Three lab animals (300AEC, 300AED, 300AEB) had small R-waves at young ages. For 300AEC, this co-presented with STE (see above), while small R-wave alone was seen in 300AEB and 300AED (at ages 0.9 and 3.0, respectively). Tall R-waves were found in 32 lab lemurs and 6 wild lemurs. In humans this is commonly caused by thickening of the myocardium from cardiomyopathy or pathological hypertrophy, but it can also be seen with performance hypertrophy ("athlete's heart") or thin chest wall. Peaked T-waves (pTWs) were observed in 27 lab lemurs and 40 wild lemurs. In humans thisAtty. Dckt.: STAN-2271 WO Client Ref.: S25-149can be a normal variant in youth and athletes36, but it can also result from acute myocardial infarction or hyperkalemia, the latter potentially contributing to its surprising prevalence in wild lemurs that are baited with a high potassium (banana) meal.

[0173] Table 2 compares the prevalence of cardiac arrhythmias and variants in laboratory and wild mouse lemurs. There were no statistically significant differences in prevalence of any of the rare arrhythmias or pathological variants, or the overall prevalence of cardiac arrhythmias and pathological variants between lab (5.9%, 15 of 255 screened) and wild (6.9%, 7 of 101) lemurs. Although a similar unbiased, systematic ECG screen has not been done for humans, the prevalence of human arrhythmias is estimated at 2-5% of the population33, similar to the value obtained here for lemurs. Curiously, in the lemurs there were striking prevalence differences in one common potentially pathological variant (pTWs: 11% lab vs 40% wild, p<1.6e-3) and one normal variant (sinus arrhythmia, SA: 2.0% vs 43%, p<1.6e-3), perhaps because young lemurs are overrepresented among wild lemurs and these variants are more prevalent in young lemurs as they are in young humans. There were no statistically significant differences in prevalence between sexes in either lab or wild animals.Lemur sick sinus syndrome

[0174] An atrial arrhythmia resembling human sick sinus syndrome (SSS) was identified in seven lab lemurs and one wild lemur (FIG. 2, Table 1). Human SSS is an episodic, substantially slow heart rate (bradycardia) that manifests symptomatically, affecting ~1 in 600 adults over age 6537,38. Most commonly it results from scarring, degeneration, or damage to the sinoatrial node from aging or primary cardiac diseases such as atrial fibrillation, myocardial infarction, and cardiomyopathies, but there are also rarer genetic causes (see below). Pathological remodeling of the sinoatrial node over time can be complicated by overcompensatory activation of ectopic atrial foci, resulting in abnormal tachycardias, so SSS can present as (and is sometimes called) tachycardia-bradycardia syndrome (TBS) that alternates between periods of unusually slow and fast heart rates37,38. As the disease progresses, it can cause sinus arrest, lethargy, dizziness, confusion, and life-threatening syncope. It is typically treated by implantation of an electronic pacemaker device that rhythmically stimulates the heart to restore normal heart rate and function37,38.

[0175] In the seven affected lab lemurs, we found episodic, substantially slow heart rates that ranged from 169 - 300 bpm during the bradycardic episodes (FIG. 4, top). Between episodes, heart rates sometimes returned to normal, but three lemurs (300AA, 300AB, 300AC) showedAtty. Dckt.: STAN-2271 WO Client Ref.: S25-149tachycardia during an interim period as in human tachycardia-bradycardia syndrome. It was an early onset disease that was detected at late juvenile stage or early adulthood (age 1.5 - 4.6 yrs) (Table 1).

[0176] Several associated clinical and ECG findings in the affected individuals suggest that the episodic bradycardia was clinically significant. First, all but one of the affected lemurs exhibited severe fatigue on physical exam or a combination of low activity scores and / or decreased grip strength in our deep phenotyping assay (Table 1), which commonly manifested at the same time or day as the recorded ECG pathology. Lethargy is often the presenting symptom of human SSS due to inadequate cerebral perfusion, warranting electronic pacemaker placement. Second, three of the affected individuals (241 EA, 300AB, 300AC) showed additional ECG pathologies beyond the episodic bradycardia, notably ST-segment depression (STD) and inverted T-waves (iTW) (FIG. 4, Table 1 ). Both of these ECG pathologies signify abnormalities in ventricular repolarization that are commonly seen in states of myocardial ischemia in humans27, suggesting that the slow heart rate in these lemurs was not meeting cardiac demand. Consistent with this interpretation, the pathological ECG triad (SSS / STD / iTW) typically presented together on the same ECG traces (FIG. 4, top, 300AB age 3.5 trace). Finally, one of the affected lemurs (300AB, with the pathological triad), died prematurely at age 3.9 yrs. His sudden death during routine anesthesia suggests that the anesthetic (isoflurane, a cardiorespiratory depressant) may have caused cardiac arrest by further compromising his SSS chronotropic incompetence. Two other affected lemurs were found dead in their cages, and 314C, although not formally diagnosed with SSS because it was only assayed by ECG once at age 1 .5 yrs, had borderline bradycardia (310 bpm) and grip strength, and was found dead at 2.2 yrs. Seven other animals in the SSS pedigree (see below, FIG. 4) also died young of unexplained death.Lemur SSS shows familial clustering

[0177] Lemur SSS was an early onset disease similarly affecting both sexes (Table 1), and the available serum profiles of affected individuals (n=4, 204FD, 241 EA, 261 BBA, 300AC) showed normal glucose levels and lipid panels including cholesterol. This suggested that advanced age and other common cardiovascular risk factors (hyperlipidemia, atherosclerosis) for the most common etiologies of human SSS did not underlie this lemur disease. The human disorder can also be a channelopathy caused by mutations in cardiac conduction channels HCN439 or SCN5A21, which result in severe symptomatic bradycardia requiring pacemaker placement. To explore potential genetic causes of lemur SSS, we constructed a pedigree of the BrunoyAtty. Dckt.: STAN-2271 WO Client Ref.: S25-149laboratory colony (Karanewsky, Pendleton, Anzeraey, Terrien et al, unpublished data) and used it to determine if there was a family relationship among affected individuals. Maternal identities were ascertained from historical breeding records, but because paternity was ambiguous (for routine breeding, estrus females are typically presented with three or four male suitors) it was resolved by DNA sequencing of five selected polymorphic loci of each individual in the colony, its mother, and all possible fathers (see Methods).

[0178] The pedigree revealed striking familial clustering of lemur SSS (FIG. 4, bottom). Five of the affected lemurs are first degree relatives: an affected father (261 BBA) and his two sons (300AA, 300AB) and daughter (300AC) from breeding with an unaffected mother (300A), as well as the daughter (241 EA) of the same father (and half-sister of the others) from breeding with another unaffected mother (241 E). The father had SB alone (mild phenotype), three children (300AA, 30300AB, 300C) had the progressively worse tachy-brady syndrome (TBS) of which two (300AB, 300AC) along with their half-sister (241 EA) had the pathological triad (SB, iTW, STD). Determining the pedigree of a sixth affected individual (204FD) is in progress, but initial genotyping data indicate that he and 261 BBA are likely half brothers, sharing the same father (206CBA); their presumptive father (206CBA) would then be the likely founder of this SSS pedigree. Pedigree construction is also underway for the seventh affected individual (397C), a potential two-generation descendant of the 300-designated animals (FIG. 7). Although thus far the next generation has not shown SSS on ECG screening, iTWs were detected at age 1.6 yrs in a female offspring (381 C) of 300AB, who was persistently tachycardic and euthanized at 5.2 yrs due to weakness and lethargy. Two other offspring of his died prematurely of unknown causes: 262DC (2.3 yrs, before ECG screening was done) and 262DA (5.1 yrs), the latter with decreased grip strength (at 4.5 yrs).

[0179] We have also begun investigating family relationships of lemurs afflicted with other arrhythmias and CVDs, and uncovered a second ECG pathology with familial clustering. Two of the three lab lemurs identified in the screen with premature atrial contractions (PAG prevalence in colony, 2.5%), one of whom also progressed to atrial fibrillation, are littermates (169AFA, 169AFB) (FIG. 8). Like SSS, PACs (potentially progressing to atrial fibrillation) is thus also likely to be familial, possibly another simple Mendelian disease segregating in the lab colony. Other potentially pathologic ECG traits as well as a serum lipid disorder resembling human familial hypercholesterolemia uncovered in the deep phenotyping screen also showed familial clustering and will be described elsewhere.Atty. Dckt.: STAN-2271 WO Client Ref.: S25-149Lemur SSS is an autosomal recessive disorder that maps to a locus on chromosome 7 including SLC41A2 magnesium transporter

[0180] The SSS pedigree suggested that this arrhythmia is a simple Mendelian disorder, consistent with either autosomal recessive or dominant inheritance pattern. To determine the inheritance pattern and map the SSS disease-causing locus, we performed Illumina paired-end, short-read shotgun whole genome sequencing (27x - 293x coverage, median 54x) for 35 lemurs from the lab colony including six lemurs with SSS (all except 397C) and 29 unaffected individuals (five unaffected family members plus 24 control animals outside the SSS pedigree) (Table 4). We used the obtained sequences to create an extensive library of M. murinus genomic sequence variants (-45 million variants, one every -55 nucleotides on average), including mostly singlenucleotide polymorphisms (SNPs, 80%) but also short (typically <50 base pair) insertion (-10% ) and deletion (-10%) alleles (Chang et al, unpublished data) that could be used for mutation mapping by linkage analysis (FIG. 5A).

[0181] We searched among the identified variants for ones that were tightly linked to (co- inherited with) the SSS phenotype in the pedigree (FIG. 5A). No variants were co-inherited with SSS in an autosomal dominant (AD) pattern, indicating the disease is unlikely to be a simple Mendelian autosomal dominant disorder. In contrast, we found 365 variants that were perfectly linked to the SSS phenotype in an autosomal recessive inheritance pattern. Nearly all of the linked variants (352, >96%) mapped to a single genomic interval spanning 1.4 Mb on chromosome 7 (FIGS. 5A, 5B); the rest (13) were scattered in several locations around the genome, all but two on short, unplaced scaffolds (FIG. 5A). The mapped 1.4 Mb region contains nine candidate genes with associated variants, with half of the linked variants (171 , 49%) localized to the -260 kb subregion at the right end of the interval containing two genes, SLC41A2 and CHST11. None of the linked variants were in coding exons, except for a single synonymous variant (c.2157A>G, ALA719ALA) in ALDH1L2 (FIG. 5B). This suggests that the disease-causing mutation is likely a regulatory mutation.

[0182] This linkage analysis and mapping of the lemur SSS locus excludes HCN4 and SCN5A, orthologs of the two canonical human SSS channelopathy qenes21 ,39, which in lemur are located on chromosomes 3 and 1 (FIG. 5A). Among genes within the mapped interval on chromosome 7 (FIG. 5B), the most appealing candidate was SLC41A2, a little studied transmembrane magnesium transporter40,41 . It is the only gene in the interval that encodes an ion transporter or channel, and it is expressed in lemur atrial cardiomyocytes where the sinoatrial node pacemaker resides (FIG. 5B)42. A mouse SLC41A2 knockout generated and systematically phenotyped byAtty. Dckt.: STAN-2271 WO Client Ref.: S25-149the Knockout Mouse Project (KOMP2) identified a cardiac ventricular conduction defect in the homozygous mutants that manifests as a widened QRS interval on ECG43 (FIG. 9). The phenotype is selective for heart and this specific conduction defect (FIG. 9), much as the lemur phenotype is selective for heart and the SSS arrhythmia and its sequelae. However, there was no evidence of a widened QRS interval in affected lemurs (32.6 ±1.2 msec, mean ±SD, n=7 affected lemurs vs. 32.4 ±1.8 msec, n=10 wild-type; p=0.87 (non-significant) by two-tailed student’s t-test with equal variance), and conversely there was no evidence of SSS or other arrhythmias or sinus node pacemaker defects in the mouse SLC41A2 knockout (FIG. 9). Hence, if SLC41A2 is the lemur SSS disease gene, then it functions differently in the mouse and lemur hearts. None of the other genes in the mapped lemur SSS disease interval had any obvious connection to cardiac pacemaking, conduction or disease, nor did any of the available mouse knockouts in these genes display a cardiac phenotype (FIG. 5B, Table 5).SLC41A2 knockout slows firing and alters magnesium dynamics of human SA node pacemaker cells

[0183] To determine if SLC41A2 functions in the cardiac pacemaker of primates, we developed the scheme shown in FIGS. 60, 12a, and 12B to create a CRISPR / Cas9-mediated knockout of SLC41A2 in SA node cardiomyocytes (SANCs) derived from human pluripotent cells. DNA sequencing of the obtained knockout SANCs showed that mutant cells had a 118 bp homozygous deletion in the targeted exon (exon 2) of SLC41A2, resulting in a frameshift mutation and early stop codon (FIGS. 6A, 12B). Immunostaining detected expression of SLC41A2 in wild-type SANCs (see below), but not in the SLC41A2 knockout SANCs (FIG. 12C).

[0184] We used functional calcium imaging of cultured SANCs to examine the effect of the SLC41A2 knockout on the transient calcium spikes that underlie cardiac pacemaker function. Control wild-type SANCs fired at —100 spikes per minute, whereas the firing rate of the SLC41A2 knockout SANCs was -20% slower (80 spikes per min) (FIG. 6E). This reduction in firing rate was associated with increased time to peak, increased tau decay time, and increased duration of the peak of the calcium transients, whereas spike amplitude was unaffected. We conclude that SLC41A2 is required cell autonomously in human SANCs to maintain their normal rate and waveform of pacemaker firing.

[0185] SLC41 A2 is one of three members of a small family of multipass transmembrane proteins that function as magnesium-selective transporters40,41 ,44,45 (FIG. 6B). The best studied member is SLC41A1, which transports magnesium ions across the plasma membrane44.Atty. Dckt.: STAN-2271 WO Client Ref.: S25-149SLC41A3 is a mitochondrial magnesium transporter44. SLC41A2 is the least well understood though it too can function as a magnesium ion-selective transporter when expressed in heterologous cells (Xenopus oocytes, chicken DT40 cells)44,46,47. In wild-type SANCs, SLC41A2 was not detected on the plasma membrane but instead localized to an intracellular compartment, the sarcoplasmic reticulum (FIG. 6D). Magnesium is well established as a gatekeeper for calcium entry and cardiac contraction^, but its role in pacemaker cells and cardiac pacemaking has not been previously investigated. To explore the impact of SLC41 A2 on magnesium levels and dynamics in cardiac pacemaker cells, magnesium functional imaging was performed on human SANCs, as done above for calcium. We discovered that magnesium levels are not constant in wild-type SANCs but rather they spike regularly, much like the canonical calcium spikes (FIG. 6F). However, in SLC41A2 knockout SANCs, the magnesium transients occurred at irregular intervals, sometimes with small ectopic spikes, and with overall increases in magnesium amplitude, time to peak, tau decay time, and peak duration. Thus, magnesium spikes regularly in human SANCs, and SLC41A2 is required for the proper timing, waveform, and amplitude of these intracellular magnesium transients.DISCUSSION

[0186] We established a primate model for cardiac arrhythmias through systematic ECG screening of over 350 mouse lemurs that identified eight naturally-occurring arrhythmias resembling human pathological conditions plus seven other variants seen in potentially pathological human conditions. The most common arrhythmia (2.2% prevalence) was a profound, intermittent bradycardia resembling human SSS. Lemur SSS is an autosomal recessive and fully penetrant disorder that can be detected early in life and have significant clinical sequelae associated with cardiac chronotropic incompetence including sudden death, like the human disease if left untreated. Genome sequencing and linkage analysis of the lemur pedigree mapped the disease locus to a 1.4 Mb interval on chromosome 7 containing nine candidate genes with linked polymorphisms. The most appealing candidate is SLC41A2, a little studied transmembrane magnesium transporter whose mouse knockout phenotype is cardiac-selective like the lemur disease but manifests as a ventricular conduction defect43 (wide QRS complex) rather than the sinoatrial node (SAN) pacemaker dysfunction of lemur and human SSS. SLC41A2 is expressed in iPSC-derived human SAN cells (SANG) and localizes to the sarcoplasmic reticulum, and CRISPR-Gas9 mediated SLC41A2 knockout slowed the rhythmic calcium transients that underlie their automaticity and pacemaker function. Thus, SLC41A2 is a critical new component of theAtty. Dckt.: STAN-2271 WO Client Ref.: S25-149human pacemaker and functions cell autonomously to increase calcium spike frequency and pacemaker activity. Other SANG ion transporters and channels such as HCN4 are also critical for calcium spikes and pacemaker activity, and when mutant cause human SSS (REF) supporting our provisional assignment of SLC41A2 as the lemur SSS disease gene and suggesting it functions similarly in the lemur but not the mouse cardiac pacemaker. Likewise, our results nominate human SLC41A2 as a candidate gene for familial forms of human SSS not attributable to a canonical SSS gene such as HCN439.

[0187] Our results also revealed rhythmic magnesium transients in human SANCs, like the classical calcium spikes. The magnesium spike pattern, level and waveform were altered in SLC4 M2-knockout SANCs, presumably due to altered magnesium flux from the sarcoplasmic reticulum normally mediated by the SLC41A2 transporter. These results lead us to propose that SLC41A2 and intracellular magnesium dynamics comprise an important but previously unappreciated axis of the cardiac pacemaker. Current models of pacemaker automaticity invoke a coupled-clock system operating within each SANC49-51 (FIG. 6G). A plasma membrane oscillator or clock ("membrane clock"), mediated by a set of time and voltage-dependent membrane ion channels including HCN4, is coupled to a sarcoplasmic reticulum calcium clock ("Ca clock"). The latter stimulates sodium influx in exchange for calcium gated by the Ryanodine Receptor (RyR), working in tandem with the membrane clock to depolarize the nodal cell membrane and activate the voltage-gated L-type calcium channel (LTCC), resulting in the rhythmic calcium spikes and firing of each heartbeat-inducing action potential. Our results identify a third oscillator ("magnesium clock") in each SANC that appears to interact with and regulate the other two clocks. Although the mechanisms by which magnesium transients are generated and impact the other clocks remain to be defined, this new oscillator must involve additional channels and transporters beyond SLC41A2 because magnesium transients persisted in SLC41A2 knockout SANCs, albeit with altered kinetics and waveforms. Magnesium has long been known to influence cardiac automaticity and conduction48, and magnesium therapy is used clinically to treat or stabilize certain human arrhvthmias52-55. The identification of SLC41A2 function and magnesium oscillations in SANCs provide a rationale and target for development of new, mechanism-based therapeutics for SSS and other sinus node arrhythmias. The current standard of care for SSS is placement of an electronic pacemaker, and SSS is the most common indication for pacemaker placement56. A medical therapy would spare patients the invasive procedure and clinical complications of the implanted device.Atty. Dckt.: STAN-2271 WO Client Ref.: S25-149

[0188] Our systematic screen and genetic mapping of a heritable trait establish mouse lemurs as a tractable genetic model organism. Their exceptionally small size (60 gm), short generation time (6-8 months), large litter size (typically 2-3), and modest lifespan (~6 years) for a primate, and the relative ease in creating, maintaining, and expanding a laboratory colony?, facilitated our systematic phenotypic screening, multigeneration pedigree analysis, and genetic mapping - classical genetic approaches impractical for other non-human primates. By focusing our screen on easy to identify and medically important traits (arrhythmias) for which there is urgent need for new preclinical models, we were able to uncover natural models for many significant human arrhythmias. Most importantly, we demonstrated the value of this new genetic model by discovering a new gene (SLC41A2), molecules (SLC41A2, magnesium ions), and mechanism (magnesium transients) of the primate pacemaker, and by identifying a novel candidate gene and therapeutic target for human sinus node arrhythmias.

[0189] These forward genetic approaches can now be applied to any familial trait in mouse lemur, including atrial fibrillation (FIG. 8), the most common human arrhvthmia33, and other extant familial diseases such as cardiovascular (hypercholesterolemia, obesity)57, oncologic (endometrial cancer)58, neurodegenerative (Alzheimer's-like)59, and motor (stutter step)60 pathologies. These complement the reverse genetic approach that we also recently established, in which natural knockout mutations in lemur genes, including three of the hundreds of primate genes missing in mice, have been identified by genome sequencing and their transcriptional effects described61 , and the cellular and molecular biology approaches enabled by an extensive transcriptomic cell atlas of over 750 cell types across 27 orqans42,61. We hope these genetic, cellular, and molecular advances for mouse lemur provide the experimental foundation to achieve new insights and ultimately interventions for many primate diseases and other aspects of primate biology, behavior, and ecology.METHODSAnimals

[0190] Laboratory M. murinus lemurs were from the closed captive breeding colony at the Museum National d'Histoire Naturelle in Brunoy, France. Lemur husbandry and care has been described32. Briefly, lemurs were housed indoors individually or in small groups in cages enriched with tree branches, wooden nest boxes, and artificial lighting. Photoperiod light cycles were alternated from 14:10-h (light) to 10:14-h (dark) every six months to stimulate photoperiod-Atty. Dckt.: STAN-2271 WO Client Ref.: S25-149dependent seasonal behavior and metabolic changes, and ambient temperature was maintained at 24-26°G and humidity at -55%. Diet included cereal, fresh fruit, gingerbread, milk, and eggs, and water was provided ad libitum. Regular health monitoring included weekly assessments and monthly veterinary examinations. All procedures adhered to European ethical regulations for animal use in biomedical research and were approved by the Animal Welfare board of UMR 7179. Seven descendants of this breeding colony, used only for whole genome sequencing analysis, were transferred to and maintained at the Stanford Animal Research Facility at Stanford Medical School for noninvasive phenotyping and genetic research as approved by the Stanford University Administrative Panel on Laboratory Animal Care (APLAC #27439) and in accordance with the Guide for the Care and Use of Laboratory Animals, as detailed oreviouslv42,62.

[0191] Wild M. rufus and M. nova lemurs living in and near Ranomafana National Park (RNP) that have been followed longitudinally in the field for decades by serial capture-and- release7,63,64 were analyzed at Centre ValBio (CVB) field station, which houses a modern genetics and molecular biology laboratory at the edge of RNP65. Briefly, individual lemurs were captured in live rodent traps baited with a banana slice and secured to a tree branch. Traps with lemurs were brought to the lab for lemur deep phenotyping including ECG analysis, and the lemur was then released back into the wild at the capture site several hours later. Lemurs were named and identification microchips placed subcutaneously the first time they were captured and phenotyped.Electrocardiography and heart rate analysis

[0192] Single-lead, 3-lead, and derived 6-lead point-of-care electrocardiography (ECG) assays were based on the Kardia system (AliveCor®), an FDA-cleared device for human ECG detection that we adapted for application to mouse lemur. For single-lead recordings, the KardiaMobile® device with two electrode pads (each designed to contact one or two fingers of a human hand) was remotely connected to a smartphone (Apple iPhone models 8, XS Max, 12 Pro, and 14) via the Kardia software app (versions 5.27.0 and 5.41 .0). For 3-lead and derived 6-lead recordings, the KardiaMobile® 6L device, which has a third electrode pad on the back of the device that is designed to contact the skin of the human left leg, was adapted by removing the back plate and soldering a wire to the conductive post of the back pad. The device was then mounted in a square (9.3 cm tall, 10 cm wide, 1 .2 cm thick) 3D-printed polylactic acid holder with a copper plate (2.9 cm x 3.2 cm) attached on top with a conductive adhesive (FIG. 1 C), and the wire from the back post was then soldered to the copper plate to complete the circuit. This provided three electrodeAtty. Dckt.: STAN-2271 WO Client Ref.: S25-149pads on top of the modified device, the two standard pads (one for each hand of the lemur) and the added copper pad (for the left foot).

[0193] Kardia software and hardware were optimized to reliably and accurately capture the mouse lemur heart rate and cardiac cycle, initially using the single- and 3-lead systems, and then validated with the derived 6-lead system. Unlike rodents, for which ECG recording typically requires anesthesia, the lemurs were docile and required only gentle support on the ECG platform, such that their arms rested on the device with one hand on each pad, and their back left leg guided onto the copper pad. ECGs were recorded for 10-30 seconds. ECGs were repeated sequentially as needed (up to 3 times) to facilitate desensitization of the subjects to the test.

[0194] Serial recordings were generally consistent, but if the first traces were different they were discarded. Any differences observed were primarily from artifacts introduced by dirty hands of the subject that caused poor electrode contact, reducing and distorting the ECG signal. Recordings were transmitted remotely to the Kardia smartphone App, with ECG raw data available online for cardiologist review and analysis. Automated ECG analysis software designed for human ECGs (Kardia App) did not reliably interpret lemur ECG traces, so ECG reading and pathology calls were done manually by two or three board-certified cardiologists (S.C., V.F., D.L.) for each trace. Some individuals were studied longitudinally. ECGs were performed from 2016-2024.

[0195] Heart rate ranges for each of the three Microcebus species were determined by calculating 95% confidence intervals (Cl) using 2 standard deviations from the mean. Values falling below the lowest limit of the 95% Cl defined the range for sinus bradycardia. For sinus tachycardia (ST), the 95% Cl was calculated using only ECGs interpreted as ST (T-wave visibly fused with preceding QRS-complex). Values below the lowest limit of this 95% Cl for ST (but above the highest cutoff for sinus bradycardia) was taken as the heart rate range for normal sinus rhythm.Lemur family pedigrees

[0196] The pedigrees of the laboratory M. murinus lemurs with sick sinus syndrome (SSS) (FIG.4) and atrial fibrillation (Afib)Zpremature atrial contractions (FACs) (FIG. 8) were constructed from breeding records of the colony and DNA genotyping of selected, highly polymorphic loci. The pedigree of the full colony is under construction, and experimental protocol and full set of results will be detailed elsewhere (C.K., J.P., C.R., A.A., J.T., unpublished data). Briefly, maternal lineage and siblings were obtained directly from the breeding record, which includes the identities of the mother and each offspring (typically 2-3) in the litter. However, in most cases paternity was ambiguous in the record because for mating a female lemur was usually bred with up to 4 adultAtty. Dckt.: STAN-2271 WO Client Ref.: S25-149males, any one of which could have fathered the litter. Maternity was confirmed and paternal ambiguity was resolved by isolation of genomic DNA from each individual, its mother, and all potential fathers, and polymerase chain reaction amplification and DNA sequencing of five selected, highly polymorphic loci (Mm03, Mm09, Mm10, Mm21 , Mm39)66,67. In almost all cases, comparison of the sequences was sufficient to identify the biological father and confirm the identity of the mother, as shown in the SSS and Afib / PAC pedigree figures (FIG. 4, FIG. 8). In the rare cases in which genomic DNA was not available for genotyping, or the genotyped loci did not fully resolve paternity, paternity is reported as “?#” in the figure.Whole-genome sequencing

[0197] Whole blood (150 -250 ul) was obtained from 35 M. murinus lab animals by saphenous vein pricks with a small gauge (22 or higher) needle and collected by capillary action into microfuge tubes. Genomic DNA (gDNA) was extracted from each blood sample using Qiagen DNeasy Blood & Tissue Kit (#69504) as described by the manufacturer, and gDNA concentration was determined by fluorimetry (Invitrogen QubitTM 3 Fluorometer, 1X dsDNA high sensitivity assay kit Q33230). Quality control to ensure absence of extensive DNA fragmentation was done by gDNA electrophoresis on 3% agarose gels. gDNA (1 ng) was used for sequencing library preparation with dual unique i5 and i7 indexing primers for the Illumina platform as described42; no significant differences in tagmentation size, library quality, and sequencing read depth were observed between libraries prepared with our in-house protocol versus the commercial Illumina kit. gDNA libraries were sequenced to achieve saturation on a NovaSeq 6000 System (Illumina) using 2 x 150 bp paired-end reads and 2 x 10 bp dual unique index reads with 300 cycle kits designed for either the S2 or S4 flow cell configuration (Illumina, 20091658, 20028314, 20028312). Sequencing data was outputted in FASTQ format and sequencing quality assessed with FastQC (v0.11.9).Sequence variant identification and segregation in SSS pedigree

[0198] The FASTQ DNA sequencing files for the 35 Microcebus murinus lemurs were aligned to Mmur 3.0 genome assembly (NCBI RefSeq assembly accession: GCF 000165445.2; indexed using Burrow-Wheeler Aligner (version BWA-0.7.17 r1188); NCBI Microcebus murinus Annotation Release 101, GTF format) and sequence variants identified using Sentieon® (software version 202112.01) DNAseq® and germline variant calling pipeline68. Mapping, alignment quality metric determination (QualiMap(v2.2.1), removal of base duplicates, baseAtty. Dckt.: STAN-2271 WO Client Ref.: S25-149quality score recalibration (BQSR), and variant identification were carried out individually for each lemur using the customized options and computational scripts available on Github (github.com / scthree / SSS). Individual variant calling files were then joint genotyped together by a coalescent model to produce a single, multi-sample variant calling file. Methods for identification and mapping of SNP / indel variants that co-segregated with SSS in the lemur pedigree are detailed below; the full M. murinus SNP / indel library created from these 35 individual genomes will be described elsewhere.

[0199] A database of the M. murinus genome (Mmur3.0 assembly and annotation files) was constructed for the SnpEff & SnpSift toolbox (v4.5)69, and then the toolbox used (java version 11.0.11 , detailed on Github, github.com / scthree / SSS) to annotate and predict the functional effect of the identified SNP / indel variants in the joint genotyped variant calling file described above. SnpSift was then used to filter for variants that co-segregated throughout the pedigree with the assigned phenotype of each individual (SSS-affected, carrier, wild-type) in a simple Mendelian autosomal dominant inheritance pattern, or an autosomal recessive fashion, assuming full penetrance of the phenotype (github.com / scthree / SSS). The SSS segregation pattern in the pedigree excluded X-linked and mitochondrial inheritance patterns, so these inheritance patterns were not further investigated here.Creating human cardiac sinoatrial nodal pacemaker cells (iSANCs) from human iPS cells (iPSCs)

[0200] Differentiation of human SANCs from iPSCs was done as described70 with the following modifications. Wild-type human female iPSCs (clone #273, Stanford Cardiovascular Institute iPSC Biobank) were cultured in 5% CO2 incubators at 37 °C in three stages (A, B, and C, 5 days each over 15 days, instead of 3 days each over 9 days as previously described) to promote SANC differentiation (FIG. 6C). Starvation of cells was carried out through SANC differentiation and purification (-day 50, instead of only through day 30 (stage B) as previously described) to enrich for nodal cells (fatty-acid metabolism) over iPSCs (anaerobic metabolism); hence, glucose and insulin were not added to the base culture medium until -day 51 (beginning of “SANC maturation”), which was then used for the remainder of the protocol: Roswell Park Memorial Institute, RPMI 1640 medium with glucose (Gibco, Thermo Scientific #11875093) supplemented with 10% B-27 containing insulin (Gibco, Thermo Scientific #12587010), glutamine substitute GlutaMAX (at 2 mM, Gibco, Thermo Scientific #35050061 ), 1 x Minimum Essential Medium, MEM non-essential amino acids (Gibco, Thermo Scientific #11140050), and 1x penicillin- streptomycinAtty. Dckt.: STAN-2271 WO Client Ref.: S25-149(Gibco, Thermo Scientific 15070063). During SANG purification and maturation, cells were washed (in phosphate buffered saline, PBS, pH 7.4) and culture media replaced every 2-3 days. Mature SANCs were identified by their morphology (small, spindle-like cells forming clusters for functional synchronization) and beating rate (~100 beats per minute) under light microscopy.Generating SLC41A2- / - knockout human iSANCs with CRISPR / Cas9

[0201] GRISPR / Cas9 single guide RNAs (sgRNAs) targeting the N-terminal coding region in an early common exon (exon 2) of human SLC41A2\Nere bioinformatically designed using CRISPR design tools from Synthego, Integrated DNA Technologies (IDT), and CRISPick (Broad Institute). Three customized sgRNAs (FIG. 12A) were selected for their predicted high targeting efficiency and specificity (low off-target effects). The SLC41A2 targeting sgRNAs (3 nmol each) were synthesized (Synthego), and a pooled sgRNA (‘multi-guide’) working stock solution (30 pM) was prepared and used along with similar working stock solutions of sgRNA controls (positive control, multi-guide sgRNAs targeting human TRAC, 14637241-2; negative control, scrambled synthetic sgRNA #1, 4637241-3) according to the manufacturer’s instructions (Gene Knockout Kit v2, 14637241-1 ; transfection optimization kit 14637241-2). CRISPR / Cas9 editing was carried out by a proprietary protocol (Neon Electroporation, Synthego). Briefly, on day 1 of the protocol, human female iPSC clone #273 cells were cultured in a humidified chamber under 5% CO2at 37°C in a serum-free complete iPSC cell culture medium (mTeSR media, Stemcell Technologies) in Matrigel-coated plates (Corning 354603). Ribonucleoprotein complexes were assembled by combining sgRNA:Cas9 in a 9:1 ratio (from 30 pM multi-guide sgRNA stock solution and 20 pM SpCas9 2NLS nuclease stock solution, to make final working solutions of 12.9 pM and 0.07 pM, respectively in proprietary resuspension buffer R). On culture day 3, when iPSCs were -70% confluent, cells were dissociated, counted, and 1-2 x 106 cells were centrifuged (500 g, 5 min, 4°C) in a sterile microfuge tube, washed with PBS, and resuspended in 50 pL of resuspension buffer R. For each transfection, RNP solution (7 pL) was added to 5 pL of cell suspension, and transferred into a chilled cuvette for electroporation (Bio-Rad Gene Pulser Xcell system, two pulses, 1.4 kV, 40 ms pulse width). Electroporated cells were immediately transferred to one well of a pre-warmed (37°C) Matrigel-coated 96-well plate (Corning 3603) containing 100 pl of mTeSR media and recovered for three days at 37°C in a humidified 5% CO2 incubator. On day 7, an aliquot of the recovered cells was harvested, and genomic DNA was isolated, the editing site amplified by PCR, and the PCR product sequenced (Sanger sequencing) to assess editing efficiency. Limit dilutions were made from the remaining cells and seeded at the followingAtty. Dckt.: STAN-2271 WO Client Ref.: S25-149densities in mTeSR, 0.25 cells / 100 pL, 0.5 cells / 100 pL, 1 cell 1100 pL, in three 96-well plates, respectively. Single colonies were then picked from wells in which only one colony had grown (day -14), ensuring isolated cells had originated from asingle cell; wells with two or more colonies were discarded. When clonal colonies reached - 100-300 pM diameter (day -17), they were passaged into 24-well plates (Corning 3524). After colonies reached -70% confluence (-day 20), SLC41A2- / - knockout was confirmed by PCR analysis on agarose gel (-320 bp amplicon vs. -440 bp in wild-type), Sanger sequencing (FIG. 12B), and immunofluorescence staining (FIG. 12C), and these were selected for subsequent differentiation into SANCs as described above. SANCs differentiated from non-CRISPR- electroporated iPSCs were used as wild-type SLC41A2+ / + controls in the immunofluorescence and functional calcium and magnesium imaging experiments.Immunofluorescence analysis of human iSANCs

[0202] Primary antibodies and dilutions used were SLC41A2 rabbit polyclonal antibody (Invitrogen, Thermo Scientific PA558483; 1 :50 dilution), PLN mouse monoclonal antibody (Invitrogen, Thermo Scientific MA3-922; 1 :50), and fluorescent secondary antibodies were donkey anti-rabbit Alexa Fluor Plus 488 (Invitrogen, Thermo Scientific A32790; 1 :200) and donkey anti-mouse Alexa Fluor Plus 555 (Invitrogen, Thermo Scientific A32773; 1:200). For immunostaining, human SLC41A2+ / + and SLC41A2- / - iSANCs were plated in 35 mm glass bottom dishes and fixed in 4% PFA (pH 7.4) at room temperature (RT) for 20 min. After washing three times with sterile PBS, cells were permeabilized in 0.1% Triton X-100 in PBS and incubated at RT for 25 min. After another round of washing, samples were blocked in 2% BSA in PBST and incubated at RT for 2 hours, washed again, and subsequently incubated in 2% BSA / PBST with primary antibody at 4°C overnight. After washing, cells were incubated with fluorescent secondary antibody and DAPI (Thermo Scientific 62248; 1 :500) in 2% BSA / PBST for 2 hours at RT protected from sunlight. After a final wash, cells were mounted in VECTASHIELD® PLUS Antifade mounting media (H-2000) and imaged by confocal fluorescence microscopy (Leica Stellaris 8).Functional calcium and magnesium imaging of human iSANCs

[0203] Live calcium imaging of human iSANCs was performed using cell permeant calcium indicator Fluo-4 AM (Thermo Scientific F14201 ) as described71. Briefly, iSANCs were seeded for imaging at a density of 500,000 cells / mL in 10% KOSR RMPI / B27 media (KnockOut Serum Replacement, Thermo Scientific 10828-028; RMPI 1640 Medium, Life Technologies 11875-119; B27 supplements, Life Technologies 17504-044). Cells were loaded with 5 pM Fluo-4 with 0.1%Atty. Dckt.: STAN-2271 WO Client Ref.: S25-149Pluronic F-127 (Thermo Scientific P3000MP) for 10 min at RT in Tyrode’s solution (140 mM NaCI, 1 mM MgCk, 5.4 mM KCI, 1.8 mM CaCh, 10 mM glucose, and 10 mM HEPES, pH 7.4 with NaOH). Ca2+ handling was observed using an inverted microscope (Zeiss LSM980) mounted with a 63x oil immersion objective. During experiments, cells were maintained at 37 °C and constantly gassed with 95% 02 / 5% CO2. Line-scan images across the whole cell were obtained to quantify local Ca2+signals with 488 nm excitation and 510 nm emission from the iSANCs. The same protocol was used for magnesium indicator Mag-Fluo-4 AM (Thermo Scientific M 14206), with fluorescence excitation at 493 nm and emission collection at 517 nm.Data and code availability

[0204] All coding scripts and computational options used are available on Github (github.com / scthree / SSS). FASTQ files of raw sequencing data will be available on Globus upon publication.REFERENCES

[0205] 1. Srinivasan, N. T. & Schilling, R. J. Sudden Cardiac Death and Arrhythmias.Arrhythm Electrophysiol Rev 7, 111-117 (2018).

[0206] 2. Milan, D. J. & MacRae, C. A. Animal models for arrhythmias. Cardiovasc. Res. 67, 426-437 (2005).

[0207] 3. Nerbonne, J. M. Mouse models of arrhythmogenic cardiovascular disease:challenges and opportunities. Curr. Opin. Pharmacol. 15, 107-114 (2014).

[0208] 4. Kaese, S. & Verheule, S. Cardiac electrophysiology in mice: a matter of size. Front.Physiol. 3, 345 (2012).

[0209] 5. Doevendans, P. A., Daemen, M. J., de Muinck, E. D. & Smits, J. F. Cardiovascular phenotyping in mice. Cardiovasc. Res. 39, 34-49 (1998).

[0210] 6. Clauss, S. et al. Animal models of arrhythmia: classic electrophysiology to genetically modified large animals. Nat. Rev. Cardiol. 16, 457-475 (2019).

[0211] 7. Ezran, C. et al. The mouse lemur, a genetic model organism for primate biology, behavior, and health. Genetics 206, 651-664 (2017).

[0212] 8. Kapourchali, F. R. et al. Animal models of atherosclerosis. World J Clin Cases 2, 126-132 (2014).

[0213] 9. Getz, G. S. & Reardon, C. A. Animal models of atherosclerosis. Arterioscler.Thromb. Vase. Biol. 32, 1104-1115 (2012).Atty. Dckt.: STAN-2271 WO Client Ref.: S25-149

[0214] 10. Emini Veseli, B. et al. Animal models of atherosclerosis. Eur. J. Pharmacol. 816, 3-13 (2017).

[0215] 11. Duncker, D. J. et al. Animal and in silico models for the study of sarcomeric cardiomyopathies. Cardiovasc. Res. 105, 439-448 (2015).

[0216] 12. Camacho, P., Fan, H., Liu, Z. & He, J.-Q. Small mammalian animal models of heart disease. Am. J. Cardiovasc. Dis. 6, 70-80 (2016).

[0217] 13. Breckenridge, R. Heart failure and mouse models. Dis. Model. Meeh. 3, 138-143 (2010).

[0218] 14. Camacho, P., Fan, H., Liu, Z. & He, J.-Q. Large Mammalian Animal Models of Heart Disease. J Cardiovasc Dev Dis 3, (2016).

[0219] 15. Cox, L. A. et al. Baboons as a model to study genetics and epigenetics of human disease. ILAR J. 54, 106-121 (2013).

[0220] 16. Cox, L. A. et al. Nonhuman Primates and Translational Research-Cardiovascular Disease. ILAR J. 58, 235-250 (2017).

[0221] 17. Carvalho, C., Gaspar, A., Knight, A. & Vicente, L. Ethical and scientific pitfalls concerning laboratory research with non-human primates, and possible solutions. Animals (Basel) 9, 12 (2018).

[0222] 18. Huber, H. F., Nathanielsz, P. W. & Clarke, G. D. Summary and assessment of studies on cardiac aging in nonhuman primates. Comp. Med. 71, 460-465 (2021).

[0223] 19. Herrmann, S., Fabritz, L., Layh, B., Kirchhof, P. & Ludwig, A. Insights into sick sinus syndrome from an inducible mouse model. Cardiovasc. Res. 90, 38-48 (2011).

[0224] 20. Fenske, S. et al. Sick sinus syndrome in HCN1 -deficient mice. Circulation 128, 2585- 2594 (2013).

[0225] 21. Benson, D. W. et al. Congenital sick sinus syndrome caused by recessive mutations in the cardiac sodium channel gene (SCN5A). J. Clin. Invest. 112, 1019-1028 (2003).

[0226] 22. Abe, K. et al. Sodium channelopathy underlying familial sick sinus syndrome with early onset and predominantly male characteristics. Circ. Arrhythm. Electrophysiol. 7, 511-517 (2014).

[0227] 23. Tanaka, T. et al. Four novel KVLQT1 and four novel HERG mutations in familial long- QT syndrome. Circulation 95, 565-567 (1997).

[0228] 24. Funato, H. Forward genetic approach for behavioral neuroscience using animal models. Proc. Jpn. Acad. Ser. B Phys. Biol. Sci. 96, 10-31 (2020).Atty. Dckt.: STAN-2271 WO Client Ref.: S25-149

[0229] 25. Moresco, E. M. Y., Li, X. & Beutler, B. Going forward with genetics: recent technological advances and forward genetics in mice. Am. J. Pathol. 182, 1462-1473 (2013).

[0230] 26. Groza, T. et al. The International Mouse Phenotyping Consortium: comprehensive knockout phenotyping underpinning the study of human disease. Nucleic Acids Res. 51 , D1038- D1045 (2023).

[0231] 27. Zipes, D. P. et al. Braunwald’s Heart Disease: A Textbook of Cardiovascular Medicine.(Elsevier, 2019).

[0232] 28. DiFrancesco, M. L. et al. Characterization of sinoatrial automaticity in Microcebus murinus to study the effect of aging on cardiac activity and the correlation with longevity. Sci. Rep.13, 3054 (2023).

[0233] 29. Kannel, W. B., Kannel, C., Paffenbarger, R. S., Jr & Cuppies, L. A. Heart rate and cardiovascular mortality: the Framingham Study. Am. Heart J. 113, 1489-1494 (1987).

[0234] 30. Mason, J. W. et al. Electrocardiographic reference ranges derived from 79,743 ambulatory subjects. J. ElectrocardioL 40, 228-234 (2007).

[0235] 31. Gillum, R. F. Epidemiology of resting pulse rate of persons ages 25-74-data from NHANES 1971-74. Public Health Rep. 107, 193-201 (1992).

[0236] 32. Languille, S. et al. The grey mouse lemur: a non-human primate model for ageing studies. Ageing Res. Rev. 11, 150-162 (2012).

[0237] 33. Khurshid, S. et al. Frequency of cardiac rhythm abnormalities in a half million adults.Circ. Arrhythm. Electrophysiol. 11, e006273 (2018).

[0238] 34. Koplan, B. A. & Stevenson, W. G. Ventricular tachycardia and sudden cardiac death.Mayo Clin. Proc. 84, 289-297 (2009).

[0239] 35. Ikeda, T. Right bundle branch block: Current considerations. Curr. Cardiol. Rev. 17, 24-30 (2021).

[0240] 36. Katritsis, G. D. & Katritsis, D. G. The electrocardiogram in athletes revisited. Arrhythm.Electrophysiol. Rev. 2, 99-104 (2013).

[0241] 37. Dobrzynski, H., Boyett, M. R. & Anderson, R. H. New insights into pacemaker activity:promoting understanding of sick sinus syndrome. Circulation 115, 1921-1932 (2007).

[0242] 38. Semelka, M., Gera, J. & Usman, S. Sick sinus syndrome: a review. Am. Fam.Physician 87, 691-696 (2013).

[0243] 39. Schulze-Bahr, E. et al. Pacemaker channel dysfunction in a patient with sinus node disease. J. Clin. Invest. 111, 1537-1545 (2003).Atty. Dckt.: STAN-2271 WO Client Ref.: S25-149

[0244] 40. Fleig, A., Schweigel-Rontgen, M. & Kolisek, M. Solute Carrier Family SLC41 , what do we really know about it?: Solute carrier family SLC41. Wiley Interdiscip. Rev. Membr. Transp. Signal. 2, 227-239 (2013).

[0245] 41. Nemoto, T., Tagashira, H., Kita, T., Kita, S. & Iwamoto, T. Functional characteristics and therapeutic potential of SLC41 transporters. J. Pharmacol. Sci. 151, 88-92 (2023).

[0246] 42. The Tabula Microcebus Consortium et al. Tabula Microcebus: A transcriptomic cell atlas of mouse lemur, an emerging primate model organism. bioRxiv 2021.12.12.469460 (2024) doi:10.1101 / 2021.12.12.469460.

[0247] 43. Slc41a2 mouse gene details. mousephenotype.org / data / genes / MGI:2442940.

[0248] 44. Sahni, J. & Scharenberg, A. M. The SLC41 family of MgtE-like magnesium transporters. Mol. Aspects Med. 34, 620-628 (2013).

[0249] 45. Schweigel-Rontgen, M. & Kolisek, M. SLC41 transporters-molecular identification and functional role. Curr. Top. Membr. 73, 383-410 (2014).

[0250] 46. Goytain, A. & Quamme, G. A. Functional characterization of the mouse [corrected] solute carrier, SLC41 A2. Biochem. Biophys. Res. Commun. 330, 701-705 (2005).

[0251] 47. Sahni, J., Nelson, B. & Scharenberg, A. M. SLC41 A2 encodes a plasma-membrane Mg2+transporter. Biochem. J. 401 , 505-513 (2007).

[0252] 48. Singh, R. B., Singh, V. P., Jha, V. K. & Katiyar, B. C. Magnesium and the heart. Acta Cardiol. 31 , 401-409 (1976).

[0253] 49. Lakatta, E. G., Maltsev, V. A. & Vinogradova, T. M. A coupled SYSTEM of intracellular Ca2+ clocks and surface membrane voltage clocks controls the timekeeping mechanism of the heart’s pacemaker. Circ. Res. 106, 659-673 (2010).

[0254] 50. Weisbrod, D., Khun, S. H., Bueno, H., Peretz, A. & Attali, B. Mechanisms underlying the cardiac pacemaker: the role of SK4 calcium-activated potassium channels. Acta Pharmacol. Sin. 37, 82-97 (2016).

[0255] 51. Tsutsui, K. et al. A coupled-clock system drives the automaticity of human sinoatrial nodal pacemaker cells. Sci. Signal. 11 , (2018).

[0256] 52. Nishikawa, M. et al. The characteristics of patients with hypermagnesemia who underwent emergency hemodialysis. Acute Med. Surg. 5, 222-229 (2018).

[0257] 53. Bhatti, H., Mohmand, B., Ojha, N., P Carvounis, C. & L Carhart, R. The role of magnesium in the management of atrial fibrillation with rapid ventricular rate. J. Atr. Fibrillation 13, 2389 (2020).Atty. Dckt.: STAN-2271 WO Client Ref.: S25-149

[0258] 54. Miller, S. et al. Effects of magnesium on atrial fibrillation after cardiac surgery: a metaanalysis. Heart 91, 618-623 (2005).

[0259] 55. Ghezel-Ahmadi, V., Ghezel-Ahmadi, D., Beck, G. & Bolukbas, S. Perioperative systemic magnesium sulfate minimizes the incidence of atrial fibrillation after thoracotomy for lung resection: a prospective observational study. J. Thorac. Dis. 15, 4648-4656 (2023).

[0260] 56. Adan, V. & Crown, L. A. Diagnosis and treatment of sick sinus syndrome. Am. Fam.Physician 67, 1725-1732 (2003).

[0261] 57. Defesche, J. C. et al. Familial hypercholesterolaemia. Nat. Rev. Dis. Primers 3, 17093 (2017).

[0262] 58. Gayther, S. A. & Pharoah, P. D. P. The inherited genetics of ovarian and endometrial cancer. Curr. Opin. Genet. Dev. 20, 231-238 (2010).

[0263] 59. D’Argenio, V. & Sarnataro, D. New insights into the molecular bases of familial Alzheimer’s disease. J. Pers. Med. 10, 26 (2020).

[0264] 60. Black, H. A. et al. Genetic epidemiology of motor neuron disease-associated variants in the Scottish population. Neurobiol. Aging 51, 178. e11 -178.e20 (2017).

[0265] 61. The Tabula Microcebus Consortium et al. Mouse lemur transcriptomic atlas informs primate genes, mutations, physiology, and disease. bioRxiv 2022.08.06.503035 (2024) doi : 10.1101 / 2022.08.06.503035.

[0266] 62. Casey, K. M., Karanewsky, C. J., Pendleton, J. L, Krasnow, M. R. & Albertelli, M. A.Fibrous osteodystrophy, chronic renal disease, and uterine adenocarcinoma in aged gray mouse lemurs (Microcebus murinus). Comp. Med. 71, 256-266 (2021).

[0267] 63. Atsalis, S. Spatial distribution and population composition of the brown mouse lemur (Microcebus rufus) in Ranomafana National Park, Madagascar, and its implications for social organization. Am. J. Primatol. 51, 61-78 (2000).

[0268] 64. Tomiuk, J. et al. The impact of genetics on the conservation of Malagasy lemur species. Folia

[0269] 65. Home, stonybrook.edu / commcms / centre-valbio.

[0270] 66. Radespiel, U., Funk, S. M., Zimmermann, E. & Bruford, M. W. Isolation and characterization of microsatellite loci in the grey mouse lemur (Microcebus murinus) and their amplification in the family Cheirogaleidae: PRIMER NOTE. Mol. Ecol. Notes 1, 16-18 (2001).

[0271] 67. Hapke, A., Eberle, M. & Zischler, H. Isolation of new microsatellite markers and application in four species of mouse lemurs (Microcebus sp.). Mol. Ecol. Notes 3, 205-208 (2003).Atty. Dckt.: STAN-2271 WO Client Ref.: S25-149

[0272] 68. Kendig, K. I. et al. Sentieon DNASeq variant calling workflow demonstrates strong computational performance and accuracy. Front. Genet. 10, 736 (2019).

[0273] 69. Cingolani, P. et al. A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff: SNPs in the genome of Drosophila melanogaster strain w1118; iso-2; iso-3: SNPs in the genome of Drosophila melanogaster strain w1118; iso-2; iso-3. Fly (Austin) 6, 80-92 (2012).

[0274] 70. Ghazizadeh, Z. et al. A dual SHOX2:GFP; MYH6:mCherry knockin hESC reporter line for derivation of human SAN-like cells. iScience 25, 104153 (2022).

[0275] 71. Zhang, J. Z. et al. Protocol to measure contraction, calcium, and action potential in human-induced pluripotent stem cell-derived cardiomyocytes. STAR Protoc. 2, 100859 (2021).

[0276] 72. Lansman, J. B., Hess, P. & Tsien, R. W. Blockade of current through single calcium channels by Cd2+, Mg2+, and Ca2+. Voltage and concentration dependence of calcium entry into the pore. J. Gen. Physiol. 88, 321-347 (1986).

[0277] 73. Zhao, M. et al. Mg(2+)-dependent facilitation and inactivation of L-type Ca(2+) channels in guinea pig ventricular myocytes. J. Pharmacol. Sci. 129, 143-149 (2015).

[0278] 74. Wang, M., Tashiro, M. & Berlin, J. R. Regulation of L-type calcium current by intracellular magnesium in rat cardiac myocytes: Magnesium regulation of calcium current. J. Physiol. 555, 383-396 (2004).

[0279] 75. Brunet, S., Scheuer, T. & Catterall, W. A. Increased intracellular magnesium attenuates p-adrenergic stimulation of the cardiac Ca(V)1.2 channel. J. Gen. Physiol. 141, 85-94 (2013).

[0280] 76. 046073 - Strain Details, jax.org / strain / 032338.Atty. Dckt.: STAN-2271 WO Client Ref.: S25-149Table 1. Mouse lemurs with cardiac arrhythmias and ECG pathologies.DxName age Sex Lab vs wild Pathology Other clinical findings (V)169AFA 2.6 Male Lab PAC Fam hx of PAC / AfibFam hx of PAC / Afib,169AFB 4.6 Male Lab Afib, PAChyperlipidemia, hyperglycemia 262DBA 3.5 Male Lab PAC Fam hx of SSS, low activity91 Male Wild rufus PAC242 Female Wild rufus PAC144 Female Wild sp nov PAC317 Female Wild sp nov PAC Low activity204FD 1.5 Female Lab SB Fam hx SSS, very low activity SB (4.6), STD241 EA 4.6 Female Lab Fam hx SSS, low activity (4.6), iTW (4.6)Fam hx SSS, low activity, 261 BBA 4.4 Male Lab SBdecreased grip strengthFam hx SSS, very lethargic, 300AA 3.4 Male Lab SB / tachy-brady very low activity, decreased grip strengthSB / tachy-brady Fam hx SSS, very lethargic, 300AB 3.4 Male Lab (3.4), STD sudden death during(3.5), iTW (3.5) anesthesiaSB / tachy-bradyFam hx SSS, very lethargic, 300AC 2.5 Female Lab (2.5), STDlow activity(3.4), iTW (2.5)397C 1.5 Female Lab SB348 Female Wild sp nov SB351 BA 2.1 Male Lab PVC243 Male Wild sp nov NSVTAtty. Dckt.: STAN-2271 WO Client Ref.: S25-149283A 4.4 Male Lab STD Persistent tachycardiaSTD (6.2), iTW Persistent tachycardia,308A 6.2 Male Lab(6.2) hyperglycemia308 Male Wild sp nov STDFam hx of SSS, persistent 381 C 1.6 Female Lab iTW tachycardia, euthanized for weakness / lethargySTE (0.9),300AEC 0.9 Female Lab Tachycardiasmall R (0.9)Deep phenotyping data of 22 animals (15 laboratory, 7 wild) with human-like ECG abnormalities. Lemurs were systematically screened (see Methods) including for the following parameters: family history, physical exam, body measure, behavior and strength assessments, serum lipids, and ECG. Dx, age in years of diagnosis; PAC, premature atrial contractions; Afib, atrial fibrillation; SB, sinus bradycardia; STD, ST-segment depression; iTW, inverted T-waves; PVC, premature ventricular contractions; NSVT, non-sustained ventricular tachycardia; STE, ST-segment elevation; Small R, small R-wave; Fam hx, family history; SSS, sick sinus syndrome (used interchangeably with tachy-brady syndrome).Table 2. Prevalence of mouse lemur arrhythmias and ECG variants in wild and laboratory mouse lemurs.Lab Lab Wild + Wild M. murinus M. rufus M. novaArrhythmias All & ECG F M F+M F M F+M F M F+M pathologies (136) (119) (255) (33) (31) (64) (19) (18) (37) (356)% (n) % (n) % % (n) % (n) % % (n) % (n) % % % PACs 0 2.5 (3) 1.2 3.0 (1) 3.2 (1) 3.1 11 (2) 0 5.4 4.0 2.0 Afib 0 0.8 (1) 0.4 0 0 0.0 0 0 0.0 0.0 0.3 SSS 2.9 (4) 2.5 (3) 2.7 0 0 0.0 5.3 (1) 0 0.0 1.0 2.2 PVCs 0 0.8 (1) 0.4 0 0 0.0 0 0 0.0 0.0 0.3 NSVT 0 0 0.0 0 0 0.0 0 5.6 (1) 2.7 1.0 0.3 STD 1.5 (2) 2.5 (3) 2.0 0 0 0.0 0 5.6 (1) 2.7 1.0 1.7 iTWs 2.2 (3) 1.7 (2) 2.0 0 0 0.0 0 0 0.0 0.0 1.4Atty. Dckt.: STAN-2271 WO Client Ref.: S25-149STE 0.7 (1) 0 0.4 0 0 0.0 0 0 0.0 0.0 0.3TOTAL 7.4 (10) 11 (13) 9.0 3.0 (1) 3.2 (1) 3.1 16 (3) 11 (2) 14 6.9 8.4 ECGvariantsSVT 7.4 (10) 3.4 (4) 5.5 0 0 0.0 0 0 0.0 0.0 3.9 WAP 0 0 0.8 0 3.2 (1 ) 1.6 0 5.6 (1) 2.7 2.0 0.6 RBBB 0.7 (1) 0 0.4 0 0 0.0 0 0 0.0 0.0 0.3 S>R 2.9 (4) 0 1.6 0 0 0.0 0 0 0.0 0.0 1.1 Small R 7.4 (10) 5.9 (7) 6.7 3.0 (1) 0 1.6 0 0 0.0 1.0 5.1 Tall R 9.6 (13) 16 (19) 12.5 3.0 (1) 13 (4) 7.8 5.3 (1) 0 2.7 5.9 11 pTWs 6.6 (9) 15 (18) 10.6 45 (15) 32 (10) 39.1 42 (8) 39 (7) 40.5 39.6 19SA 0.7 (1) 3.4 (4) 2 61 (20) 48 (15) 54.7 32 (6) 11 (2) 21.6 42.6 13Arrhythmias / pathologies and variants were detected using an adapted 6-lead human ECG assay (Kardia, AliveCor®, see Methods). This enabled successful diagnosis of the following arrhythmias (PACs, Afib, SSS, PVCs, NSVT, SVT, WAP, SA). Other diagnoses were made provisionally (STD, iTWs, STE, RBBB, S>R, Small R, Tall R, pTWs) with the 6-lead assay, but require further corroboration with standard 12-lead ECG. Prevalence comparisons of cardiac arrhythmias and variants between lemur sexes and species were determined by two-tailed Fisher’s exact test. P- values were corrected for multiple hypotheses using the Holm-Sidak method.Abbreviations: ECG, electrocardiogram; F, female; M, male; (), number of female / male animals; % (n), % of animals with a given arrythmia / pathology or variant, n= # of animals with a given arrythmia / pathology or variant; PACs, premature atrial contractions; Afib, atrial fibrillation; SSS, sick sinus syndrome; PVCs, premature ventricular contractions; NSVT, non-sustained ventricular tachycardia; STD, ST-segment depression; iTWs, inverted T-waves; STE, ST-segment elevation; SVT, supraventricular tachycardia; WAP, wandering atrial pacemaker; S>R, large S- and small R-waves; Small R, small R-wave; Tall R, tall R-wave; pTWs, peaked T-waves; SA, sinus arrhythmiaValues shown are number (n) and percent individuals affected for each species and screening site (and totals): M. murinus lab mouse lemurs (MNHN, Brunoy, France; 255 screened), M. rufus and M. nova wild mouse lemurs (Ranomafana National Park, Madagascar; 101 mouse lemurs screened). Values are stratified by sex (F, female, M, male). Overall prevalence was 8.4% (30Atty. Dckt.: STAN-2271 WO Client Ref.: S25-149diagnosed arrhythmias), which were found in 6.2% of all mouse lemurs screened (22 mouse lemurs, 5 showed >1 ECG abnormality). PACs, premature atrial contractions; Afib, atrial fibrillation; SSS, sick sinus syndrome; PVCs, premature ventricular contractions; NSVT, nonsustained ventricular tachycardia; STD, ST-segment depression; iTWs, inverted T-waves; STE, ST-segment elevation; SVT, supraventricular tachycardia due to an unknown underlying rhythm; WAP, wandering atrial pacemaker; RBBB, right bundle branch block; S>R, S wave larger than R wave; Small R, small R-wave; Tall R, tall R-wave; pTWs, peaked T-waves; L-voltage, low voltage.Table 3. Major differences between mouse and human cardiac conduction systems.Major differences in anatomy, molecular biology, genetics, biochemistry, and physiology between the cardiac conduction systems of humans and mice. ECG, electrocardiogram; SVC, superior vena cava; RV, right ventricle; LV, left ventricle; QRS, QRS complex (representing ventricular depolarization) on ECG. Abbreviations: ECG, electrocardiogram; SVC, superior vena cava; RV, right ventricle; LV, left ventricle; QRS, QRS interval on electrocardiogram; bpm, beats per minuteConduction SystemFeature Mice HumanSinoatrial node location Superior vena cava / Right Right atriumatriumAtrioventricular node Less distinct DistinctHis-Purkinje system Less distinct and organized, Distinct and organized fewer fibersSuperior vena cava (trigger Two (retained left SVC) Onefor arrhythmias)Pulmonary veins (site of Converge to a solitary opening Four distinct openings in left origin for arrhythmias) in left atrium atriumK+ channels for KCNA5, KCNB1, KCNQ1, KCNH2 repolarization KCNKA / KCNB3Sinoatrial node action No clear plateau phase, rapid Defined plateau phase, potential repolarization slower repolarizationT-wave on ECG Not well resolved, merged with Discrete from QRSQRSVentricular depolarization RV -> LV or LV apex -> RV Interventricular septum -> pattern both ventriclesHeart rate 600-800 bpm 60-100 bpm Abbreviations: ECG, electrocardiogram; SVC, superior vena cava; RV, right ventricle; LV, left ventricle; QRS, QRS interval on electrocardiogram; bpm, beats per minuteAtty. Dckt.: STAN-2271 WO Client Ref.: S25-149Table 4. Genome sequencing of individual mouse lemursName Sex Age SSS phenotype ^ uu3veuraiciayeu ^ iecaddU^o 261 BBA M 4.0 Affected 27X 98.9% 300AA M 3.4 Affected 40X 99.5% 300AB M 3.4 Affected 32X 99.1% 300 AC F 2.5 Affected 37X 99.5% 241 EA F 1.6 Affected 37X 99.4% 204FD F 1.5 Affected 112X 99.5% 261 BB F 4.6 Presumed carrier 31 X 99.5% 300A F 3.5 Presumed carrier 31 X 99.4% 300ACA M 2.5 Presumed carrier 32X 99.4% 241 E F 2.5 Presumed carrier 84X 99.5% 261 BBC F 3.5 Unaffected family member 55X 99.6% 277AB F 4.9 Outside family control 30X 99.4% 208CBE F 3.7 Outside family control 48X 99.4% 288H M 1.6 Outside family control 56X 99.3% 223HCB F 2.4 Outside family control 54X 99.0% 245BAB F 3.3 Outside family control 32X 99.5% 374C M 1.5 Outside family control 31 X 99.2% 283E F 2.3 Outside family control 34X 99.1% 352A M 3.5 Outside family control 29X 99.0% 245BAA M 3.4 Outside family control 42X 98.9% 275BBC F 1.4 Outside family control 34X 99.3% 277AH F 1.3 Outside family control 46X 99.0% 283BB M 2.4 Outside family control 88X 98.9% 316A M 3.9 Outside family control 108X 99.2% 277C M 3.9 Outside family control 201X 99.4% 283C F 4.9 Outside family control 293X 99.2% 288F M 4.5 Outside family control 129X 99.4% 244DBD F 2.4 Outside family control 149X 99.5% Antoine M 6.2 Outside family control 88X 99.7% Bernard M 5.4 Outside family control 67X 99.6% Inina F 2.3 Outside family control 67X 99.7% Martine F 11 .8 Outside family control 75X 99.7% Nadine F 12.9 Outside family control 290X 99.1% Pascal M 3.5 Outside family control 67X 99.6% Stumpy F 5.4 Outside family control86X 99.7%Atty. Dckt.: STAN-2271 WO Client Ref.: S25-149Table 5. Metadata for additional genes in the SSS mapped interval on Chromosome 7 Position P1 P2 P3 P4 P5 P6Gene POLR3B TCP11 L2 NUAK1 LOC105875605 LOC105875604 LOC105875644 Gene product RNA polymerase Promotes differentiation NUAK family Uncharacterized Uncharacterized Uncharacterized III subunit B of muscle-derived kinase i ncRNA. no ncRNA. no ncRNA. no satellite cells human ortholog human ortholog human orthologTranscriptionLemur heart Endothelialexpression cell,Fibroblast,Myeloid cellMouse KO Intestinal NA Global + / - NA NA NA epitheliumshowspecific KO defectiveresults in spatialdecreased memorygrowth / survival consolidation,during 1 st abnormalpostnatal week, sensorimotordecreased gating,proliferation, abnormalabnormal socialepithelial behaviorarchitectureMouse IMPC Embryonic and Decreased BMD / lean NA Preweaning body mass, increased lethality body fat, abnormallocomotionPosition P7 PS P9 P10 P11 P12 Gene LOC105875643 WASHC4 C7H12orf45 TXNRD1 NFYB HCFC2 Gene product Uncharacterized Polymerizes actin at Protein Thioredoxin Nuclear Host cell factor, ncRNA, no endosomes chaperone reductase 1 transcription initiates HSV human ortholog that binds to factor Y subunit infection RNP complex betaTranscription < < < < > <Lemur heart - Endothelial cell. Pericyte, - Endothelial cell. Endothelial cell, expression Fibroblast, Myeloid cell Neutrophil Fibroblast, Fibroblast, Vascular smooth Vascular smooth muscle cell muscle cellMouse KO NA Mouse with human NA Global - / - are NA Decreased WASHC4(c 3056O>G) embryonic lethal; macrophage disrupts endo-lysosomal Cardiomyocyteresponse to HSV pathways, causes specific mouse - / - neurodegeneration, appear healthymotor deficitsAtty. Dckt.: STAN-2271 WO Client Ref.: S25-149 Mouse IMPC NA HOM: embryonic and NA NA NA preweaning lethality,HET: increasedglucose, hyperactivityAbbreviations: see FIG. 5 legend; Gene product, gene product function; Lemur heart expression, lemur heart cell types in which the given gene is highly and differentially expressed; gene is not detected or differentially expressed; Mouse KO, mouse knockout phenotypes in published literature; Mouse IMPC, mouse knockout phenotypes determined by the International Mouse Phenotyping Consortium; BMD, bone mineral density; HSV, herpes simplex virus; HOM, homozygous; HET, heterozygous

Claims

Atty. Dckt.: STAN-2271 WO Client Ref.: S25-149WHAT IS CLAIMED IS:

1. A genetically modified non-human primate comprising a loss-of-function mutation in an SLC41 A2 gene, wherein the non-human primate has atrial arrhythmia.

2. The genetically modified non-human primate of claim 1 , wherein the atrial arrhythmia comprises intermittent bradycardia resembling human sick sinus syndrome (SSS).

3. The genetically modified non-human primate of claim 1 or 2, wherein the loss-of-function mutation results in slowed cardiac pacemaker firing compared to cardiac pacemaker firing in a non-genetically modified non-human primate having a wild-type SLC41A2 gene.

4. The genetically modified non-human primate of any one of claims 1 -3, wherein the non-human primate is a lemur.

5. The genetically modified non-human primate of claim 4, wherein the lemur is Microcebus m annus, Microcebus rufus, or Microcebus nova.

6. The genetically modified non-human primate of any one of claims 1-5, wherein both alleles of the SLC41 A2 gene comprise the loss-of-function mutation.

7. The genetically modified non-human primate of claim 6, wherein the loss-of-function mutation is an exon deletion, a frameshift mutation, a missense mutation, or a nonsense mutation.

8. The genetically modified non-human primate of claim 7, wherein the loss-of-function mutation comprises a deletion of all or a portion of exon 2 or exon 4 of the SLC41A2 gene.

9. The genetically modified non-human primate of claim 7 or 8, wherein the loss-of-function mutation comprises a deletion of all or a portion of exon 2 of the SLC41 A2 gene, a codingAtty. Dckt.: STAN-2271 WO Client Ref.: S25-149sequence deletion in codon 4 of the SLC41A2 gene, a frameshift mutation in codon 4 of the SLC41 A2 gene, or any combination thereof.

10. The genetically modified non-human primate of any one of claims 1 -9, wherein the genetically modified non-human primate is a transgenic non-human primate.

11. A method of screening a candidate agent for treating atrial arrhythmia, the method comprising:administering the candidate agent to the genetically modified non-human primate of any one of claims 1-10; andmonitoring heart rhythm and heart rate of the genetically modified non-human primate before and after said administering the candidate agent, wherein detecting a normal heart rhythm or a closer to normal heart rhythm after said administering the candidate agent compared to before said administering the candidate agent indicates that the candidate agent is a potential therapeutic for treating the atrial arrhythmia.

12. The method of claim 11, wherein said monitoring the heart rhythm and heart rate comprises performing single-lead, 3-lead, or 6-lead electrocardiography.

13. The method of claim 11 or 12, further comprising measuring rhythmic calcium transients and / or magnesium transients associated with pacemaker activity before and after said administering the candidate agent, wherein detecting normal or a closer to normal rhythmic calcium transients and / or magnesium transients after said administering the candidate agent compared to before said administering the candidate agent indicates that the candidate agent is a potential therapeutic for treating sinus node dysfunction.

14. The method of claim 13, wherein said measuring calcium transients associated with pacemaker activity comprises performing functional calcium imaging.

15. The method of claim 13 or 14, wherein said measuring magnesium transients associated with pacemaker activity comprises performing functional magnesium imaging.Atty. Dckt.: STAN-2271 WO Client Ref.: S25-14916. The method of any one of claims 11-15, wherein the candidate agent is a small molecule, a peptide, a protein, a peptoid, an aptamer, an antibody, an antibody mimetic, an inhibitory nucleic acid, or a Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) system.

17. The method of any one of claims 11-16, wherein the candidate agent improves pacemaker function of a magnesium transporter.

18. The method of claim 17, wherein the magnesium transporter is the SLG41 A2 magnesium transporter.

19. An isolated cardiac sinoatrial nodal pacemaker cell from the genetically modified non-human primate of any one of claims 1-10.

20. A method of producing the genetically modified non-human primate of any one of claims 1-10, the method comprising genetically modifying a host non-human primate to introduce a loss-of-function mutation into the SLC41 A2 gene, wherein the genetically modified non-human primate has atrial arrhythmia.

21. The method of claim 20, wherein said genetically modifying the host non-human primate comprises using a clustered regularly interspaced short palindromic repeats (CRISPR) system, a transcription activator-like effector nuclease (TALEN), or a zinc-finger nuclease to introduce the loss-of-function mutation into the SLC41 A2 gene.

22. The method of claim 21 , wherein the CRISPR system, TALEN, or zinc-finger nuclease is used to introduce the loss-of-function mutation into one allele of the SLC41 A2 gene.

23. The method of claim 21 , wherein the CRISPR system, TALEN, or zinc-finger nuclease is used to introduce the loss-of-function mutation into both alleles of the SLC41 A2 gene.

24. The method of any one of claims 20-23, wherein the loss-of-function mutation is an exon deletion, a frameshift mutation, a missense mutation, or a nonsense mutation.Atty. Dckt.: STAN-2271 WO Client Ref.: S25-14925. The method of claim 24, wherein the loss-of-function mutation comprises a deletion of all or a portion of exon 2 or exon 4 of the SLC41 A2 gene.

26. The method of claim 24 or 25, wherein the loss-of-function mutation comprises a deletion of all or a portion of exon 2 of the SLC41 A2 gene, a coding sequence deletion in codon 4 of the SLC41A2 gene, a frameshift mutation in codon 4 of the SLC41A2 gene, or any combination thereof.

27. The method of any one of claims 21-26, wherein the CRISPR system comprises Cas9 or Cas12a.

28. The method of any one of claims 21-27, wherein the CRISPR system comprises a single guide RNA (sgRNA) targeting a Cas nuclease to the SLC41 A2 gene.

29. The method of claim 28, wherein the sgRNA specifically binds to a target sequence in a target region of exon 2 of the SLC41 A2 gene.

30. The method of claim 29, wherein the target region comprises the sequence of SEQ ID NO:8.

31. The method of claim 29 or 30, wherein the sgRNA comprises a sequence selected from the group consisting of SEQ ID NOS:1-3 or a sequence having at least 90% identity to a sequence selected from the group consisting of SEQ ID NOS:1 -3.

32. An induced pluripotent stem cell-derived sinoatrial nodal pacemaker cell (iSANC) comprising a loss-of-function mutation in an SLC41 A2 gene.

33. The iSANC of claim 32, wherein the iSANC has slowed rhythmic calcium transients and magnesium transients compared to an iSANC having a wild-type SLC41 A2 gene.

34. The iSANC of claim 32 or 33, wherein the iSANC is a mammalian iSANC.Atty. Dckt.: STAN-2271 WO Client Ref.: S25-14935. The iSANC of claim 34, wherein the mammalian iSANC is a human iSANC.

36. The iSANC of any one of claims 32-35, wherein both alleles of the SLC41 A2 gene comprise the loss-of-function mutation.

37. The iSANC of any one of claims 32-36, wherein the loss-of-function mutation is an exon deletion, a frameshift mutation, a missense mutation, or a nonsense mutation.

38. The iSANC of claim 37, wherein the loss-of-function mutation comprises a deletion of all or a portion of exon 2 or exon 4 of the SLC41 A2 gene.

39. The iSANC of claim 37 or 38, wherein the loss-of-function mutation comprises a deletion of all or a portion of exon 2 of the SLC41 A2 gene, a coding sequence deletion in codon 4 of the SLC41A2 gene, a frameshift mutation in codon 4 of the SLC41A2 gene, or any combination thereof.

40. The iSANC of any one of claims 32-39, wherein the iSANC is produced from an iPSC generated from a somatic cell obtained from a patient with sick sinus syndrome who has the loss-of-function mutation in at least one allele of the SLC41 A2 gene.

41. The iSANC of any one of claims 32-39, wherein the iSANC is genetically modified to introduce the loss-of-function mutation into at least one allele of the SLC41 A2 gene.

42. A method of screening a candidate agent for treating sinus node dysfunction, the method comprising:contacting the iSANC of any one of claims 32-41 with the candidate agent; and measuring calcium transients, magnesium transients, or both calcium transients and magnesium transients in the iSANC before and after said contacting the iSANC with the candidate agent, wherein detecting increased calcium transients, increased magnesium transients, or increased calcium transients and increased magnesium transients after said administering the candidate agent compared to before said administering the candidate agent indicates that the candidate agent is a potential therapeutic for treating the sinus node dysfunction.Atty. Dckt.: STAN-2271 WO Client Ref.: S25-14943. The method of claim 42, wherein said measuring calcium transients comprises performing functional calcium imaging of the iSANC.

44. The method of claim 42 or 43, wherein said measuring magnesium transients comprises performing functional magnesium imaging of the iSANC.

45. The method of any one of claims 42-44, wherein the candidate agent is a small molecule, a peptide, a protein, a peptoid, an aptamer, an antibody, an antibody mimetic, an inhibitory nucleic acid, or a Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) system.

46. The method of any one of claims 42-45, wherein the candidate agent improves pacemaker function of a magnesium transporter.

47. The method of claim 46, wherein the magnesium transporter is the SLC41 A2 magnesium transporter.

48. A method of producing the iSANC of any one of claims 32-41 , the method comprising genetically modifying a host iSANC or an induced pluripotent stem cell from which the host iSANC is produced to introduce a loss-of-function mutation into the SLC41 A2 gene, wherein the genetically modified iSANC comprising the loss-of-function mutation in the SLC41 A2 gene has slowed rhythmic calcium transients and magnesium transients compared to an iSANC having a wild-type SLC41 A2 gene.

49. The method of claim 48, wherein said genetically modifying comprises using a clustered regularly interspaced short palindromic repeats (CRISPR) system, a transcription activator-like effector nuclease (TALEN), or a zinc-finger nuclease to introduce the loss-of-function mutation into the SLC41 A2 gene.

50. The method of claim 49, wherein the CRISPR system, TALEN, or zinc-finger nuclease is used to introduce the loss-of-function mutation into one allele of the SLC41 A2 gene.Atty. Dckt.: STAN-2271 WO Client Ref.: S25-14951. The method of claim 49, wherein the CRISPR system, TALEN, or zinc-finger nuclease is used to introduce the loss-of-function mutation into both alleles of the SLC41 A2 gene.

52. The method of any one of claims 48-51, wherein the loss-of-function mutation is an exon deletion, a frameshift mutation, a missense mutation, or a nonsense mutation in the SLC41 A2 gene.

53. The method of claim 52, wherein the loss-of-function mutation comprises a deletion of all or a portion of exon 2 or exon 4 of the SLC41 A2 gene.

54. The method of claim 52 or 53, wherein the loss-of-function mutation comprises a deletion of all or a portion of exon 2 of the SLC41 A2 gene, a coding sequence deletion in codon 4 of the SLC41A2 gene, a frameshift mutation in codon 4 of the SLC41A2 gene, or any combination thereof.

55. The method of any one of claims 49-54, wherein the CRISPR system comprises Cas9 or Cas12a.

56. The method of any one of claims 49-55, wherein the CRISPR system comprises a single guide RNA (sgRNA) targeting a Cas nuclease to the SLC41 A2 gene.

57. The method of claim 56, wherein the sgRNA specifically binds to a target sequence in a target region of exon 2 of the SLC41 A2 gene.

58. The method of claim 57, wherein the target region comprises the sequence of SEQ ID NO:8.

59. The method of claim 57 or 58, wherein the sgRNA comprises a sequence selected from the group consisting of SEQ ID NOS:1-3 or a sequence having at least 90% identity to a sequence selected from the group consisting of SEQ ID NOS:1 -3.Atty. Dckt.: STAN-2271 WO Client Ref.: S25-14960. A method of screening a candidate agent for treating an arrhythmia, the method comprising:administering the candidate agent to a lemur having the arrhythmia; andmonitoring heart rhythm and heart rate of the lemur before and after said administering the candidate agent, wherein detecting a normal heart rhythm or a closer to normal heart rhythm after said administering the candidate agent compared to before said administering the candidate agent indicates that the candidate agent is a potential therapeutic for treating the arrhythmia.

61. The method of claim 60, wherein the lemur is Microcebus murinus, Microcebus rufus, or Microcebus nova.

62. The method of claim 60 or 61 , wherein the arrhythmia is an atrial arrhythmia or a ventricular arrhythmia.

63. The method of claim 62, wherein the arrhythmia is sinus bradycardia, sinus tachycardia, ventricular tachycardia, non-sustained ventricular tachycardia, supraventricular tachycardia, tachycardia-bradycardia syndrome, atrial fibrillation, premature atrial contractions, premature ventricular contractions, sick sinus syndrome, or wandering atrial pacemaker.

64. The method of any one of claims 60-63, wherein the lemur has ST-segment depression, inverted T-waves, ST-segment elevation, ST-segment depression, small R-waves, tall R-waves, large S-waves and small R-waves, peaked T-waves, a right bundle branch block, a prolonged QRS-complex, or any combination thereof.

65. The method of any one of claims 60-64, wherein said monitoring the heart rhythm and heart rate comprises performing single-lead, 3-lead, or 6-lead electrocardiography.

66. The method of any one of claims 60-65, further comprising measuring rhythmic calcium transients and / or magnesium transients associated with pacemaker activity before and after said administering the candidate agent, wherein detecting normal or a closer to normal rhythmic calcium transients and / or magnesium transients after said administering the candidateAtty. Dckt.: STAN-2271 WO Client Ref.: S25-149agent compared to before said administering the candidate agent indicates that the candidate agent is a potential therapeutic for treating sinus node dysfunction.

67. The method of claim 66, wherein said measuring calcium transients associated with pacemaker activity comprises performing functional calcium imaging.

68. The method of claim 66 or 67, wherein said measuring magnesium transients associated with pacemaker activity comprises performing functional magnesium imaging.

69. The method of any one of claims 60-68, wherein the candidate agent is a small molecule, a peptide, a protein, a peptoid, an aptamer, an antibody, an antibody mimetic, an inhibitory nucleic acid, or a Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) system.

70. The method of any one of claims 60-69, wherein the candidate agent improves pacemaker function of a magnesium transporter.

71. The method of claim 70, wherein the magnesium transporter is the SLC41 A2 magnesium transporter.